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Abbrevations 
3-PPA    3-phenylpropionic acid 
3,4-MPPA   3-(4-methoxyphenyl)propionic acid 
4-MCA    4-methoxycinnamic acid 
ax    axial 
bidest    double distilled  
BMI    body mass index [kg/m2] 
bw    body weight 
°C    degree celsius 
c    centi (10-2) 
CA    caffeic acid 
CAG    caffeic acid glucuronide 
CAS    caffeic acid sulfate 
CFQA    caffeoylferuloylquinic acid 
CGA    chlorogenic acid 
CinA    cinnamic acid 
CoA    coenzyme A 
COMT    catechol-O-methyltransferase 
CQA    caffeoylquinic acid 
CQA15L   caffeoylquinic acid-1,5-lactone 
CQAS    caffeoylquinic acid sulfate 
CQL    caffeoylquinic acid lactone, caffeoylquinide 
DAD    diode array detection 
DC    decarboxylation 
DH    dehydrogenase 
DHCA    dihydrocaffeic acid 
DHCAG   dihydrocaffeic acid glucuronide 
DHCAS   dihydrocaffeic acid sulfate 
DHFA    dihydroferulic acid 
DHFAG   dihydroferulic acid glucuronide 
DHFAS   dihydroferulic acid sulfate 
DHiFA    dihydroisoferulic acid 
DHiFAG   dihydroisoferulic acid glucuronide 
DHiFAS   dihydroisoferulic acid sulfate 
diCQA    dicaffeoylquinic acid 
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diMeDHCA   dimethoxydihydrocaffeic acid 
DiMeCA   dimethoxycaffeic acid 
DMeOX   demethoxyesterase 
DMSO    dimethylsulfoxide 
e.g.    for example, exempli gratia 
eq    equatorial 
ESI    electrospray ionization 
EST    esterase 
et al.    et alii 
EtOH    ethanol 
f    femto (10-15) 
FA    ferulic acid 
FAG    ferulic acid glucuronide 
FAS    ferulic acid sulfate 
FIA    flow injection analysis 
FQA    feruloylquinic acid 
FQA15L   feruloylquinic acid-1,5-lactone 
FQAG    feruloylquinic acid glucuronide 
FQAS    feruloylquinic acid sulfate 
g    gram 
GIT    gastrointestinal tract 
h    hour 
HCl    hydrochloric acid 
HCOOH   formic acid 
HPLC    high performance (pressure) liquid chromatography 
HPLC-ESI-MS/MS high performance-electrospray ionization-tandem mass 
spectrometry 
iFA    isoferulic acid 
iFAG    isoferulic acid glucuronide 
iFAS    isoferulic acid sulfate 
J    coupling constant 
Keap1    Kelch Like ECH Associated Protein 1 
kg    kilogram 
l    liter 
m    meter 
m    milli (10-3) 
M    molar (mol/L) 
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mCoA    meta-coumaric acid 
mCoAG   meta-coumaric acid glucuronide 
mCoAS   meta-coumaric acid sulfate 
mDHCoA   meta-dihydrocoumaric acid 
mDHCoAG   meta-dihydrocoumaric acid glucuronide 
mDHCoAS   meta-dihydrocoumaric acid sulfate 
MeCN    acetonitrile 
MeDHFA   methyldehydroferulic acid 
MeFA    methylferulic acid 
MHz    megahertz 
min    minute 
mol    SI unit for an amount of substance 
MRM    multiple reaction monitoring 
MS    mass spectrometer, mass spectrometry 
MS/MS   tandem mass spectrometry 
µ    micro (10-6) 
n    variable quantity 
n    nano (10-9) 
Nrf2    NF-E2 p45 subunit-related factor 2  
NMR    nuclear magnetic resonance 
NRC    Nestlé Research Center 
nm    nanometer 
oCoA    ortho-coumaric acid 
oDHCoA   ortho-dihydrocoumaric acid 
p    pico (10-12) 
p.a.    pro analysis 
pCoA    para-coumaric acid 
pCoAG   para-coumaric acid glucuronide 
pCoAS   para-coumaric acid sulfate 
pCoQA   para-coumaroylquinic acid 
pCoQA15L   para-coumaroylquinic acid-1,5-lactone 
pDHCoA   para-dihydrocoumaric acid 
pDHCoAG   para-dihydrocoumaric acid glucuronide 
pDHCoAS   para-dihydrocoumaric acid sulfate 
pH pH    negative decimal logarithm of the hydrogen ion activity in a  
solution (potentia hydrogenii) 
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pKS    logarithm of the acid dissociation constant 
Q    quadrupole 
QA    D-(-)-quinic acid 
RA    reductase 
RP    reversed phase 
rpm    rotations per minute 
RT    room temperature 
s    second 
SD    standard deviation 
SIDA    stable isotope dilution analysis  
SPE    solide phase extraction 
ST    sulfuryl-O-transferase 
T    temperature 
UDP-GT   uridindiphosphate glucuronosyl transferase 
UV    ultra-violet 
Vis    visible 
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Summary 
Chlorogenic acids (CGA) are phenolic compounds that form during the esterification of 
certain trans-cinnamic acids with (-)-quinic acid. According to several human intervention 
studies, they may have potential health benefits. Coffee is the main source of CGA in human 
nutrition, and is consumed either alone or in combination with a variety of foods. For this 
reason, the presented study aimed to clarify whether the simultaneous consumption of food, 
for example, a breakfast rich in carbohydrates, with instant coffee affects the absorption and 
bioavailability of CGA. The research specifically focused on how various food matrices, 
which are consumed at the same time as a coffee beverage, will influence kinetic parameters 
such as area under the curve (AUC), maximum plasma concentration (cmax), and time 
needed to reach maximum plasma concentration (tmax). 
In a randomized crossover study, fourteen healthy participants consumed either pure instant 
coffee or coffee with a carbohydrate- or fat-rich meal. All of the subjects consumed the same 
quantity of CGA (3.1 mg CGA/kg body weight). Blood samples, collected at various time 
points up to 15 h after instant coffee consumption, were quantitatively analysed. Additionally, 
three urine collection intervals were chosen over a time period of 24h. High performance 
liquid chromatography electrospray ionization tandem mass spectrometry (HPLC-ESI-
MS/MS) was used to determine the CGA present, along with the concentrations of respective 
metabolites. 
During a blind data review meeting, 20 of the 56 analysed plasma metabolites were chosen 
for further statistical analysis. A total of 36 metabolites were monitored in the urine samples. 
Similar as in the plasma samples,  between-treatment differences, measured through AUC, 
Cmax, and tmax, of various CGA derived metabolites were to estimate. Each treatment was 
also analysed in terms of the correlation between the plasma AUC and urinary excretion of 
seven metabolites. 
It is already known that inter-individual variations in CGA absorption depends on gut 
microbial degradation and affects the efficacy of these compounds. Microorganisms present 
in the gastrointestinal tract metabolise CGA to form dihydroferulic acid (DHFA) and 
dihydrocaffeic acid (DHCA) derivatives, which precede the subsequent formation of a wide 
range of metabolites. Therefore stool samples were collected from the participants within 
12 h before the second study day. Subsequent an ex-vivo incubation of faecal samples with 
5-O-caffeoylquinic acid (5-CQA), the main chlorogenic acid found in coffee was performed. 
An HPLC system connected to a CoulArray® detector was used to measure the 
concentrations of 5-CQA and its metabolites. Reduced concentrations of 5-CQA as well as 
the appearance of DHCA and caffeic acid (CA) in the gut microbiota medium, were 
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monitored to calculate the inter-individual kinetics for each compound. In addition, these 
samples were analysed for microbiota content by an external laboratory (L&S, Bad Bocklet, 
Germany). These results were used to distinguish whether the decreased or increased 
content of a specific microorganism was related to an individual’s decreased or increased 
metabolic efficiency. Finally, we used to aforementioned results to evaluate if any correlation 
could be drawn between the plasma appearance, urinary excretion and ability of 
microorganisms to degrade 5-CQA. 
Strong inter-individual variation was observed for AUC, Cmax and tmax. The AUC measured 
the quantity of CGA in plasma samples. We noted that pure instant coffee consumption 
resulted in slightly higher CGA bioavailability than instant coffee with the additional 
consumption of a meal. However, these differences were not statistically significant. 
Additionally, the metabolites were divided into groups, according to similarity and chemical 
properties. They were further classified into three groups according to their physical structure 
and predicated from the area of appearance: directly from coffee (quinics), after first 
degradation and metabolism (phenolics, all trans-cinammic acids and their sulfates and 
glucuronides) as well as colonic degradation and metabolism (colonics, all dihydro 
compounds). These respective metabolic classes showed significant differences in the AUC 
values of certain classes yet no significant between-treatment differences. Our results 
corroborated earlier studies in that the three caffeoylquinic acid (CQA) isomers were 
absorbed to a lower extent whereas all feruloylquinic acids (FQA) were detected in 
comparably high amounts in the plasma samples of the volunteers. However, the amount of 
these quinic acid conjugates in the plasma samples accounted for only 0,5% of the total 
amount of identified. In contrast, at least 8.7% of the investigated compounds were identified 
to be phenolics.  Dihydro compounds, the so known colonics, were identified as the most 
common metabolites (90.8%). Additionally, dihydroferulic acid (DHFA), meta-
dihydrocoumaric acid (mDHCoA), dihydrocaffeic acid-3-sulfate (DHCA3S) and 
dihydroisoferulic acid (DHiFA) were identified to account for 78% of the studied metabolites, 
and thus represent the most abundant compounds circulating in the plasma after coffee 
consumption.  
Irrespective of treatment, the tmax value for early metabolites (quinic and phenolic 
compounds) was observed between 0 and 2 h after the ingestion of coffee and tmax value for 
late metabolites (colonic metabolites) was observed between 7 and 10 h. The amount of 
colonic metabolites had not returned to the baseline level 15 h after the ingestion of coffee. 
The co-ingestion of breakfast and coffee, when compared to the ingestion of coffee alone, 
significantly increased the Cmax values for all quinic and phenolic compounds, as well as two 
colonic metabolites (DHCA and DHiFA). These differences also revealed that the three 
treatments differed in terms of the kinetics of release. Thus, future studies should use an 
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extended plasma collection time with shorter intervals (e.g. 2 h) to provide a full 
pharmacokinetic profile.  
There were no statistically significant between-treatment differences in the urine samples 
collected 24 h after coffee ingestion. However, urine samples collected within six hours of the 
consumption of coffee alone or in combination with a fat-rich meal showed significantly 
higher CGA quantities than samples collected at the same time point for coffee ingested with 
a carbohydrate-rich. Strong inter-individual variability and the fact that only 14 healthy 
subjects participated in the study hindered the identification of any clear trend between the 
plasma concentrations of metabolites and their excretion in urine.  
Four hours after the ex vivo incubation of 5-CQA with individual faecal samples the sum of 5-
CQA, CA, and DHCA varied strongly between participants. These findings could result from 
binding effects of the phenolic compounds with faecal constituents, further degradation or 
metabolism, and/or the release of bound phenolic substances before the experiment started. 
We hypothesized that for participants with high plasma AUCs of dihydro compounds, their 
incubation samples show also high concentrations of CA and DHCA in the incubation 
medium after four hours. No significant correlation could be found. 
This study and all of the outcomes were exploratory. Due to the limited number of 
participants, we could only investigate tendencies for how the co-ingestion of food affects the 
bioavailability of CGAs and their respective metabolites following coffee consumption. 
Therefore, the achieved results are only indicative. Despite this limitation, the data highlight 
that even though all three treatments had strong similarities in the total bioavailability of 
CGAs and metabolites from instant coffee, there were between-treatment differences in the 
kinetics of release. The co-ingestion of breakfast and coffee favoured a slow and continuous 
release of colonic metabolites while non-metabolized coffee components were observed in 
plasma within the first hour when coffee was ingested alone.  
In conclusion, both a shift in gastrointestinal transit time and the plasma metabolite 
composition were observed when the ingestion of coffee alone or in combination with 
breakfast were compared. These results showed that breakfast consumption induces the 
retarded release of chlorogenic acid metabolites in humans. The data from our human 
intervention study suggest that the bioavailability of chlorogenic acids from coffee and their 
derivatives does not only depend on chemical structure, molecular size and active or passive 
transport ability, but is also influenced by inter-individual differences. Therefore, we strongly 
recommend that future studies include metabolism experiments that focus on microbiota 
genotypes and/or the genotyping of individual subjects. This type of research could be pivotal 
to elucidating whether, and how, genotype affects the metabolic profile after chlorogenic acid 
intake.  
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Zusammenfassung 
Chlorogensäuren (CGA) sind Ester der trans-Zimtsäure und (-)-Chinasäure. Die Ergebnisse 
humaner Interventionsstudien weisen auf einen potentiellen Nutzen dieser Substanzklasse 
für die Gesundheit hin. Kaffee stellt eine der Hauptquellen an CGA in der Ernährung dar. 
Kaffee wird alleine oder in Kombination mit einer Vielzahl an Lebensmitteln konsumiert. Es 
war bisher nicht bekannt, ob der gleichzeitige Konsum mit anderen Lebensmitteln die 
Resorption von CGA aus Kaffee beeinflussen kann. Aus diesem Grund war es das primäre 
Ziel dieser Studie aufzuklären, ob die Aufnahme eines Lebensmittels, beispielsweise eines 
kohlenhydratreichen Frühstücks, gemeinsam mit Kaffee, einen Effekt auf die Absorption und 
Bioverfügbarkeit der CGA zeigt. Der Fokus dieser Forschungsarbeit lag darin, die 
kinetischen Parameter wie die Fläche unter der Kurve (area under the curve (AUC)), die 
maximale Plasmakonzentration (Cmax) und die Zeit, die benötigt wird, um die maximale 
Plasmakonzentration zu erreichen (tmax), zu erfassen.  
In einer randomisierten ’crossover‘-Studie konsumierten vierzehn gesunde Probanden 
entweder Instantkaffee allein oder Instantkaffee zusammen mit einer kohlenhydrat- oder 
fettreichen Mahlzeit. Jeder Proband konsumierte die gleiche Menge CGA bezogen auf sein 
Körpergewicht (3,1 mg CGA / kg Körpergewicht). Blutproben, die zu verschiedenen 
Zeitpunkten bis 15 h nach Kaffeekonsum gesammelt wurden, wurden im Anschluss 
analysiert. Zusätzlich wurden drei Urinsammelzeiträume über 24 h gewählt. 
Hochleistungsflüssigkeitschromatographie-Elektrospray-Massenspektrometrie (HPLC-ESI-
MS/MS) wurde genutzt, um die Konzentrationen der CGA und deren entsprechende 
Metaboliten zu bestimmen.  
Während einem ’blind data review‘ wurden 20 der 56 analysierten Plasmametaboliten für 
weitere statistische Analysen ausgewählt. In den Urinproben wurden insgesamt 36 
Metaboliten erfasst und ebenso wie im Plasma die Unterschiede der jeweiligen 
Darreichungen, gemessen an der AUC, Cmax, und tmax verschiedener CGA und ihrer 
Metaboliten, ermittelt. Für jede Darreichung wurden sieben Metaboliten zusätzlich auf ihre 
Korrelation von AUC im Plasma und auf die renale Ausscheidung hin untersucht. 
Es ist bekannt, dass interindividuelle Unterschiede der CGA-Absorption und die Wirksamkeit 
dieser Verbindungen von einem mikrobiellen Abbau abhängen. Mikroorganismen, die im 
Gastrointestinaltrakt lokalisiert sind, sind dazu in der Lage, CGA zu Dihydroferulasäure 
(DHFA) und Dihydrokaffeesäure (DHCA) zu metabolisieren. Diese Derivate gehen einer 
großen Anzahl im Organismus gebildeter Metaboliten voraus. 12 h vor dem zweiten 
Studientag wurden Stuhlproben von jedem Probanden gesammelt und im Anschluss wurde 
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eine ex vivo-Inkubation mit Faecesproben und 5-O-Caffeoylchinasäure (5-CQA) 
durchgeführt. Ein HPLC-System mit CoulArray®-Detektor wurde verwendet, um die 
Konzentrationen von 5-CQA und seinen Metaboliten zu bestimmen. Die ermittelten 
Konzentrationen von 5-CQA, DHCA und Kaffeesäure (CA) im Darm-Mikrobiota-Medium (gut 
microbiota medium (GMM)) wurde genutzt, um die interindividuellen Kinetiken jeder 
Substanz zu bestimmen. Zusätzlich wurden die einzelnen Proben auf ihre mikrobielle 
Zusammensetzung hin in einem externen Labor (L&S, Bad Bocklet, Germany) untersucht. 
Diese Ergebnisse wurden genutzt, um erniedrigte oder erhöhte Gehalte an spezifischen 
Mikroorganismen in individuellen Proben mit den Ergebnissen der ex vivo-Inkubation zu 
vergleichen. Es war von Interesse, ob erhöhte Gehalte an spezifischen Mikroorganismen zu 
einem erhöhten Abbau von 5-CQA und somit zu einem vermehrten Auftreten von DHCA und 
CA führten. Schließlich wurden diese Ergebnisse genutzt, um mögliche Korrelationen 
zwischen dem Auftreten der CGA Metaboliten im Plasma, deren renale Ausscheidung und 
der Fähigkeit der Mikroorganismen 5-CQA abzubauen, zu evaluieren.  
Starke interindividuelle Unterschiede wurden für AUC, Cmax und tmax beobachtet. Es war zu 
beobachten, dass der Konsum von Instantkaffee allein in einer gering erhöhten AUC, im 
Vergleich zum Verzehr des Kaffees in Kombination mit einer Mahlzeit, resultierte. Diese 
Ergebnisse zeigten allerdings keine statistische Signifikanz. Die Metaboliten wurden in 
verschiedene Klassen eingeteilt. Die Einteilung erfolgte nach physikalischer Struktur und 
chemischen Eigenschaften, sowie der Erscheinung und dem Ort der Modifikation: quinics 
schlossen die Substanzen ein, die schon im Kaffee detektiert werden konnten, phenolics 
(trans-Zimtsäuren und deren Sulfate und Glucuronide) beinhalteten alle Substanzen, die 
einem ersten Abbau und Metabolismus unterlagen und colonics (alle Dihydro-Verbindungen) 
stellten die Klasse an Substanzen dar, die einem weiteren Abbau und Metabolismus im 
Kolon unterlagen. Für die entsprechenden Metabolitklassen, konnten signifikant 
unterschiedliche AUC-Werte für bestimmte Klassen, aber nicht zwischen den Darreichungen 
ermittelt werden. Unsere Ergebnisse bestätigen ältere Untersuchungen, bei denen die drei 
Caffeoylchinasäureisomere (CQA) zu einem geringeren Anteil absorbiert wurden als die 
entsprechenden Feruoylchinasäureisomere (FQA). Die Gehalte der quinics in den 
Plasmaproben wurden jedoch nur als 0,5% der Gesamtmenge erfasst. Im Gegensatz dazu 
waren 8,7% aller untersuchten Substanzen phenolics. Colonics wurden als meist 
vorkommende Metaboliten mit 90,8% identifiziert. Zusätzlich wurden Dihydroferulasäure 
(DHFA), meta-Dihydrocumarsäure (mDHCoA), Dihydrokaffeesäure-3-Sulfat (DHCA3S) und 
Dihydroisoferulasäure (DHiFA) mit 78% aller untersuchten Metaboliten, als die 
Hauptmetaboliten, die nach Kaffeekonsum im Plasma zirkulieren, identifiziert. 
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Ungeachtet der Darreichung war tmax für die frühen Metaboliten (quinics und phenolics) 
zwischen 0 und 2 h und tmax für die späten Metaboliten (colonics) zwischen 7 und 10 h nach 
der Kaffeeaufnahme. Die Gehalte der colonics, waren innerhalb von 15 h nach 
Kaffeekonsum nicht zum Basislinienlevel zurückgekehrt. Die kombinierte Aufnahme von 
Kaffee mit Frühstück im Vergleich zu Kaffee ohne Frühstück führte zu einer signifikanten 
Abnahme von Cmax für alle quinics und phenolics sowie zwei der im Kolon gebildeten 
Metaboliten (DHCA and DHiFA). Es zeigte sich, dass sich die drei Darreichungen in der 
Kinetik der Freisetzung unterschieden. Daher sollte bei zukünftigen Studien verlängerte 
Plasmaprobennahmen in kürzeren Intervallen (z. B. 2 h) erfolgen, um ein vollständiges 
pharmakokinetisches Profil zu erhalten.  
Für die unterschiedlichen Darreichungen konnten keine statistisch signifikanten Unterschiede 
zwischen den 24 h-Sammelurinproben festgestellt werden. Jedoch wiesen Urinproben, die 
innerhalb der ersten sechs Stunden nach Kaffeekonsum allein oder in Kombination mit einer 
fettreichen Mahlzeit gesammelt wurden, signifikant höhere CGA-Gehalte, als die Proben, die 
im gleichen Zeitraum nach Kaffeekonsum in Kombination mit einer kohlenhydratreichen 
Mahlzeit gesammelt wurden, auf. Starke interindividuelle Schwankungen und die Tatsache, 
dass nur 14 Probanden an der Studie teilgenommen haben, erschwerten die Ermittlung 
eines klaren Trends zwischen den Plasmakonzentrationen der Metaboliten und deren renaler 
Ausscheidung.  
Die Ergebnisse der Inkubationen zeigten nach einer Inkubationszeit von vier Stunden (5-
CQA mit den Stuhlproben) stark variierend Gehalte von 5-CQA, CA und DHCA zwischen den 
einzelnen Proben. Diese Beobachtung könnte durch Bindungseffekte der phenolischen 
Substanzen an fäkalen Bestandteilen, weiterem Abbau oder Metabolismus und / oder der 
Freisetzung von bereits vor dem Experiment gebundenen phenolischen Substanzen erklärt 
werden. Zur Untersuchung möglicher weiterer Korrelationen wurden die Einzel-AUC-Gehalte 
der Dihydroverbindungen im Plasma der Probanden in hohe und niedrige Gehalte unterteilt. 
Im Anschluss wurde untersucht, ob entsprechende Inkubationsproben gleicher Probanden 
hohe bzw. niedrige Konzentration von CA und DHCA im Inkubationsmedium aufwiesen. Es 
konnte keine Korrelation nachgewiesen werden.  
Diese Studie und alle erhaltenen Ergebnisse sind als Pilotstudie zu sehen. Aufgrund der 
eingeschränkten Anzahl an Teilnehmern konnten nur Tendenzen für den Effekt eines 
Lebensmittels auf die Bioverfügbarkeit von CGAs und deren Metaboliten aus Kaffee 
beobachtet werden. Deshalb sind die gezeigten Ergebnisse nur indikativ. Trotz dieser 
Einschränkung ist hervorzuheben, dass die gezeigten Daten keinen Einfluss des Frühstücks 
auf die Bioverfügbarkeit der CGA und ihrer Metaboliten aus Kaffee aufwies, aber ein 
bedeutender Unterscheid in deren Kinetik der Resorption vorlag. Die kombinierte Aufnahme 
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eines Frühstücks mit Kaffee führte zu einer verlangsamten und kontinuierlichen Bildung der 
Kolonmetaboliten. Die nicht-metabolisierten Chlorogensäuren aus Kaffee wurden hingegen 
innerhalb der ersten Stunde nach Kaffeeverzehr im Plasma nachgewiesen.  
Zusammenfassend konnten, beim Vergleich der Ergebnisse der verschiedenen 
Darreichungen, sowohl Verschiebungen der gastrointestinalen Transitzeit als auch der 
Zusammensetzung der Plasmametaboliten festgestellt werden. Der Frühstückverzehr führte 
zu einer verzögerten Resorption der Chlorogensäuren im Menschen. Die Daten unserer 
Humanstudie zeigten, dass die Bioverfügbarkeit von CGA aus Kaffee nicht nur von der 
Struktur, der Molekülgröße und aktiver oder passiver Transportfähigkeit des Gewebes des 
Organismus abhängt, sondern oder auch von individuellen Unterschieden des Probanden. 
Deshalb empfehlen wir, dass zukünftige Metabolismusexperimente die Typisierung der 
Mikrobiota und / oder die Genotypisierung eines Individuums, beinhalten. Diese Forschung 
könnte entscheidend sei, um zu klären, ob und wie, die Zusammensetzung der Mikrobiota 
als auch der Genotyp eines Individuums den Metabolismus und die Bioverfügbarkeit von 
Chlorogensäuren beeinflussen können. 
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1 Introduction 
Classically, chlorogenic acids (CGA) are a family of esters formed between certain trans 
cinnamic acids and (-)-quinic acid [Clifford, 1999, Clifford, 2000, IUPAC, 1969]. The cinnamic 
acid conjugates are known to occur widely in dicotyledenous plants [Mølgaard&Ravn, 1988], 
especially in coffee. Previous studies have investigated, and linked, physiological effects 
such as free-radical scavenging, metal chelation, modulation of signal transduction, gene 
expression, modulation of enzymatic activity, and activation of transcription factors to the 
CGAs [Nardini et al., 2002]. Also Coffee, one of the most popular beverages worldwide, has 
been widely studied in many scientific reports for its potential effect on health [Natella et al., 
2002]. Recent epidemiological studies indicate that coffee consumption reduces the risk of 
degenerative diseases such as type 2 diabetes [Nyambe-Silavwe and Williamson, 2016], 
cardiovascular disease, or cancer [Zhang et al., 2009]. To date, the specific coffee 
ingredients that are associated with these effects have not been adequately established.  
Coffee is rich in several different compounds including the main coffee antioxidants, the 
chlorogenic acids (CGAs) [Stalmach et al., 2006]. Caffeic, ferulic, and p-coumaric acids react 
with quinic acid to form a range of conjugates respectively caffeoylquinic acids (CQAs), 
feruloylquinic acids (FQAs), and p-coumaroylquinic acids (p-CoQAs) [Clifford et al., 2000]. 
Although coffee alkaloids, like trigonelline, roasting products such as melanoidins, and the N-
methylpyridinium ion in particular, are considered antioxidants [Lemanska et al., 
2001].Nevertheless, physiological effects such as free-radical scavenging, metal chelation, 
modulation of signal transduction, gene expression, modulation of enzymatic activity, and 
activation of transcription factors, have been studied and linked to the CGAs [Nardini et al., 
2002]. 
Bioavailability is extremely important for assessing the preventive efficacy effects of coffee 
consumption. Studies have focused on the bioavailability of hydroxycinnamic acids and their 
derivatives in rodents and mammals. For instance, Azuma et al. found glucuronide and 
sulphate conjugates of caffeic and ferulic acid in rat plasma after consumption of caffeic acid, 
whereas ingested 5-CQA was found almost exclusively in the small intestine [Azuma et al., 
2000]. To date, only a limited number of studies in humans have investigated the systemic 
circulation after absorption of coffee CGAs [Erk et al., 2013, Renouf et al., 2014, Stalmach et 
al., 2009]. In a study by Olthof et al., 5-CQA is poorly absorbed in the human small intestine 
[Olthof et al., 2003]; the prevailing microbiota degrade it prior to absorption [Plumb et al., 
1999], metabolizing it into hippuric acid [Olthof et al., 2003]. In addition, Rechner and 
coworkers observed glucuronide as well as sulfate conjugates of caffeic acid (CA) in plasma 
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samples of five volunteers after coffee consumption (in sum 449.1 mg, quantified relative to 
5-CQA). In addition, free acids as well as glucuronides and sulfates of ferulic (FA), iso-ferulic 
(iFA), methylferulic (MeFA) and hippuric acids were detected in urinary samples of these five 
probands and were concluded as specific biomarkers for the bioavailability and metabolism 
of dietary caffeic acid (CA) esters [Rechner et al., 2001]. The colonic degradation and 
metabolism is well investigated by Ludwig and coworkers. Up to 6 h, they investigated the 
identity and quantity of breakdown products generated during incubation of espresso coffee 
with human fecal samples. They detected 11 catabolites with dihydrocaffeic, dihydroferulic, 
and 3-(3´-hydroxyphenyl)propionic acids as the major end products, comprising 25 – 75% of 
the total catabolites [Ludwig et al., 2013]. In another study, increases in free and conjugated 
caffeic acid, but no CQAs, were reported in human plasma [Nardini et al., 2002]. Monteiro et 
al. detected inter-individual variations of CGA concentrations in plasma after coffee 
consumption [Monteiro et al., 2008]. Farah et al. detected 30% hydroxycinnamic acids in 
plasma after consumption of encapsulated green coffee [Farah et al., 2008]. In volunteers, 
29% of the CGAs consumed in coffee were detected as metabolites, like dihydroferulic acid, 
dihydrocaffeic acid-3-sulphate, and -4-sulphate in urine [Stalmach et al., 2009]. These results 
were confirmed by a study with ileostomy subjects investigating CGA absorption and 
metabolism in a dose-response manner [Erk et al., 2012]. In summary, the absorption or 
non-absorption of the CGA in the small intestine is mainly depending on the chemical 
structure and any attached chemical groups. The absorbed substrates may appear in plasma 
as methylated, sulphated and glucuronidated derivatives or as unchanged molecules. When 
the CGA were not absorbed and reach the colon, they are substrates for extensive 
catabolism by colonic microbiota. Subsequent absorption in the colon results in similar 
derivatives in plasma like found already after absorption in the small instetine or as glycine 
derivatives [Williamson and Clifford, 2017].  
A majority of the German population daily consumes coffee or its products during breakfast. 
However, at present, data regarding the influence of food consumption on CGA absorption 
and availability is limited. For example, one study found that milk did not affect bioavailability 
parameter of CGAs from coffee; instead non-dairy creamer showed a delayed tmax of CGAs 
[Renouf et al., 2010]. Additionally, there is currently no data available regarding the effects of 
consumed food composition on absorption rates and excretion of CGAs after coffee 
consumption. As coffee is one of the most popular beverages worldwide and oftentimes 
consumed in combination with food, we performed a human intervention study with healthy 
volunteers who consumed only coffee (T1), coffee with a carbohydrate-rich breakfast (T2), 
and coffee with a fat-rich breakfast (T3). Blood and urine samples were collected and 
analyzed for information on absorption, body distribution, and excretion. We have observed, 
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for the first time, the absorption and excretion of coffee ingredients (CGAs and their 
derivatives) as affected by food matrix simultaneously consumed with coffee.  
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2 State of knowledge 
2.1 Phenolcarbonic acids - Classification, occurence, role 
Phenolcarbonic acid is a general term for phenolic compounds such like hydroxycinnamic 
acids and hydroxybenzoic acids as well as their derivatives (see Figure 1).  
hydroxybenzoic acids R1 R2 hydroxycinnamic acids R1 R2 
 
GA OH OH 
 
pCoA H H 
PA OH H FA H OCH3 
SyA OCH3 OCH3 SA OCH3 OCH3 
VA OCH3 H CA H OH 
Figure 1 Chemical structures of hydroxycinnamic (pCoA: p-coumaric acid, FA: ferulic acid, SA: 
sinapinic acid, CA: caffeic acid) and hydroxybenzoic acids (GA: gallic acid, PA: protocatechuic 
acid, SyA: syringic acid, VA: vanillic acid) [after Watzl, 2001] 
 
Caffeic acid (CA, 3,4-dihydroxycinnamic acid), p-coumaric acid (pCoA, trans-4-
hydroxycinnamic acid) and ferulic acid (FA, 4-hydroxy-3-methoxycinnamic acid) are 
representative for hydroxycinnamic acids, and gallic acid (GA, 3,4,5-trihydroxybenzoic acid) 
and vanillic acid (VA, 4-hydroyx-3-methoxybenzoic acid) for hydroxybenzoic acids. Their 
main occurrence is in fruits of rosaceae, potatoes, red wine and coffee as free compounds or 
as esters of acids, sugars and alcohols [Mattila&Hellström, 2007, Römpp, 1996]. Mostly, 
hydroxycinnamic acids are esterified with quinic acid (QA) what give rise to a new substance 
class, for example the quinic acid esters with trans-CA called caffeoylquinic acids (CQA) (see 
Figure 2) [Clifford, 1999]. 
 
Figure 2 Chemical structure of 5-O-caffeoylquinic acid (5-CQA) 
Additionally, esters from pCoA with QA (p-coumaroylquinic acid, pCoQA) and FA with QA 
(feruloylquinic acid, FQA) exist in plants. These three QA ester groups belong to the so 
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called family of chlorogenic acids (CGA). In addition to the monoesters, there is also the 
presence of diesters in plants. Diesters comprise either two molecules of the same 
hydroxycinnamic acid or an alloy. For example two molecules of CA esterified with QA make 
dicaffeoylquinic acid (diCQA) and an alloy of CA and FA, generates a caffeoylferuloylquinic 
acid (CFQA) [Clifford, 1999]. Possible positions for conjugations are: 1,3- 1,4-, 1,5-, 3,4- and 
3,5-diCQA or the correlated CFQA [ChemSpider]. 
 
2.1.1 Biosynthesis of chlorogenic acids 
Chlorogenic acids are formed via the shikimate pathway, which is also important for the 
biosynthesis of specific amino acids. At this pathway, phosphoenol pyruvate (PEP) and 
erythrose-4-phosphate (E4P) are precipitated and after seven metabolic steps converted into 
chorismate, the precursor of many aromatic secondary metabolites is formed only in 
microorganisms and plants, never in animals (see Figure 3): After condensation of PEP and 
E4P the shikimic acid pathway intermediate 3-dehydroquinate occurs. It is transformed into 
quinic acid (QA) or after a number of two steps into shikimic acid. Via shikimate-5-phosphate 
chorismate is formed [Stryer, 1995], where the pathway bifurcates into the formation of 
tyrosine and phenylalanine, respectively. Thereby the different hydroxycinnamic acids are 
formed. This final biosynthesis steps occurs via the phenylpropanoid pathway. After 
deamination of phenylalanine by ammonium lyase, trans-cinnamic acid is formed. pCoA is 
hydroxylated at position C-4 and by hydroxylation at position C-3 CA is formed. Catechol-O-
methyl transferase (COMT) methylates CA to FA, which is finally transformed into sinapic 
acid [Dixon et al., 2002]. Last step is the formation of different mono esters, like 5-CQA, 5-
FQA or 5-pCoQA: After coupling of trans-cinnamic acid to coenzyme A (CoA) by CoA lyase, 
followed the transfer to QA by hydroxycinnamoyl CoA shikimate/quinate hydroxycinnamoyl 
transferase [Farah et al., 2006, Lepelley et al., 2007]. The subsistence of the 3- and 4-
isomers may be based on acyl migration [Farah&Donangelo, 2006]. 
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Figure 3 Biosynthesis of CGA in plants via shikimat and phenylpropanoid pathway (*via 
catechol-O-methyl transferase (COMT)) [modified after [Farah&Donangelo, 2006]. 
 
* * 
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2.1.2 Occurrence and intake 
In comestible goods, hydroxycinnamic acids are present in higher amounts in a large number 
of fruits and vegetables. Fruits like apples, grapes and blueberries, vegetables like lettuce, 
spinach and broccoli and cereal brans are rich in hydroxycinnamic acids (see Table 1) 
[Clifford, 1999, Phenolexplorer]. 
Table 1 Exemplary amounts of phenolic acids and derivatives in selected foodstuffs; FW: fresh 
weight. DW: dried weight. 
Comestible goods amount references 
apple 3 – 57 mg/100 g FW Dragovic-Uzelac et al., 2005, 
Mattila&Kumpulainen, 2002, 
Möller&Herrmann, 1983, van 
der Sluis et al., 2001, van 
der Sluis et al., 2002, 
Vrhovsek et al., 2004 
aronia berry 103 mg/100 g FW Mattila et al., 2006 
artichoke heads 202 mg/100 g FW Romani et al., 2006 
peanuts 106 mg/100 g FW Mattila&Hellstrom, 2007 
bilberry 3 – 85 mg/100 g FW Ehala et al., 2005, Mattila et 
al., 2006 
Arabica coffee beverage 89 mg/100 mL Moreira et al., 2005 
Robusta coffee beverage 205 mg/100 mL Moreira et al., 2005 
Instant coffee Nestlé Green 
Blend® 
10.26 g/100 g DW Witt, 2015 
potato peel 32-636 mg/100 g FW Weidel, 2014 
potato flesh 7-306 mg/100 g FW Weidel, 2014 
white wine 2 – 10 mg/100 ml Frankel et al., 1995, Minussi 
et al., 2003, Rodrı́guez-
Delgado et al., 2001, 
Teissedre&Landrault, 2000, 
Tinttunen&Lehtonen, 2001 
salad (lollo rosso) 52 mg/100 g FW Mattila&Hellstrom, 2007 
   
 
2 State of knowledge 
8 
 
Comestible goods amount references 
common wheat, refined flour 0 – 10 mg/100 g FW Adom et al., 2005, 
Selinheimo et al., 2006 
hard wheat, refined flour 14 mg/100 g FW Lempereur et al., 1997 
spearmint, dried 613 – 1491 mg/100 g FW Kivilompolo&Hyötyläinen, 
2007, Wang et al., 2004 
 
Coffee and potatoes represent the major sources of phenolic acids. The available 
epidemiological data allows no exact calculation of the daily intake for CGA, but it is well 
known that coffee and coffee products play an important role due to the large CGA content in 
coffee. According to the different human diets, the daily CQA intake ranges between 100 mg 
and up to 1 g [Clifford&Knight, 2004]. 
Radtke and coworkers calculated a mean intake of phenolic acids of 222 mg/d in a Bavarian 
human subgroup (63 woman and 56 men, age 19 – 49 years), though there was a large 
range from 9 – 989 mg/d [Radtke et al., 1998]. Likewise, they reported a higher intake of 
hydroxycinnamic acids (211 mg/d thereof 205 mg CA/d) compared to hydroxybenzoic acids 
(11 mg/d). Coffee consumption of woman exceeds that of men, so that the gender 
dimorphism for CA intake is a factor of 1.3 higher for woman. The intake of the other phenolic 
acids such as vanillic or sinapinic acid is higher for men than for woman. A reason could be 
the different diet of the two genders. Cereal bran, which is rich in FA, is oftentimes not 
considered for the overall intake. Therfore, it is possible that the amount of real intake is far 
higher [Radtke et al., 1998]. Further findings of a Finnish study reported in a daily intake of 
641 ± 363 mg phenolic acids, and a total intake of 863 ± 415 mg/d as sum of all polyphenols. 
Here again, CA was the main phenolic acid with 417 ± 325 mg/d. In addition, FA from cereal 
bran was considered and calculated with 120 ± 60 mg/d, as the second most consumed 
hydroxycinnamic acid after CA [Ovaskainen et al., 2008]. 
Wide ranges of phenolic acid intake amounts results from different diets and diverse pattern 
in food. Cultivar, season, cultivation and ripeness of the fruits and vegetables have an 
influence on quantities. Secondly, the processing changed the distribution pattern and 
content of CGA, whereat raw products usually have higher contents [Radtke et al., 1998]. 
 
2.1.2.1 Coffee and the influence of roasting and brewing on 
chlorogenic acid contents 
Coffee is a beverage prepared by brewing from the roasted and grinded seeds of the coffee 
plant. Also, the row or roasted seeds of several species of a small evergreen bush of the 
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family Rubiacea of the biological genus Coffea, are called coffee. Coffee is among the most 
widely consumed beverages in the world [Belitz et al., 2009]. In Germany, 162 L per capita 
were consumed in 2014 [deutscher Kaffeverband]. 
Coffee is native to Africa, more precisely the contemporary Ethiopia. By the 16th century, it 
had reached the rest of the Middle East, then Constantinople and Venice. By the middle of 
the 17th century, coffee was widely consumed across all over Europe. Today, averages of 
140 million bags coffee containing 60 kg are collected per year [deutscher Kaffeeverband]. 
Almost the half of the worldwide produced coffee comes from Brazil and Vietnam.  
Preferentially, the coffee plant grows in high tropical altitude as evergreen shrubs or small 
trees, which are 3 – 12 m tall when unpruned. Such, used for harvesting, are pruned to keep 
them 2 – 2.5 m height. At the beginning, jasmine-like fragrant flowers prosper. These flowers 
turn into the stone fruits, the so called coffee berries. The fruit of berry has a green outer 
skin, which with increasing maturation colored red-violet till deep red. The ripe coffee berries 
were hand-picking harvested one or two times a year. Different varieties of the 70 Coffea 
species exist. The two most commonly grown are the Coffea arabica with 75% of worldwide 
production, and the Coffea canephora (the so called Robusta) with 25% [Belitz et al., 2009].  
Pre preparation of coffee beverage, the processing methods of coffee berries occur in one of 
two processes: dry/natural or wet. At the dry process the whole fruit is spread out on sun-
drying terraces, whereat the flesh of the berries peels off and also the parchment and the 
silver skin. After that, dehulled and cleaned coffee beans are classified, packed and shipped 
away. The wet process is more sophisticated and used for premium-priced coffee beans. 
Freshly harvest beans are brought to a pulper, which detaches the skin and the pulp without 
damaging the seed. During this process, the silver skin is still preserved. Beans are carried 
into water stream fermentation tanks, the water is drained off and the beans are left to 
ferment. After collection, the beans are dried, processed by dehulling machines, packed and 
shipped [Belitz et al., 2009]. 
After arrival of dried, green coffee beans in the coffee roasting facility, a heat treated process 
called roasting is used, which forms the delightful aroma and taste. Roasting process 
consists of four major phases: drying, development, decomposition and full roasting. Finally, 
these phases result in denaturation of proteins, evaporation of water, changes in structure 
and color and an increase in volume of the beans. Heat is transferred either by ‘contact 
roasting’ or by ‘contact convection’. ‘Contact roasting’ uses direct contact of the beans with 
the walls of the roasting equipment. ‘Contact convection’ means, that hot air pass through 
the beans. The roasting process is characterized by degradation of existent and formation of 
new compounds. This varies greatly, depending on coffee variety and extent of roasting, and 
also on species of coffee beans. The extent of roasting depends on the wished roast profile 
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to achieve flavor characteristics. The roast temperature can vary between 196°C and 245°C 
[Coffee Glossary]. There is a shift of the amino acid composition caused by degradation 
processes via acidolysis, which results in a decrease of about 30% of solids. The fraction of 
carbohydrates, mainly polysaccharides, fragmented into soluble compounds, however the 
lipid fraction survives the roasting process with only minor changes. The content of 
components like chlorogenic acids (CGA) decreases by roasting, while melanoidins are 
formed via Maillard reaction. Different contents of coffee ingredients for non-roasted and 
roasted coffee of species Coffea arabica and canephora (Robusta) are shown in Table 2 
[Belitz et al., 2009].  
 
Table 2 Composition of green and roasted (medium degree of roasting) Coffea arabica and 
canephora (Robusta)
a,b
 [Belitz et al., 2009]. 
components 
[values in % of solids] 
green coffee roasted coffee 
 Arabica Robusta Arabica Robusta 
carbohydrates 55 – 65.5 40 – 55.5 38.0 41.5 
proteins 8.5 – 12.0 10.0 
chlorogenic acidsc 6.7 – 9.2 7.1 – 12.1 2.6 3.1 
lipids 16.5 10.0 17.0 11.0 
trigonelline 0.6 – 1.2 0.1 – 0.7 
caffeine 0.8 – 1.4 1.7 – 4.0 1.3 2.4 
minerals 3.0 – 5.4 4.6 
melanoidins   23.0 
aroma substances   0.1 
a Values in % of solids. 
b Water content of raw coffee: 7 – 13% 
c Main components: 5-O-caffeoylquinic acid (chlorogenic acid: Arabica 3.0 – 5.6%; Robusta 
4.4 – 6.6%). 
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Influence of roasting and brewing on chlorogenic acid contents 
Coffee is considered as major source for CGA in the human diet. Green coffee contains the 
highest amounts (see Table 2) and is jointly responsible for bitterness, acidness and 
adstringency. The contents range from about 0.8 to 11.9% of dry mass [Campa et al., 2005, 
Farah&Donangelo, 2006]. Approximately 80% of this CGA is represented by caffeoylquinic 
acids (CQA). From the three available CQA-isomers,  3-O-caffeoylquinic acid (3-CQA), 4-O-
caffeoylquinic acid (4-CQA) and 5-O-caffeoylquinic acid (5-CQA), 5-CQA is the major isomer. 
The three di-caffeoylquinic acids (diCQA) isomers are the next most-abundant CGA with up 
to 15%. With up to 6.2% represented the feruloylquinic acid (FQA) isomers a minor group 
[Farah et al., 2005]. During processing, the CGA composition changes, which take part in the 
generation of color, flavor and aroma [Montavon et al., 2003, Trugo&Macrae, 1984]. Total 
CGA contents in commercial roasted coffee ranged from about 0.5 to 7%, according to 
processing, roasting degree, blend and analytical conditions. The content of quinides 
(caffeoylquinic acid lactones) ranges from about 0.4 to 0.5%. Every 1% loss of dry matter, 
leads to 8 to 10% loss of CGA [Clifford, 1999, Clifford, 2000, Clifford et al., 2003, 
Farah&Donangelo, 2006]. CGA are thermally instable, what effect a breakage of the carbon-
carbon bonds and gives completely degraded phenolic derivatives. Table 3 presents the 
contents of CGA in C. arabica Cv. Bourbon (Brazil) in relation to the roasting time. As 
described above, 5-CQA was the major CGA in green coffee with a content of 
3126.1 ± 29.7 mg/100 g. When coffee was roasted for 6 min, isomerization processes 
occurred, followed by a decrease of 5-CQA to 1995.8 ± 19.9 mg/100 g and an increase of 3-
CQA and 4-CQA to 816.1 ± 13.1 mg 3-CQA/100 g (483.3 ± 6.1 mg 3-CQA/100 g in green 
coffee) and 999.6 ± 45.1 mg 4-CQA/100 g (543.5 ± 9.3 mg 4-CQA/100 g in green coffee), 
respectively. Though, 9 min roasting reduced all three isomers to 244.3 ± 17.9 mg 5-
CQA/100 g, 155.8 ± 7.6 mg 4-CQA/100 g and 122.8 ± 3.0 mg 3-CQA/100 g. In this dark 
roasting process, CQA were hydrolyzed and transferred into low molecular weight 
compounds like for example caffeic acid (CA) [Clifford, 2000, Farah et al., 2005, 
Trugo&Macrae, 1984]. Similar results were found for the FQA isomers. 5-FQA was the major 
compound with a content of 210 ± 1.8 mg/100 g in green coffee, whereas 4-FQA was 
determined with a content of 40.1 ± 1.8 mg/100 g and 3-CQA of 28.3 ± 0.9 mg/100 g. After 
6 min roasting, 5-FQA was decreased to 109.1 ± 8.2 mg/100 g and 4-FQA and 3-FQA were 
increased to 68.0 ± 3.8 mg/100 g and 47.8 ± 7.9 mg/100 g, respectively. Intensive roasting 
over 9 min revealed decreased values of 22.1 ± 0.8 mg 5-FQA/100 g, 19.9 ± 1.0 mg 4-
FQA/100 g and 9.7 ± 0.2 mg 3-FQA/100 g. The three diCQA isomers were not isomerized, 
but only degraded from approxametely 250 mg/100 g in green coffee to less than 
10 mg/100 g in dark roasted coffee. Additionally, the roasting process supports the 
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Table 3 Total CGA and CGL amounts for C. arabica Cv. Bourbon (Brazil) and coffee beans 
roasted at different conditions (green, light (6 min of roasting), dark (9 min of roasting); 
T = 230 °C); Results are shown as the means of roasting in duplicates and extractions in 
triplicates ± standard deviation, expressed in mg/100 g of coffee, dry weight, nd: not detected 
[Farah et al., 2005]. 
 green light dark 
3-CQA 483.3 ± 6.1 816.1 ± 13.1 122.8 ± 3.0 
4-CQA 543.5 ± 9.3 999.6 ± 45.1 155.8 ± 7.6 
5-CQA 3126.1 ± 29.7 1995.8 ± 19.9 244.3 ± 17.9 
3-FQA 28.3 ± 0.9 47.8 ± 7.9 9.7 ± 0.2 
4-FQA 40.1 ± 1.8 68.0 ± 3.8 19.9 ± 1.0 
5-FQA 210.7 ± 1.8 109.1 ± 8.2 22.1 ± 0.8 
3,4-DiCQA 236.2 ± 4.0 119.7 ± 2.3 7.4 ± 1.2 
3,5-DiCQA 254.9 ± 4.7 88.6 ± 3.8 5.1 ± 2.7 
4,5-DiCQA 278.9 ± 12.5 127.8 ± 4.0 9.2 ± 1.8 
3-CQA15L nd 160.2 ± 2.3 95.7 ± 4.7 
4-CQA15L nd 92.1 ± 2.9 53.1 ± 3.5 
3-FQA15L nd 14.1 ± 1.2 21.2 ± 1.9 
4-FQA15L nd 7.0 ± 0.4 7.8 ± 0.3 
3,4-DiCQA15L nd 4.1 ± 0.4 1.0 ± 0.2 
3-p-CoQA15L nd 4.6 ± 0.4 4.4 ± 0.2 
4-p-CoQA15L nd 5.3 ± 0.2 4.0 ± 1.6 
total 5202 ± 70.8 4658.9 ± 115.9 783.5 ± 48.6 
 
transformation of the CGA, diCQA and CoGA into quinides due to dehydration and formation 
of an intramolecular bond [Clifford, 2000, Farah et al., 2005, Trugo&Macrae, 1984]. 
Converted CGA from the green coffee beans formed the corresponding lactones such as 3-
O-caffeoyl-1,5-qunide (3-CQA15L, 160.2 ± 2.3 mg/100 g in light roasted coffee) and 4-O-
caffeoyl-1,5-qunide (4-CQA15L, 92.1 ± 2.9 mg/100 g in light roasted coffee), whereat the 
major compound was 3-CQA15L. Both isomers are shown in Figure 4 Formation of 3- and 4-
O-caffeoylquinide (3-CQA15L and 4-CQA15L) by thermal rearrangement of 4-CQA [after 
Farah et al., 2005].. Additionally, after roasting for 6 min 3-FQA15L (14.1 ± 1.2 mg/100 g), 4-
FQA15L (7.0 ± 0.4 mg/100 g), 3,4-DiCQA15L (4.1 ± 0.4 mg/100 g), 3-p-CoQA15L 
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(4.6 ± 0.4 mg/100 g) and 4-p-CoQA15L (5.3 ± 0.2 mg/100 g) were determined, but also these 
compounds were degraded when coffee was roasted for 9 min [Farah et al., 2005].  
 
 
Figure 4 Formation of 3- and 4-O-caffeoylquinide (3-CQA15L and 4-CQA15L) by thermal 
rearrangement of 4-CQA [after Farah et al., 2005]. 
Table 4 presents more data of CGA contents in commercially more sold Ethiopian green 
coffee beans and coffee beans roasted at different conditions. The conditions are much 
stronger than in the previous experiment, but similar results were observed. 5-CQA is with a 
content of 5070 ± 161 mg/100 g the major CGA in green coffee. During the light roasting 
process (12 min, 230 °C) occurred isomerization brought an increase of 3-CQA and 4-CQA, 
in parallel to decrease of 5-CQA. Stronger roasting conditions caused a decrease of all three 
isomers up to less than 20 mg/100 g in the coffee beans. In contrast to the C. arabica Cv. 
Bourbon (Brazil), 4-FQA is the major compound with a content of 358 ± 8 mg/100 g in green 
coffee, whereas 5-FQA showed a content of 29 ± 0 mg/100 g. During the roasting process, 
4-FQA was decreased and not any longer detectable under city (17 min, 250 °C) and French 
roasting (21 min, 250 °C) conditions. 5-FQA contents increased to 52 ± 2 mg/100 g under 
4-O-caffeoylquinic acid (4-CQA) 
2 State of knowledge 
14 
 
light roasting conditions and decreased under stronger roasting conditions. All diCQA 
isomers were degraded during the roasting process and not any longer detectable under city 
and French roasting conditions. All in all, the total CGA amount was 6909 ± 236 mg/100 g in 
green coffee decreasing to 34 ± 3 mg/100 g in French roasted coffee [Moon et al., 2009]. 
 
Table 4 Total CGA amounts in commercial Ethiopian green coffee beans and coffee beans 
roasted at different conditions (green, light roasted (12 min, 230 °C), medium roasted (14 min, 
240 °C), city roasted (17 min, 250 °C), French roasted (21 min, 250 °C)). Results are shown as 
the means in triplicates ± standard deviation, expressed in mg/100 g of coffee, dry matter 
basis; nd: not detected; * trace or not detected [Moon et al., 2009]. 
 
green light roast medium roast city roast French roast 
3-CQA 208 ± 5 545 ± 10 337 ± 7 38 ± 1 7 ± 1 
5-CQA 5070 ± 161 1511 ± 35 927 ± 18 79 ± 1 16 ± 1 
4-CQA 428 ± 13 756 ± 23 487 ± 10 59 ± 2 11 ± 1 
4-FQA 358 ± 8 128 ± 3 89 ± 2 * nd 
5-FQA 29 ± 0 56 ± 2 42 ± 1 nd nd 
3,4-diCQA 101 ± 5 65 ± 1 29 ± 1 nd nd 
3,5-diCQA 575 ± 30 56 ± 0 21 ± 3 nd nd 
4,5-diCQA 133 ± 14 92 ± 1 40 ± 1 nd nd 
total 6909 ± 236 3209 ± 75 1972 ± 43 176 ± 4 34 ± 3 
 
In Table 5 the total CGA amounts in brewed Coffea arabica and canephora (Robusta) 
beverages are shown. The total amount depends on the type of coffee and is 
87.7 mg/100 mL for coffee Arabica and 204.6 mg/100 mL for coffee Robusta [Moreira et al., 
2005]. Finally, it is of interest which amount of the respective CGA in powder is transferred in 
the brewed beverage, which is described to be more than 90% when a water volume/coffee 
powder ratio of >16 is used [Lang et al., 2013b].  
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Table 5 Total CGA amounts [mg/100 mL] for Coffea arabica and canephora (Robusta) 
beverages [Moreira et al., 2005] 
  Arabica [mg/100 mL] Robusta [mg/100 mL] 
3-CQA N/A 32.3 
4-CQA 19.0 36.5 
5-CQA 43.1 75.8 
4-FQA 13.3 30.1 
5-FQA 4.6 16.6 
3,4-DiCQA 3.5 6.0 
3,5-DiCQA 2.7 4.4 
4,5-DiCQA 1.5 3.1 
sum 87.7 204.6 
   
Next to roasting, the beans undergo different important processing steps until the finished 
coffee beverage is available. The mechanical removement of the flesh from the cherry which 
yields the green coffee bean before roasting per se could have an influence. After roasting, 
the beans are either packed or grounded into a powder and the powder is used to brew the 
coffee beverage with hot water. At each of these processing steps it must be considered that 
the chemical content of the coffee beans change [Matei et al., 2012]. The influence of the 
roasting process of the chlorogenic acid content was well investigated in several studies. In 
contrast, not many data of the influence of brewing of coffee powder with boiling water on the 
CGA pattern are available. For instance, Matei and coworker reported from novel 
compounds to be formed from CGA during the brewing process. Hydroxylation of the 
chlorogenic acid cinnamoyl subsituentd by conjugation of water formed 
hydroxydihydrocaffeic acid derivatives in the first step. As second step acyl-migration 
products were detected, including different caffeoylquinic acid regioisomers, which formed 
finally cis-caffeoylquinic acids via trans-cis isomerization. The quantity of these novel 
compounds in the brewed coffee beverage is not determined yet [Matei et al., 2012]. 
Additionally, a number of people are consuming instant coffee or also be denoted as coffee 
extract. Coffee extract is a solid product offered as powder, grain or flocculation, which 
contains as minimum 950 g dry matter of coffee extract per kilogram. In modern processes, 
the roasted and grounded beans are used in 8 – 12 percolates, whereat the coffee grounds 
are separated and beverage is used for the final product. Separation techniques extract the 
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flavor compounds via an active cooling step. These flavor compounds are readded to the 
final concentrated extract, which is obtained in several extraction and flash evaporation 
steps. The final processing step is spray drying or freeze drying, what agglomerate the coffee 
extract, which can be packed and shipped [Römpp, 1996]. 
Analysis of CGA contents in commercially available instant coffees revealed large variations.  
The investigations included 13 samples from the UK and nine samples from Brazil. For the 
instant coffee samples form the UK, the content was between 3.6 and 10.7% of dry mass, 
whereat the samples from Brazil showed values between 0.6 and 5.9% of dry mass. 
Differences in CGA levels were explained by the use of different roasting degrees and 
different blends. The low content or absence of lactones and diCQAs were explained by a 
hydrolysis or loss during processing [Trugo et al., 1984, Nogeuira et al., 2003, Bennat et al., 
1994]. Based on the beneficial biological effects of various coffee ingredients, such as CGA 
(see Chapter 2.1.5 Physiological effects of hydroxycinnamic acids and their derivatives), the 
manufacturers are anxious to optimize the roasting process in order to protect physiological 
active substances like CGA. For this reason, some manufacturers add green beans to the 
roasted coffee to increas the content of CGA. It is important to consider that the preservation 
of the typical taste and aroma of coffee plays an important role for the consumer 
expectations. An example for such an optimized processed coffee is Nescafé Green Blend® 
– a typical tasting and desirable smelling instant coffee with an elevated amount of CGA. 
 
2.1.3 Absorption, metabolism and bioavailability of 
hydroxycinnamic acids and their derivatives  
An accurate appraisement of the different existent data of the biological effects of 
hydroxycinnamic acids and their derivatives is not possible as long as it is not completely 
clarified which influence potential differences in dosing, interactions with the food matrix, and 
differences in bioavailability may have [Bohn, 2014]. “Bioavailability can be defined as the 
fraction of a nutrition or non-nutrition that is available for the human body for physiological 
functions and/or storage.” [Bohn, 2014, p. 6] For hydroxycinnamic acids and their derivatives 
this process includes the following digestive steps: For the first step, the release of 
hydroxycinnamic acids and their derivatives from the food matrix is of interest. The second 
step investigates the changes in hydroxycinnamic acids and their derivatives during gastric 
and small-intestinal digestion. The third step includes the cellular uptake of aglycons and 
some conjugated hydroxycinnamic acids by enterocytes. The fourth step is the 
microbiological fermentation of non-absorbed hydroxycinnamic acids or their derivatives as 
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well as those re-excreted via bile or the pancreas to yield additional metabolites. Step five 
investigates the phase I and II enzyme modifications that occur upon absorption [Bohn, 
2014]. The main reactions caused by bacteria and phase I (such as cytochrome P450 
monooxygenase, alcohol dehydrogenase, aldehyde dehydrogenase, esterases, and others) 
and II enzymes (such as methyltransferase, sulfotransferase, UDP-glucuronosyltransferase, 
and others) are deglycosylation, dihydroxylation, demethylation, deconjugation [Cermak et 
al., 2006], epimerization, ring cleavage, hydrolysis, and chain-shortening reactions [Ferruzzi, 
2010]. Step six includes the transport in the bloodstream and subsequent tissue 
redistribution. Finally in step seven, the excretion via the kidney or re-excretion into the gut 
via bile and pancreatic juices is of interest [Bohn, 2014]. 
In general, the percentage of absorbed polyphenols is usually low [Konishi et al., 2005]. 
Basically, the absorption may starts in the oral cavity, but due to the short interaction time 
between amylase and polyphenols, the impact of enzymatic digestion is assumed to be low 
[Laurent et al., 2007]. Hydroxycinnamic acids compared with their respective esters are 
basically different in their properties such as molecular size and hydrophilicity, consequently 
different absorption ways may be assumed. Free hydroxycinnamic acids could easily be 
absorbed in the small intestine as well as the colon. Esters mostly have to be hydrolyzed by 
esterases of the small intestine or of the colonic microbiota prior absorption [Mateos et al., 
2006]. 
Absorption in vitro 
In the late 20th and early 21st century, different researchers investigated the absorption of of 
CGA with the aid of in vitro studies with different cells systems. A simple model for the 
possible route for absorption of ingested 5-CQA and CA was published by Konishi and 
Kobayashi (see Figure 5). In Caco-2 cells, in the presence of a proton gradient (apical pH, 
6.0; basolateral pH, 7.4), they observed a considerable amount of CA to be transported to 
the basolateral side, although >99% of apically loaded 5-CQA remained on the apical side. 
Potentially, the transit of CA occurred via paracellular diffusion, by a proton gradient or as 
substrate of a monocarboxylate transporter (MCT). The intestinal transport mechanism of 
CQA was nondistinctive [Konishi&Kobayashi, 2004]. As a substrate for MCT, a monoanionic 
carboxyl group and a nonpolar side chain are necessary structural elements [Rahman et al., 
1999]. CQA seems theoretically to provide the structural criteria to be a MCT substrate, but 
the ester group may impede the interaction.  
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Figure 5 Possible routes (simplified pictured) for absorption in the small intestine of ingested 
5-O-caffeoylquinic and caffeic acid; 5-CQA: 5-O-caffeoylquinic acid, CA: caffeic acid, MCT: 
monocarboxylate transporter, m-CoA: m-coumaric acid, 3-HPPA: 3-(m-
hydroxyphenyl)propionic acid [modified after Konishi&Kobayashi, 2004] 
Recent studies investigated the possible absorption routes with more modern experiemental 
setups. Human-differentiated Caco-2 cell monolayers were used to simulate the 
transformation processes of CGA after reaching the small intestine. The hydrolysis of 
caffeoylquinic and dimethoxycinnamoyl quinic acid, but not feruloylquinic acids, by 
enterocyte, mammalian esterases and pancreatic esterases is potentially a contributing 
mechanism to small intestinal absorption. The hydrolysis is relatively slow and not the entire 
amount of CGA is hydrolysed [Encarnacao et al., 2015]. In Caco-2 cells an absorption rate of 
5-CQA of about 0.1% at physiological concentrations equivalent to gut lumen concentrations 
(0.1 ~ 1 mM) was found. In this experimental setup, the transepithelial transport was 
demonstrated to be bidirectional permeation with no transport into the basolateral side. As 
the permeation rate was concentration-dependent and not saturable, Liang and Kitts 
hypnotized a passive diffusion [Liang and Kitts, 2015]. In cultured gastric epithelial 
monolayers and the Ussing chamber model using ileal pig mucosa, different rates of 
absorption of several CGA have been reported [Erk et al., 2013a]. Hereby, pig mucosa was 
used as it provides strong similarities with the human gastrointestinal tract (GIT) and in 
combination with the Ussing chamber, it mimics the functional and morphological 
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organization of the intestinal epithelium. Across pig mucosa, CGA, metabolites and QA were 
found to be absorbed in the following order: diCQA (trace) < CQA < CA < FQA < QA. Erk 
and coworkers determined only low amounts of esters, especially of CQA, being absorbed. 
The percentage of initially applied CGA that was absorbed through the jejunal pig mucosa 
was approximately 2% for FQA and approximately 1% for CQA depending on the pH. The 
crucial factors for absorption have been suggested to be the molecular weight, hydrophilicity 
and physicochemical properties of the subgroups, as well as the presence of stretchable and 
elastic bonds, such as in QA [Erk et al., 2013a]. All these structure and dose dependency 
were confirmed in Ussing chamber experiments with the human colon carcinoma cell line 
Caco-2 [Müntnich, 2013]. Non-saturable transport and linear dose-flux relationship were 
observed with pig mucosa as well as Caco-2 cells for different CGA at various concentrations 
[Erk et al., 2013a, Scherbl et al, 2014]. 
After absorption to the blood stream, the CGA and free acids arrive in the systemic 
circulation. For interactions, in vitro experiments investigated the binding ability e.g. to bovine 
serum albumin. The distribution of CA occurred coupled with bovine serum albumin by a 
binding ability between 61 to 95%. In contrast, the binding capacity of FA and pCoA to 
bovine serum albumin is proved to have a binding ability of less than 10% [Adzet et al., 
1988]. The strength of binding affinity to human serum albumin follows the order 
CA >> CQA >>> QA [Muralidhara&Prakash, 1995].  
Metabolism in vitro 
For the investigation of compartments and mechanisms, which generate these metabolites, 
different experiments were performed. In vitro studies in Caco-2 cells provided first data of 
hydroxycinnamic acids and derivatives metabolism, respectively. Extra and intra cellular 
esterases hydrolyzed esters and in addition, phase I and II enzymes, such as UDP-
glucuronosyl transferase (UDP-GT) and sulfotransferase (ST), could simulate parts of 
biotransformation in vivo [Kern et al., 2005]. Poquet and coworkers investigated the transport 
of FA across a cell monolayer of co-cultured Caco-2 and HT29-MTX cells in vitro and 
demonstrated the formation of several conjugates, such as ferulic acid sulfate (FAS), ferulic 
acid glucuronide (FAG), and dihydroxyferulic acid (DHFA) [Poquet et al., 2008]. 
Absorption, metabolism and bioavailability in vivo 
Additionally to the various in vitro experiments, different in vivo studies investigated the 
amounts and mechanism of absorption as well as (systemic) availability of CGA. 
Unfortunately, the available data on absorption but especially on metabolism are not 
sufficient and further investigation of CGA metabolism is of importance. As nowadays known, 
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metabolism takes mainly place into the intestinal mucosa, the liver and the kidney. The typ of 
metabolites formed depends on the place of absorption and the kind of enzymes involved 
[Stalmach et al., 2009]. Furthermore, the microbiota, such like Escherichia coli, 
Bifidobacterium lactis and Lactobacillus gasseri, has an importance when talking about 
metabolism. This is discussed in detail in chapter 2.1.4 Influence of the human microbiota on 
the intestinal metabolism of hydroxycinnamic acids and their derivatives.  
Azuma and coworkers demonstrated that in rats only traces of 5-CQA were absorbed from 
the alimentary tract after orally administration of 700 µmol 5-CQA/kg bw. 5-CQA easily 
entered blood vessels after i. p. injection and was afterwards partly metabolized [Azuma et 
al., 2000]. A study with ileostomists demonstrated a comparatively low absorption of 
esterified compounds such as 5-CQA compared to free acids like CA [Olthof et al., 2001]. 
These findings could be approved by a study from Nardini and coworkers, in which ten 
healthy volunteers consumed a coffee beverage (95.8 ± 4.6 mg 5-CQA/200 ml, consumed 
within 10 min after brewing). In the collected plasma samples, a significant rise in free and 
bound plasma CA levels were measured, even if free CA was absent in coffee brews. It was 
argued that 5-CQA is the source of CA in plasma, but it has to be considered that they failed 
to detect 5-CQA in plasma samples. In light of this, Nardini and coworkers could not 
completely excluded that traces of 5-CQA were present in plasma samples below the limit of 
detection, but concluded that CA is bioavailable to humans, even if present in the diet in 
bound forms, such as 5-CQA [Nardini et al., 2002]. Olthof and coworkerss executed 
intervention studies with ileostomists to achieve more information on the absorption of CGA, 
but also CA. They worked with ileostomy subjects, as degradation by the colonic microbiota 
is almost excluded. Thus, a calculation of absorption can take place by substract the amount 
excreted in ileostomy effluent from the ingested amount. After consumption of about 
1000 mg of total CGA from coffee beverage, 67% of the ingested 5-CQA was excreted into 
ileostomy effluents within 24 h. This means, a maximum of 33% of the ingested 5-CQA was 
absorbed in the small intestine of the ileostomists. In contrast, 95% of the ingested CA 
(500 mg) was absorbed [Olthof et al., 2001].  
In further investigations, Rechner and coworkers observed glucuronide as well as sulfate 
conjugates of CA in plasma samples of five volunteers after coffee consumption (in sum 
449.1 mg, quantified relative to 5-CQA). In addition, free acids as well as glucuronides and 
sulfates of ferulic acid (FA), iso-ferulic acid (iFA), methylferulic acid (MeFA) and hippuric acid 
were detected within 24 h in urinary samples of these five volunteers. All these free acids as 
well as conjugates were concluded as specific biomarkers for the bioavailability and 
metabolism of dietary caffeic acid esters [Rechner et al., 2001a]. Stalmach and members 
determined 71 ± 7% CGA and their metabolites in ileal excretions within 24 h after ingestion 
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of 385 µmol CGA. Thereof, 78% were lead compounds whereat 22% were metabolites 
preferrably free and sulfated CA and FA, what argued for a first metabolism step through the 
small intestine. Overall 21 metabolites were determined by Stalmach and coworkers whereof 
only 17 were detectable in urinary samples. The amounts determined in urinary samples 
corresponded with 8 ± 1% of the ingested CGA dose. The observed metabolites are 
summarized and pictured in Figure 6. The main compounds found in urine were FA4S, 
CA3S, iFA3G and DHCA3S. In contrast to the results achieved in ileostomist (8%), urinary 
excretion by humans with an intact colon corresponded to 29 ± 4% of CGA intake. This 
higher amount can be linked by higher levels of DHFA, FAG, DHCAG, DHCAS, DHFAG and 
DHFAS. These findings highlight the high contribution of colonic metabolism to the overall 
pattern of metabolites in healthy people. Additionally, in this study, metabolites in plasma 
were investigated. The major compounds in plasma after 5 h were DHCA, DHCA3S, DHFA 
and DHFA4S. A secondary compound in plasma was the sulfate of CQA15L [Stalmach et al., 
2009, Stalmach et al., 2010]. Not sulfated CQA15L was a substrate for intestinal esterases 
and could be hydrolyzed into CA [Crozier et al., 2012]. The transformation into CA3S 
occured by sulfuryl-O-transferase (ST) after hydrolysis of CGA into CA [Stalmach et al., 
2009]. Additionally, a tissular methylation by COMT to FA and iFA was emphasized [Gonthier 
et al., 2003]. The sulfation of DHCA and DHFA by ST occurred in the liver. In contrast to 
experiments using the human colon carcinoma cell line Caco-2, in vivo the colon mucosa 
was not able to sulfate phenolic acids [Poquet et al., 2008]. The major metabolite of QA is 
hippuric acid formed by aromatization into benzoic acid and subsequent conjugation with 
glycine, whereat the stepwise metabolization of CA could also result in the formation of 
hippuric acid (see Figure 7) [Gonthier et al., 2003]. Microbial reduction followed by sulfation 
in the liver, forms glucuronidation products of primary metabolites by UDP-
glucuronyltransferase (UDP-GT) as well as conjugation of FA with glycine [Gonthier et al., 
2003]. The sulfate/glucuronide-ratio is 5.6 to 1 based on a higher affinity of phenolic acids to 
ST as to UGT [Kern et al., 2003, Stalmach et al., 2010]. Erk and coworkers confirmed these 
results in ileal effluent, but reported additionally that the ratio depends on the ingested 
amount of CGAs. They reported a sulfation/glucuronidation-ratio of 8.2:1 for an ingestion of 
4525 ± 155 µmol total chlorogenic acids, 10.4:1 for an ingestion of 2219 ± 113 µmol total 
chlorogenic acids and 13.4:1 for an ingestion of 1053 ± 40 µmol total chlorogenic acids [Erk 
et al., 2012]. Lang and coworkers performed and human intervention study with 13 healthy 
volunteers who consumed a single cup of coffee beverage (350 mL; 526 mg CGA absolut) 
after a 10-day washout period.  
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Figure 6 Metabolism of CGA after ingestion via coffee by human volunteers. 5-CQA and 5-FQA are the illustrated structures in this figure but 
their respective 3- and 4-isomers as well as 4- and 3-CQA15L would be metabolized in a similar manner; COMT: catechol-O-methyltransferase, 
EST: esterase, RA: reductase, UDP-GT: UDP-glucuronyltransferase, ST: sulfuryl-O-transferase; CoA: coenzyme A; bold arrows indicate major 
routes [modified after [Stalmach et al., 2010]. 
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Figure 7 Proposed catabolic pathway of CGA and its microbial degradation in the colon. EST: 
esterase, RA: reductase, DH: dehydrogenase, DMeOX: demethoxyesterase, DC: 
decarboxylation, COMT: catechol-O-methyltransferase; modified according to [Gonthier et al., 
2003, Ludwig et al., 2013, Stalmach et al., 2009] 
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They observed different pharmacokinetic properties of metabolites that allow a separation of 
metabolites into two groups. With an early appearance in plasma after approximately 1 h, FA 
and FAS were detected. Secondly, particularly CGA metabolites formed by the intestinal 
microbiota, such as DHFA, FAG and DHFAS were determined late and persisted in the 
plasma for 6 h and longer [Lang et al., 2013a]. This is in line with data published by Renouf 
and coworkers (see Figure 8) reporting CA, FA and iFA equivalents appearing early within 
the first hour after ingestion and DHCA and DHFA showing the Cmax 8 to 12 h after ingestion 
of 900 µmol total CGAs [Renouf et al., 2010b, Renouf et al., 2010c]. Additionally, an 
accumulation was observed by Lang and coworkers due to their extended half-life times 
during habitual consumption of several cups of coffee per day [Lang et al., 2013a]. The 
possibility, that absorbed and metabolized compounds could be reabsorbed in the colon 
(enterohepatic circulation), where glucuronides are cleaved by β-glucuronidase activity 
[Williamson et al., 2000], is for example in line with data determined for FA which is 
reabsorbed in the level of the colon what resulted in a second peak of apperance in plasma 
[Renouf et al., 2010b].  
Figure 8 Pathway of absorption and metabolism of CGA using the example of 5-CQA. Note: 
Some isomerization can occur between different isomers of CQA and of FQA under 
physiological conditions [Renouf et al., 2010b, Williamson et al., 2011].  
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As already mentioned before, Erk and coworkers performed a crossover study with five 
ileostimists which consumed a coffee beverage with three different CGA contents to 
determine the absorption of CGAs (CQAs and CQLs and their corresponding metabolites 
quantified as 5-CQA equivalents, FQAs and metabolites quantified as 5-FQA equivalents, FA 
and feruloylglycine quantified as FA equivalents, FA-glucuronide derivatives quantified as 
iFA-glucuronide equivalents, sulfated derivatives quantified as FA-sulfate equivalents and CA 
and DHCA metabolites quantified as 3’ conjugated meatbolites) in the small intestine and to 
investigate additionally the impact of the ingested dose. Plasma samples were collected for 
0 – 8 h, urine smples were collected for -24 – 48 h and ileostomy effluents were collected for 
8 – 12 h. As already mentioned, in ileal effluent and urinary samples CA and derivatives as 
well as FA and derivatives were in this study predominantly sulfated. In contrast, iFA 
determined in the urinary samples were to a greater extent glucuronidated than sulfated. 
With increasing doses, CGA were preferred conjugated to glucuronic acid. Total ileal 
excreted amounts were determined between 69 ± 9% for the high dose and 77 ± 4% for the 
low dose of the CGA metabolites, which is in line with the findings of Stalmach and 
coworkers [Erk et al., 2012]. Inferential, 25 to 30% of the ingested CGA were absorbed in the 
small intestine comparable to other single-dose studies with ileostomists [Olthof et al., 2001, 
Stalmach et al., 2010]. In general, systemic available metabolites were predominantly renally 
excreted. In the urine samples, Erk and coworkers determined CGA to 8.0 ± 4.6% for the 
high dose and 14.6 ± 6.8% for the low dose coffee, with a diversified spectrum of metabolites 
and a faster transit time for ileostomists after ingestion of the higher coffee dose [Erk et al., 
2012]. Taken together, in the frame of this dose response study, the consumption of high 
CGA amounts influenced the gastrointestinal transit time and affected CGA absorption and 
metabolism, even if Erk and coworkers cannot explain the controversial bioavailability shown 
[Erk et al., 2012].  
In contrast to previous studies, a major part of population is consuming coffee or its products 
every day in combination with food. In light of this, the influence of breakfast consumption on 
the bioavailability of CGA from coffee should also be of scientific importance. Up to date, only 
one study focused on the consumption of coffee beverage (332 mg CGA absolute) pure, with 
10% whole milk or with sugar and nondairy creamer (as a premixture). 12 h after coffee 
consumption, blood samples were taken and phenolic acid equivalents were determined. 
The comparison of the results after pure black coffee consumption with them after the 
additional consumption of milk did not significantly change the areas under the curve (AUC), 
maximum plasma concentrations (cmax), or the time needed to reach cmax (tmax). A significant 
decrease in cmax of CA and iFA was observed as well as a significant longer tmax of FA and 
iFA for the treatment with sugar and nondairy creamer [Renouf et al., 2010c]. However, the 
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AUC did not significantly differ. During alnalysis a full enzymatic cleavage of all samples to 
hydrolyze all CGA and conjugates was performed. So only the overall pattern of plasma 
appearance was observed. Due to this fact, a change in the distribution pattern of single 
plasma metabolites cannot be exclude and must be investigated seperately [Renouf et al., 
2013]. 
The studies from Erk and coworkers with ileostomists showed possible effects of food 
matrices on CGA bioavailability. In these studies different sources of CGA (cloudy apple 
juice, apple smoothie and coffee) were used. The variation in food matrices and phenolic 
composition had a major influence on intestinal availability and also of interesterification of 
the investigated subclass of CGA [Erk et al., 2013b]. Nevertheless, it is of scientific interest to 
investigate in more detail the influence of a food matrix on the bioavailability and metabolism 
of CGA in humans. 
 
2.1.4 Influence of the human microbiota on the intestinal metabolism of 
hydroxycinnamic acids and their derivatives 
In the centuries BC, the origins of anaerobic microbiology emerged, when Hippocrates 
described the clinical symptoms and high mortality rate associated with what we now known 
as tetanus [William, 2012]. In 1680, Van Leeuwenhoek discovered the anaerobes, as he 
observed the presence of ‚animalcules’ which could exist in the absence of air [Gest, 2004]. 
Nowadays, a definition of ‚anaerobic’ in the respective case is necessary. Numerous 
definitions have been offered for anaerobes or sometimes also obligate anaerobes, such as 
they create energy and metabolize its substrate without using oxygen and they demonstrates 
extreme oxygen-sensitivity which means they cannot grow in an aerobic atmosphere. Finally, 
the best definition of an obligate anaerobe is an organism for which anaerobic cultivation 
methods give optimum growth and for which oxygen is inhibitory [Brazier, 1982, 
Phillips&Willis, 1981, Sisson et al., 1987, Wren, 1977, McKinney, 2004].  
Irrespective of methodology, the state of microbiota depends on the quality of the collected 
samples. It is essential that samples, in which the anaerobic microbiology will be 
investigated, have to be protected from oxygen toxicity during the period from collection of 
species to handling in the laboratory [Brazier, 1982, Phillips&Willis, 1981, Sisson et al., 1987, 
Wren, 1977, McKinney, 2004]. 
For the handling of respective samples in the laboratory, numerous types of established 
anaerobic chambers are commercially available. Typically, they are based on the 
introduction or generation of a gas mixture containing hydrogen into a jar, followed by 
catalytic conversion of the residual oxygen with hydrogen in the presence of a cold catalyst 
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to generate water, thus establishing an anaerobic environment [Brazier, 1982, Phillips&Willis, 
1981, Sisson et al., 1987, Wren, 1977].  
Within the human digestive system different microorganisms live in endosymbiotic 
relationships to fulfill their functions. E.g. during the gastrointestinal tract (GIT) passage 
bacteria have different tasks such as the fermentation of indigestible carbohydrates. It is well 
known, that also CGA are metabolized extensively to a wide range of low-molecular 
catabolites during the pass along the GIT. The dietary phenolic compounds are transformed 
to a much smaller number of metabolites, but the formation pathways and kinetics are not 
clearly understood. To understand these mechanisms, the knowledge of the identity and type 
of responsible microorganisms is important, but not as easy to identify them. Investigations 
determined special esterases as enzymes for hydrolization of ester bonds of CGA. These 
esterases are not present in human tissues, but in colonic microbiota, some digestive fluids 
and also in smaller amounts in small intestine microbiota. In detail, Couteau and members 
identified Escherichia coli, Bifidobacterium lactis and Lactobacillus gasseri as esterase-
producing bacteria with the ability to hydrolyze the ester bonds of CGA amongst others 
[Couteau et al., 2001]. First studies dealed with the identification and quantification of 
structural changes of phenolic compounds driven by the importance that beneficial biological 
effects and bioavailability may largely depend on their molecular structure [Selma et al., 
2009, Stalmach et al., 2010, Williamson&Clifford, 2010]. Ludwig and coworkers investigated 
the identity and quantity of breakdown products generated during incubation of espresso 
coffee with human fecal samples. Up to 6 h incubation period, they detected 11 dominating 
catabolites including dihydrocaffeic acid, dihydroferulic acid, and 
3-(3´-hydroxyphenyl)propionic acid as the major end products, comprising 25 – 75% of the 
total catabolites. Additionally, they observed a clear influence on the rate and extent of 
degradation in relation to the composition of the gut microbiota of individual volunteers 
[Ludwig et al., 2013].  
The detailed proposed catabolic pathways (enzymes, microbiota, etc.) are shown in Figure 7, 
where CA is the direct product of CQA hydrolysis, whereat FA and IFA were tissulare formed 
by methylation of CA. The microbiota formed various metabolites of CA, such as mCoA and 
hydroxylated derivatives of phenylpropionic, benzoic and hippuric acids. mCoA was formed 
by dehydroxylation, 3,4-hydroxyphenylpropionic, and 3-hydroxyphenylpropionic acids by 
hydrogenation and dehydroxylation. Finally benzoic acid was formed by dehydroxylation and 
subsequent β-oxidation in tissue. A conjugation of benzoic acid with glycine led to the 
formation of hippuric acid [Booth, 1963, Chesson et al., 1999, Griffiths, 1964, Gumbinger et 
al., 1993, Perez-Silva, 1966, Quick&Cooper, 1931, Scheline, 1968]. It has to be kept in mind, 
that through enterohepatic circulation conjugated compounds are excreted by the liver as bile 
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constituents into the intestine, and the deconjugated compounds are again metabolized or 
‚regenerated’ by microbial enzymes before being reabsorbed into the circulating system. 
 
2.1.5 Physiological effects of hydroxycinnamic acids and their 
derivatives 
Polyphenol rich diets correlated with different health effects such as free-radical scavenging, 
metal chelation, modulation of enzymatic activity, alteration of signal transduction pathways 
and exhibit in vitro many biological activities such as an antimutagenic, anticarcinogenic, 
anti-inflammatory and antioxidant potential [Budryn et al., 2014, Dziki et al., 2014, Liang and 
Kitts, 2015, Stocker, 1999]. The importance of these compounds was also shown in 
epidemiological studies. A decrease of diseases such likes cancer, coronary heart diseases, 
osteoporosis and dementia were observed when these kind of compounds were ingested 
[Sato et al., 2011, Steinmetz&Potter, 1996]. Also antioxidant, antidiabetic and anticarcinogen 
effects are demonstrated as properties of CGA [Karthikeyan et al., 2011, Natella et al., 2002, 
Thom, 2007b]. 
Antioxidative effects 
In the organism, as a toxic but natural byproduct of aerobic metabolism, reactive oxygen 
species (ROS) are formed [Eisenbrand, 2005]. Normal cells maintain their capability to 
neutralize reducing or oxidizing compounds by the storage of other reducing or oxidizing 
compounds. An imbalance of this pool of compounds, which help the cells with their repair 
and detoxification functions, can lead to a damage of cellular and extracellular 
macromolecules. An exceeding ROS level above the physiological normal level refers to 
oxidative stress [Heber et al., 2006, Schmidt, 2007]. Oxidative modifications at cell structures 
such like DNA, RNA, proteins and lipids by ROS are associated with the pathogeneses of 
chronicle disease and the natural aging process [Balaban et al., 2005]. In combination with 
many endogenous defense mechanisms such as enzymes (superoxiddismutase, katalase, 
glutathion peroxidase, etc.), also compounds with a low molecular size are able to inhibit the 
oxidation of for example DNA, and consequently DNA damages. These compounds are 
named antioxidants, such as vitamin C, A and E, and have the capability to intercept free 
radicals and minimize oxidative chain reactions, subsequently. The reason is an decrease in 
oxidative stress [Eisenbrand, 2005].  
Already in the last century, the antioxidative potential of CGA was hypotized. Radical 
scavenging activity and thus the in vitro antioxidant effects of CGA are stronger than the 
known antioxidant impacts of ascorbic acid and α-tocopherole [Ohnishi et al., 1994, Sawa et 
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al., 1998, Vinson et al., 1995]. The –C=C-COOH group linked to the phenyl ring as in 
cinnamic acids ensures greater proton-donating ability and plays consequently a role in 
stabilizing the radical by resonance. FA is expected to be more effective than pCoA because 
the electron-donating methoxy group allows increased stabilization of the resulting aryloxyl 
radical trough electron delocalization after hydrogen donation by the hydroxyl group [Rice-
Evans, 1996]. The radical may react with a second radical (R·), acquiring a stable quinone 
structure (see Figure 9) [Pietta, 2000]. 
 
            
Figure 9 Scavenging of ROS (R
·
) by hydroycinnamic acid among building of quinone [modified 
according to [Pietta, 2000]. 
 
In vitro as well as in vivo studies proved this antioxidant potential of 5-CQA and CA. In an in 
vitro ischemia/reperfusion model, Sato and members showed the antioxidant potential of 
5-CQA as well as CA. Via 2-methyl-6-p-methoxyphenylethynylimidazopyrazynone (CMPEC) 
assay, an assay for measuring superoxide anion-scavening activities of various compounds, 
an IC50 of 10.1 ± 9.3 µM for 5-CQA and of 41.0 ± 12.2 µM for CA was determined. This test 
showed a stronger antioxidative activity for CA than for 5-CQA. In addition, the total 
antioxidant performance (TAP) showed concentration dependence for both substances [Sato 
et al., 2011].  
Sirota and coworker hypotized that CA might act as an electrophile in addition to its 
nucleophilic properties, and is capable of inducing the Nrf2/Keap1 (NF-E2 p45 subunit-
related factor 2/Kelch Like ECH Associated Protein 1) pathway in cancer cells. Nrf2 is one 
example of genes involved in the cellular antioxidant defense. They finally found that CA 
induced Nrf2 translocation into the nucleus and consequently its transcription what is 
predominantely induced via the double bound in CA (Michael acceptor). The mechanism of 
induction of Nrf2 pathway and phase II enzymes by CA occurred on one hand by the 
electrophilic moiety in CA. It is essential for the oxidation of the Keap1 protein. The 
nucleophilic moiety (the catechol/quinone moiety) can provide scavenging ability, but it 
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cannot contribute directly to Nrf2 induction. In this process also generated hydrogen peroxide 
(produced by the catechol group) was involved or may also induce the process [Sirota et al., 
2015].  
Two similar in vivo studies were performed in which the volunteers consumed coffee rich in 
CGA. Both groups observed a decreas of total DNA strand breaks in lymphozytes [Hoelzl et 
al., 2010] and blood samples [15] as well as an increased expression of Nrf2.  
 
Antiinflammatory effects 
Inflammation is the activation of the immune system as protective response of body tissues 
to germs, toxicants, pathogens, damaged cells, or irritants. Substances or treatments with 
the property to reduce the inflammation are known to have an anti-inflammatory effect 
[Ferrero-Miliani et al., 2007]. 
In an animal model of chronic neuroinflammation performed by Wenk and coworkersr, a 
lipopolysaccharide was infused into the 4th ventricle of 3-month-old F-344 rats for 14 days. 
This treatment is known to reproduce a variety of behavioral, neurochemical and 
neuropathological changes associated with Alzheimer’s disease. Knowing the potential 
beneficial effect of ferulic acid (FA), 3 or 30 mg FA/kg/day were administered 
subcutaneously. A dose-dependent reduction in microglia activation within the temporal lobe 
was observed, when rats were treated with FA. In addition, they suggested a relation of the 
antioxidant properties of FA and a significant attenuation of the pathological process within 
the brain associated with Alzheimer’s diseas. However, this age-associated process can only 
be decreased, if the treatment takes place in the early stage [Wenk et al., 2004]. Another 
study evaluated the anti-inflammatory, antinociceptive and antipyretic activities of 5-CQA in 
male Wistar rats. 5-CQA doses of 10, 50 and 100 mg/kg administered orally inhibited 
carrageenin-induced paw edema compared to the control. An additional inhibition of the 
numbers of flinches in the late phase of formalin-induced pain test was observed. Dos 
Santos and coworkers suggested an inhibitory action of 5-CQA in the peripheral synthesis / 
release of inflammatory mediators involved in these responses [dos Santos et al., 2006]. 
 
Antidiabetic effects 
Diabetes mellitus is a group of metabolic diseases caused by the lack of insulin or of insulin 
resistance of cells. There are different types of diabetes mellitus but the two main types are 
type I and type II. Referring to the classification after ICD-10-WHO, type I diabetes is a 
primary insulin-dependent diabetes mellitus, whereat type II diabetes is a primary non-
insulin-dependent diabetes mellitus and the most commonly with 90 to 95% of all diabetes 
diseases [ICD-10-WHO Version 2016, Mutschler, 1975]. Supernutrition, overweight (obesity) 
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and somatic anergia play an important role in the occurrence of diabetes mellitus typ II 
[Mutschler, 1975]. 
Founded by a great interest in diabetes mellitus, already 30 years ago different groups 
investigated the antidiabetic effects of CGA. It was shown that CA and CQA had an inhibition 
effect on the α-amylase activity. Additionally, investigations had shown an inhibition effect of 
glucose absorption from intestine as well as an inhibition effect on the α-glucosidase activity 
by CA, FA and CQA [Adisakwattana et al., 2009, Funk et al, 2005, Ishikawa et al., 2007, Iwai 
et al., 2006, Narita et al., 2009, Welsch et al., 1989]. Welsch and coworkers investigated in 
an in vitro experiment the interaction of 5-CGA, FA and CA, respectively and the sodium-
dependent glucose transporter in brush border membrane vesicles isolated from rat small 
intestine. Welsch and coworkers reported a decrease of 80% of the Na+-dependent glucose 
transport capacity via, when the vesicles were treated with 1 mM 5-CQA. The treatment with 
1 mM FA and CA, respectively gave still a reduction of 35 – 40% [Welsch et al., 1989].  
In an in vivo study with male albino Wistar rats, a 3.5 mg CA/kg bw solution was given to rats 
(gavage) and after 10 min a solution of glucose (200 mg/kg bw) in combination with CA 
(3.5 mg CA/kg bw) was fed. In a time period of 0 to 90 min, blood samples were collected 
and glucose was determined. In untreated rats as well as in treated rats, glycaemia started to 
rise 5 min after ingestion of glucose and peak values were reached at 10 to 15 min. Thereat, 
the glycemic peak after CA-treatment during the oral glucose tolerance test was significantly 
(p < 0.05) reduced by ~22% at 10 min and ~17% at 15 min [Bassoli et al., 2008]. In forty 
male Sprague-Dawley rats, a high dose of CGA (90 mg/kg) inhibited a high-fat diet-induced 
elevation in SGLT1 expression. High-dose CGA controlled the levels of blood glucose and 
insulin to maintain glucose homeostasis [Peng et al., 2015]. 
A similar result showed van Dijk and coworkers in a human oral glucose tolerance test 
(oGTT) where 15 overweight men consumed either 12 g decaffeinated coffee, 1 g 5-CQA or 
a placebo (1 g mannitol) in a randomized order. The glucose and insulin concentrations were 
determined. In blood samples, early glucose and insulin concentrations tended to be lower 
than those of the collective treated with the placebo during an oGTT [van Dijk et al., 2009].  
Due to this, Thom and coworkers performed two human intervention studys in parallel. The 
first study should carry out the differences in blood glucose concentrations (glucose 
absorption) after ingestion of three different test beverages. Therefor, three human 
collectives volunteered: Group one ingested only a solution containing 25 g sucrose (control 
group), the second group consumed normal instant coffee plus 25 g sucrose and the third 
group were treated with a CQA-enriched coffee plus 25 g sucrose. After consumption of the 
CGA-enriched coffee, the AUC of blood glucose was significantly reduced as compared with 
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the control group, but not with the group which ingested normal instant coffee plus 25 g 
sucrose.  
As a controlled body weight conduces as prevention for diabetes mellitus type II, in the 
second 12-weeks study, the body mass of 30 moderately overweight people was monitored, 
when 50% of the group consumed 5-CQA enriched instant coffee and the other half only the 
instant coffee. A weight reduction for CQA-enriched coffee drinkers of 5.4 ± 0.6 kg compared 
with 1.7 ± 0.9 kg for the instant coffee drinkers was observed. The difference in weight loss 
between the two groups was significant (p < 0.05). Thom and coworkers concluded that 
consumption of an with 5-CQA-enriched coffee may have an significant effect on the 
absorption and utilization of glucose from the diet [Thom, 2007a]. A similar effect was 
reported by Bakuradze and coworkers in a human intervention study comprising 33 healthy 
volunteers. A daily ingestion of 750 mL of freshly brewed coffee rich in green coffee 
constituents and roast products for four weeks showed a body weight (p<0.01) and body fat 
reduction (p<0.05) [Bakuradze et al., 2011]. Bakuradze and coworkers performed a second 
similar human intervention study with 84 volunteers. Against former findings, no changes in 
body weight were reported [Bakuradze et al., 2015].  
Anticarcinogenic effects 
Phenolic acids have the capability to impede following mechanism: Inhibition of phase I 
enzymes, interactions with the activated carcinogen, interactions with the DNA, induction of 
phase II enzymes and antioxidative activity. Accordingly, phenolic acids may also inhibit both 
the initiation and promotion phase of the cancerogenesis [Watzl, 2001].  
As one of these studies, Kampa and members performed an in vitro experiment using T47D 
human breast cancer cells. They investigated the antiproliferative action of six phenolic acids 
(CA, FA, syringic acid, sinapinic acid, protocatechuic acid and 3,4-dihydroxyphenylacetic 
acid). The tested compounds (10-7 M) showed an inhibitory antiproliferative effect on T47D 
cells, with the maximum effect on the 5th day of incubation. The most potent inhibitor of cell 
growth by 80% was CA, followed by FA, protocatechuic acid and 3,4-dihydroxyphenylacetic 
acid, which showed a similar inhibition on cell growth by 40%. For the six compounds under 
study, the IC50 values varying from the nanomolar to the picomolar range (CA: 2.2 · 10
-9 M, 
FA: 2.3 · 10-9 M, syringic acid: < 10-12 M, sinapinic acid: 7 · 10-11 M, protocatechuic acid: 
2 · 10-11 M and 3,4-dihydroxyphenylacetic acid: < 10-12 M) [Kampa et al., 2004]. As shown for 
quercetin and kaempferol before [Ciolino et al., 1998, Ciolino et al., 1999], also CA regulated 
CYP1A1 gene expression through binding to the aryl hydrocarbon receptor (AhR). This 
means that the activation of transcription factors could be blocked, if CA is binding to AhR 
instead of the possible formation of an AhR-TCDD (2,3,7,8-tetrachlorodibenzodioxin) 
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complex, which induces CYP1A1, resulting in an increase in DNA binding activity of NF-κB 
and apoliprotein 1 [Kampa et al., 2004]. 
In the human colon cancer cell line HT29 an inhibition (IC50 = 133 ± 18 µg/mL) of growth after 
treatment with a polyphenol-rich extract of an apple juice was shown in vitro. This 
concentration is clearly below the concentration of determined polyphenols in consumer-
relevant apple juice (about 500 µg/mL). Testing of single compounds, CA gave the strongest 
growth inhibitory properties (IC50 = 132 ± 19 µM), whereas 5-CQA showed only marginal 
growth inhibition (IC50 =  205 ± 53 µM) [Kern et al., 2005]. In addition, Karthikeyan and 
coworkers investigated the potential of FA on radiosensitidation in two cervical cancer cell 
lines (HeLa and ME-180). In this in vitro experiment, the percentage of growth inhibition 
(MTT assay), the colony survival, the levels of lipid peroxidation (TBARS, CD and LHP), the 
antioxidant status (SOD, CAT, GPx and GSH), the oxidative DNA damage (% tail DNA, tail 
length, tail moment and Olive tail moment), the apoptotic morphological changes (AO/EtBr 
staining) and the intracellular ROS levels (DCFH-DA) were estimated. In both cell lines, FA 
(10 µg/mL) enhanced radiation effects by increasing lipid peroxidative markers as well as by 
significant enhancement of ROS levels. In contrast, FA treatment without radiation increased 
intracellular ROS levels what indicated the prooxidant nature. Also the observed enhanced 
oxidative DNA damage and apoptotic morphological changes when cervical cancer cells 
were treated with FA plus radiation, suggested the radiation sensitizing property of FA 
[Karthikeyan et al., 2011].  
To examine whether CQA showed anticarcinogenic effects in vivo, the inhibition effect on 8-
hydroxydeoxyguanosine formation in animal organs was investigated. Therefore an oxygen 
radical-forming carcinogen, 4-nitroquinoline-1-oxide (25 ppm) was administered in the 
drinking water to all rats. Additionally, a selected group of these rats were fed a diet 
containing 250 ppm CA. The 8-hydroxydeoxyguanosine level in the DNA of the rat tongue, 
the target tissue, was significantly reduced in the CA-treated group (250 ppm). This may 
suggest an indication for mechanisms of cancer chemoprevention by CQA [Kasai et al., 
2000]. Also (spontaneous) DNA strand breaks play a role in carcinogenesis. Bakuradze and 
coworks showed in two different studies a significant decrease of spontaneous DNA strand 
breaks of the coffee-consuming volunteers, as compared to the control group (only water) 
[Bakuradze et al., 2015, Bakuradze et al., 2016].  
Toxicological effects 
The acute toxicity of CQA and CA was examined in a multitude of toxicological studies and is 
considered to be low [Tice, 1998]. 
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Schafer and coworkers determined the acute oral toxicity and found LD50 values for CQA and 
CA in redwing blackbirds of more than 100 mg/kg bw (sex and strain not provided) [Schafer 
et al., 1983]. In mice, dosages in the range of 3.5 – 381 mg CQA/kg bw showed no adverse 
effects [Hach&Heim, 1971]. Intraperitoneal administration of 4000 mg CQA/kg bw induced 
death in 4 of 6 treated rats, while doses lower than 2497 mg/kg bw revealed no obvious 
toxicity [Chaube&Swinyard, 1976]. In contrast the LD50 for CA was in a range of 
1500 mg/kg bw after i.p. administration (death of 5/8 rats). Dosages below 1250 mg/kg bw 
were nontoxic [Chaube&Swinyard, 1976]. However, the relevant exposure route for humans 
is the oral administration. Dosages between 50 – 500 mg CA/kg bw given to rats by gavage 
revealed no clinical symptoms of toxicity. The only substance related effect was reduced 
glutathione-S-transferase (GST) activity in the liver of these rats [Ploemen et al., 1993]. 
After administration of up to 0.2% CQA or CA respectively via the isocaloric and 
isonitrogenous diet of mice no clinical symptoms of toxicity were detectable. Substance 
related effects were limited to effects in modulating hepatic xenobiotic activating-
detoxification enzymes [Kitts&Wijewickreme, 1994]. There are different short-term and sub-
chronic studies in rats known, using a dose range of 10,000 – 20,000 ppm in the diet. 
Adverse effects observed caused by substance uptake were reduced kidney and adrenal 
weights as well as hyperplasia and increased cell proliferation of the forestomach [Eklund, 
1975, Hirose et al., 1987, Ito et al., 1993, Kagawa et al., 1993]. Additionally, daily i.p. 
injections on Wistar rats for 8 days with dosages up to 500 mg CQA/kg bw and 187.5 mg 
CA/kg bw respectively were not lethal [Chaube&Swinyard, 1976]. 
There is one prenatal developmental toxicity study with CA in rats available, where i.p. 
administrations of 40 – 187.5 mg/kg bw day on days 5 through 12 of gestation induced rib 
defects in 7.4% of the 21-day-old fetuses [Chaube&Swinyard, 1976]. At no dosage, fetal 
central nervous system defects or maternal and fetal mortality were detectable. 
Hirose and coworkers showed a carcinogenic potential in a long term study in rats (n = 20). 
For two years, rats were fed with CA-enriched feed (2%). Histological examination revealed 
that CA induced forestomach squamous cell carcinoma in 57% of the animals (p < 0.001) 
[Hirose, 1990]. An extrapolation for humans occurs in 140 g CA/d which is 140 fold higher 
than maximal daily intake of CGA. Additionally, carcinogenicity was determined in mice, 
where administrations of CQA given via the diet (CQA-enriched feed, 2%) over 96 weeks 
induced squamous-cell papillomas and carcinomas of forestomach, alveolar type II-cell 
tumors of the lung andrenal-cell adenomas [Hagiwara et al., 1991, IARC, 1993]. In rats, 
administrations of CA-enriched feed (2%) over 51 to 104 weeks showed a significantly 
increased in papillomas of the forestomach [Hagiwara et al., 1991, IARC, 1993] while shorter 
exposure periods with the same diet not resulted in such effects [Hirose et al., 1992, Kagawa 
et al., 1993]. The dosage of CA-enriched feed (2%) for two years induced carcinomas of the 
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forestomach, increased the incidence of renal adenomas [Hagiwara et al., 1991, IARC, 1993] 
and did produce significant hyperplasia [Hirose et al., 1993], whereat no hepatocellular 
adenomas or carcinomas, glandular stomach adenomas or carcinomas [Hagiwara et al., 
1996], or kidney adenomas were observed [Hirose et al., 1993]. In contrast, the 
administration of 250 ppm (0.025% enriched feed) CQA respectively 10,000 ppm CA (1% 
enriched feed) over 24 respectively 20 weeks to hamsters did not induce any tumors. 
Epidemiological data on the toxicological effects of pure CQA and CA are limited. Initially, 
Freedman and coworkers, observed an allergic response of industrial workers on green 
coffee [Kaye&Freedman, 1961]. Hence, studies were performed investigating the allergic 
response of CQA and CA. If CQA and CA were administered subcutaneously only CQA was 
able to show an allergic response. In the passive transfer method, CQA was analyzed 
against serum from an individual allergic to green coffee, where doses as low as 20 µM 
induced a positive reaction. However, based on different other studies, no reactions were 
observed so that CQA seems not to be one of the allergens responsible for atopic allergy to 
green coffee [Karr et al., 1978, Layton et al., 1965a, Layton et al., 1968, Layton et al., 
1965b].  
In human intervention studies, the plasma total homocysteine concentrations was increased 
after 5-CQA. For seven days, healthy volunteers ingested 2 g 5-CQA, subsequent plasma 
was collected 4 to 5 h and 20 h after intake and total homocysteine was determined. 
Compared to the placebo group, concentrations were 12 respectively 4% higher after 5-CQA 
intake. It is known that higher homocysteine concentrations in plasma come along with an 
increased incidence of cardiovascular diseases. Extrapolated, 2 g 5-CQA corresponds with 
1.5 L of a strong coffee, which is above the mean intake of 2 – 3 cups of coffee 
(approximately 172 – 259 mg 5-CQA, Arabica coffee beverage) [Moreira et al., 2005]. 
Moridiani and members shown a formation of mono- and bi-glutathione conjugates when 
glutathione was present during the peroxidase/H2O2-catalyzed oxidation of CA, DHCA or 5-
CQA. Finally, glutathione depletion is possible what caused an absence of defense 
mechanism and following susceptibility to oxidative stress [Moridani et al., 2001]. 
Finally, only topical CQA and CA treatment induced clinical symptoms of toxicity, tumors or 
death. In epidemiological studies in industry workers who were processing green coffee only 
allergic effects were detectable whereat CQA seems not to be one of the allergens 
responsible for atopic allergy to green coffee. Additionally higher homocysteine 
concentrations and glutathione conjugation were observed in humans. Nevertheless, the 
toxicological effects are considered to be low [Tice, 1998]. 
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2.2 Methodologies 
2.2.1 High performance liquid chromatography (HPLC) 
High performance liquid chromatography (HPLC) compares to the classical column 
chromatography with enhancements. The efficiency increased based on reduction of particle 
size of sorbents material as well as instrumentalization. The fain-grained sorbent material is 
capable of providing better separation, shorter analytical times, and a more sensitive limit of 
determination [Kromidas, 2017].  
The schematic setup of an HPLC unit is shown in Figure 10. After degassing (2), pumps (3) 
move the mobile phases (1) to an injection valve (autosampler) (4). Following sample 
injection, the mobile phase moves through the guard (5) and analytical column (6). 
Afterwards, the sample components to be separate are determined by one of different 
possible detectors (7). All HPLC detectors are present to monitor physical parameters of the 
mobile phase and change the signal if a substance elutes from the column. A plot of the 
detector response as a function of time is called a chromatogram. The data are transmitted 
(8) and converted at the connected computer (9) [Cammann, 2000].  
                    
Figure 10 Schematic figure of a high performance liquid chromatography (HPLC) unit: (1) 
solvent reservoirs, (2) degasser, (3) high pressure pumps, (4) autosampler/sample injection 
loop, (5) guard column, (6) analytical column, (7) detector, (8) data acquisition, (9) computer 
[modified after Camman, 2006]  
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2.2.2 Detectors – CoulArray® detector coupled with high 
performance liquid chromatography (HPLC) 
The CoulArray® detector is a detector coupled with high liquid chromatography (HPLC) 
system, which offers the ability to detect and quantitate trace levels of 
electroactive/redoxactive substances in complex matrices. The observed signal might be due 
to the compound of interest or due to other compounds in the sample, which have the same 
electroactivity / redoxactivity as the compound of interest. For this problem, the CoulArray® 
detector offers the possibility to use a multi-electrode detector system in which a series of 
electrochemical cells (up to 16) are set at different potentials (for each electrode 
independently controlled from -1000 mV to 2000 mV) to oxidize or reduce the substances 
that elute from the column. Due to that it is unlikely that two substances have a similar 
retention time as well as the same redoxactivity, the collection of a number of 
chromatograms allows the identification (and quantification) of the substance interested in 
[RADANAL].  
 
2.2.3 Detectors – Mass spectrometry (MS) coupled with high 
performance liquid chromatography (HPLC) 
Mass spectrometry is a physical analytical technique that determines the mass to charge 
ratio (m/z) of in vacuum stable ions. MS analysis are performed in different fields (physics, 
astrophysics, gas phase chemistry, organic chemistry, biology, medicine, etc.) and used to 
analyse pure samples as well as complex mictures. It is used for determining mass to charge 
ratios of particles, which could be precursor-ions or product-ions after fragmentation, but also 
for elucidating the chemical structure. Ionization depends on used method and is caused by 
to determine analytes. Organic compounds are quantified at concentrations of pico to 10 atto 
mol, generally. Mass spectrometry works by generation of positive or negative ions and 
radical ion, respectively, whereas the electrical high voltage allows acceleration of these 
produced ions. The reached velocity of ions is due to the kinetic energy and the acceleration 
in the electric field. The rate of ion yield is the determining factor of limit of detection for a 
mass spectrometer [Cammann, 2000, Lottspeich, 2008]. 
Please Note: Some technical terms referd to the mass spectrometry are provider-specific 
and based on the instruments and techniques offered by AB Sciex GmbH. 
 
One special technique to ionize molecules is electrospray ionization (ESI). ESI is a viable, 
mild ionization method used as ion source to couple HPLC with MS. Precursors are not or 
marginal fragmented and desired precursor-ions or quasimolecular ions such as [M+H]+ are 
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generated, generally. Under atmospheric pressure the molecules are desolvated, which 
means formed ions are transferred from solvent into gas phase. That process is classed in 
four steps: First, solvent containing the analytes is dispersed by electrospray into a fine 
aerosol and loaded droplets are formed. Extensive solvent evaporation result in decrease of 
the initial droplet size and in increase of density of charge on the surface. The droplet 
becomes unstable reaching its Rayleigh limit. At this point, the charge to surface ratio of the 
droplet increase, the droplets deforms and emits charged jets in a process known as 
Coulomb fission. After completed desolvation, precursor-ions formed at atmospheric 
pressure are accelerated first into the prevakuum area and afterwards into the high vacuum 
region of the mass spectrometer. Curtain gas, what is in general nitrogen, furthers 
desolvation and collides with neutral particles to prevent the entrance of contaminants 
through the interface plate. Also, arrangements of lenses and skimmer cones or additional 
quadrupols are used to desolvate and focus ions into the first quadrupole (Q1). Analysis 
occurs by a continuous flow, which is injected by a capillary tube, called probe. The probe 
with impressed high voltage serves as backing electrode to the interface plate, which 
implicate an electric field. Nebulizer gas around the probe enhances the formation of droplets 
[Cammann, 2000, Lottspeich, 2008]. The schematic representation of electrospray ionization 
is illustrated in Figure 11. 
 
Figure 11 Schematic representation of electrospray ionization [modified after ABSciex, 2008] 
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Following separation, an analysis of compound ions is generated in high vacuum. That 
avoids scattering and impacts of ions with gas molecules. Separation of m/z ratios could 
occur after six principles: magnetic and sector field separation, quadrupol mass filter, ion 
trap, ion cyclotron resonance cell and time of flight spectrometer [Cammann, 2000, 
Lottspeich, 2008]. 
Quadrupol mass filter are commonly used. Here four concentric parallel rods with opposite 
direct voltage and switching polarity of the electrodes result in an oscillating electrical field. 
Ions are accelerated in the opposite direction and only ions with a certain m/z ratio are 
confident between the electrodes. Changes to the potentials on the rods allow a wide range 
of m/z values. Triple quadrupole mass spectrometer has four consecutive quadrupole 
stages, Q0 to Q3, which allow the determination of the chemical structure of compounds, 
supplementary. Such systems are called tandem mass spectrometer, as well. Q0 is only for 
motion of ions in an oscillating electric field. First Q1 act as mass filter, where ions are 
scanned at their m/z values. Q2 is no quadrupol as defined, rather a collision cell. Collision 
gas and impressed voltage fragment precursor-ions in the corresponding product-ions. m/z 
values of formed ions are determined at Q3, the second quadrupol [Cammann, 2000, 
Lottspeich, 2008].  
 
Multiple reaction monitoring (MRM) 
Scanning a certain m/z value at Q1, fragmentation at Q2 and transmitted an identified 
product-ion by Q3 to the detector gives the possibility for quantification and is known as 
multiple reaction monitoring (MRM) mode (see Figure 12 Schematic representation of the 
multiple reaction monitoring (MRM) mode [modified after ABSciex, 2008]) [Cammann, 2000, 
Lottspeich, 2008]. 
Essential advantage of MRM is the fade-out of interfering signals of complex matrices, such 
like in biological material. The high sensitivity involves a good signal to noise ratio, with a low 
limit of detection. 
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Figure 12 Schematic representation of the multiple reaction monitoring (MRM) mode [modified 
after ABSciex, 2008] 
Product-ion scans 
Product-ion scans are a commonly employed MS/MS method for sequence analysis or 
identification and/or structure determination of single components in alloys or after synthesis 
of standards. A precursor-ion is isolated by setting Q1 to transfer only the m/z ratio of that ion 
into Q2. In the collision cell (Q2), the ion is fragmented and the generated product-ions are 
mass analyzed in Q3 (see Figure 13 Schematic representation of the product-ion scan 
[modified after ABSciex, 2008]) [Cammann, 2000]. 
                      
Figure 13 Schematic representation of the product-ion scan [modified after ABSciex, 2008] 
 
2.2.4 Calibration and tuning of a AB Sciex Triple Quad or QTrap® 
mass spectrometer 
Calibration is the process of calibrating the mass scale using polypropylene glycol (PPG), 
called calibration standard, which has peaks with accurately known masses. They provide a 
benchmark for comparison when calibrating the instrument. Using this calibration standard 
ensures the mass peaks are assigned to the correct m/z values, thereby ensuring the highest 
possible mass accuracy of instrument. To assure the mass peaks are assigned to the correct 
m/z values, the mass shift have to be equal to or less than 0.1 Da. Tuning the instrument is 
the process of optimizing the resolution and instrument parameters to ensure the best 
sensitivity and performance of the mass spectrometer. Optimizing the resolution means 
adjusting the peak width and peak shape. A maximal sensitivity is resulted in a peak width 
between 0.6 and 0.8 Da at 50% of the maximal peak high of a given m/z ratio. The sensitivity 
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is disproportioned to the resolution; the higher the resolution, the lower the sensitivity. For 
optimized analysis, compound-dependent and source-dependent parameters have to be 
tuned in. Compound-dependent parameters are optimized by infusion via syringe pump for 
each substance. Optimization occurs by Analyst Software 1.4.2 and 1.6 (AB Sciex GmbH 
Germany, Darmstadt, Germany) and a flow of 10 µL/min. Source-dependent parameters are 
determined by flow injection analysis (FIA) via HPLC and injections of a standard solution via 
the autosampler. That means without column and the accordant conditions (flow and mixture 
of mobile phase) for one of all analytes. Also for this process steps Analyst Software 1.4.2 
and 1.6 (AB Sciex GmbH Germany, Darmstadt, Germany) was used. Compound-dependent 
and source-dependent parameters and their functions are described in Table 6 and Table 7. 
 
Table 6 Compound-dependent MS parameters and their functions. 
parameter function 
declustering potential (DP) 
voltage between skimmer and orifice plate, 
minimization of analyt-eluent-clusters  
entrance potential (EP) focusing and transport of ions in Q0 
collision energy (CE) 
voltage between Q0 and Q2, control of 
collision energy  
collision cell entrance potential (CEP) 
voltage between Q0 and entrance of Q2, 
focusing of ions in Q2 
collision cell exit potential (CXP) 
voltage between Q2 and Q3, transport of 
ions from Q2 to Q3 
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Table 7 Source-dependent MS parameters and there functions. 
parameter  function 
curtain gas (CUR) 
pressure of gas between curtain plate and 
orifice plate, prevention against 
contamination 
collision activated dissociation (CAD) 
pressure of collision gas, fragmentation of 
analytes on Q2 
ionspray voltage (IS) voltage of ESI-probe, ionization of analytes 
temperatur (TEM) 
temperature, increase of volatility of eluate 
and formation of precursor-ions in gas phase 
gas 1 (GS1) 
nebulizer gas, formation of small eluate 
droplet and influence of stability of 
electrospray  
gas 2 (GS2) 
turbo gas, evaporation of eluate in eluate 
droplet 
 
2.2.5 Stable isotope dilution analysis (SIDA) 
For the quantification of chemical compounds with a mass spectrometer the stable isotope 
dilution analysis (SIDA) is recommended. Using SIDA, a defined amount of isotopically 
labeled standard is added to the sample. After equilibration, the ratio of the isotopologues is 
stable because of their nearly identical chemical and physical properties. During sample 
preparation, losses of the analyte are completely compensated by identical losses of the 
isotopologue. Final mass spectrometry allows differentiation based on the m/z ratios. With 
the known amount of the labeled standard, the content of the analyte can be calculated via 
the ratios of the peak areas vs. ratios of the concentrations (see Figure 14 Schematic 
representation of stabile isotop dilution analysis (SIDA) [modified after Rychlik&Asam, 2008]) 
[Cammann, 2000, Rychlik&Asam, 2008]. 
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Figure 14 Schematic representation of stabile isotop dilution analysis (SIDA) [modified after 
Rychlik&Asam, 2008] 
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3 Aim 
Chlorogenic acids (CGA) are a family of esters of certain trans-cinnamic acids and (-)-quinic 
acid and well known to provide beneficial effects on human health. Apart from almost every 
vegetable comestible goods, coffee is reported to be the main source of CGA in human 
nutrition. A major part of population consumes coffee or its products every day in 
combination with a meal such as a breakfast. A central point to assign the beneficial effect of 
CGA from coffee is the influence of a food matrix on the bioavailability and the metabolism of 
CGA. Only limited data are available on how the bioavailability as well as absorption and 
excretion of these coffee ingredients and their derivatives are influenced depending on the 
kind of food consumed at the same time. 
In our human intervention study, the consumed coffee beverage (instant study coffee) used 
to investigate the above mentioned bioavailability, absorption and excretion. Fourteen 
healthy participants consumed either the coffee beverage only (COFFEE), the coffee 
beverage with a breakfast rich in carbohydrates (CARB) or the coffee beverage with a 
breakfast containing high levels of fat (FAT), in a random order, to investigate the influence 
of a food matrix on the bioavailability of CGA from coffee.  
One main point of interest was to determine to what extent the CGA present in the coffee 
beverage were circulating and excreted. Therefore, existing CGA and their respective 
metabolite concentrations were determined in the collected plasma and urine samples using 
high performance liquid chromatography electrospray ionisation tandem mass spectrometry 
(HPLC-ESI-MS/MS). Thus, the primary goal of the study was to estimate differences in 
absorption and bioavailability between the different metabolites in plasma and urine after one 
of the three treatments in terms of: area under the curve (AUC), maximum plasma 
concentration (Cmax), and time needed to reach maximum plasma concentration (tmax). 
Additionally, it was already known that the microbiota is responsible for metabolism of CGA 
to DHFA and DHCA derivatives, with subsequent formation of a wide range of metabolites. 
Therefore, as second aim, ex vivo incubations of the volunteers’ faecal samples with 5-O-
caffeoylquinic acid as the main cholorgenic acid in coffee were performed to achieve data for 
metabolic efficiency and interindividual variabilities. In addition, these samples were analysed 
for their microbiota content by an external laboratory (L&S, Bad Bocklet, Germany). These 
results were used to correlate a change in special microorganism related to a decreased or 
increased metabolic efficiency of the individual.   
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Finally, statistical evaluation was performed between plasma appearances, urinary excretion, 
and the ability of the microorganisms to degraded 5-O-caffeoylquinic acid as coffee 
constituent to figure out any potential correlations. These results should help to come to the 
conclusion if and which influence a breakfast consumption have on the chlorogenic acid 
metabolism in humans.  
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4 Results and discussion 
4.1 Study design and subjects  
The study was subdivided in five study days, shown in Figure 15. At the beginning of the 
study, a general medical screening was carried out to exclude any known or unknown 
disorders or disease.  
 
 
 
 
 
 
 
 
Figure 15 Design oft the performed human intervention study. 
 
Bioimpedance measurements and demographic data 
The body composition determined by bioimpedance measurement of each proband can have 
an impact on the absorption and metabolisation of coffee polyphenols.  
Appendixes, Table 51 to Table 53 show the physiological data of the 14 probands. The 
average of BMI of all probands was 23.0 ± 1.6 kg/m2, the average of the percental fat free 
mass was 76.2 ± 7.5%, the average of percental total body water was 55.8 ± 5.5% and the 
average of percental fat mass was 17.4 ± 6.0 h.  
For detailed basline demographic data see chapter 6.4.1 Study design and subjects, page 
145. 
Oral glucose tolerance test (oGTT) 
Oral glucose tolerance test (oGTT) was performed by a single intake of 75 g glucose and 
measurement of blood glucose concentrations in the peripheral blood (fingertip) were 
performed after 0, 30, 60, 120, 180, 240 and 300 minutes were performed.  
Wash-out min 7 days Wash-out min 7 days Wash-out min 7 days 
Screening V1 V2 V3 V4 
Medical questionnaire 
Physical examination 
Anthropometry 
Check IC & EC 
 
Glucose tolerance test 
Blood collection 
Gastrointestinal transit 
time 
Polyphenol-free diet 
 
Test breakfast (3 different one in a cross-over 
design) 
Stool collection (V2 only) 
Blood collection 
Urine collection 
Polyphenol-free diet 
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Appendix, Table 55 shows the blood glucose concentrations of each proband (01 – 14) until 
300 min after intake of glucose. The fasting plasma glucose of all probands was less than 
126 mg/dL and the 2 h-plasma glucose lay between 140 mg/dL and 200 mg/dL. Only the 2 h-
plasma glucose of proband 14 was slightly increased in an acceptable magnitude. 
Probands 
Finally, our subject collective consisted of seven health men and seven healthy women, 
29 ± 8 years old. GIT transit time was 17.4 ± 6.0 h and all other inclusion/exclusion criteria 
were also achieved.  
The result-providing study days took place on three separate days (V2 to V4). In each case, 
test subjects consumed 200 mL of a coffee beverage prepared from instant coffee with 
3.1 mg chlorogenic acids/kg bw. As coffee is oftentimes consumed as a breakfast beverage, 
three different breakfasts were consumed in a cross-over design in a randomized order. As 
test breakfast, there were the coffee beverage only (COFFEE), the coffee beverage with a 
breakfast rich in carbohydrates (two bread rolls and honey, CARB) or the coffee beverage 
with a breakfast containing high levels of fat (one bread roll and peanut butter, FAT). These 
two breakfasts were equicaloric (~626 kcal calculated with nutrition facts on the product).  
Diagnostics of microbiota 
The microbiota species and amounts in fecal samples can have an important impact on the 
metabolization of coffee polyphenols. In order to determine the microbiota contents we 
transferred aliquots of fresh faeces (time points: between -24 and 0 h) at +4 °C to an external 
laboratory (L&S laboratories, Bad Bocklet, Germany) (Appendix, Table 54). 
For most samples, the microbiota content was in a normal range as defined by L&S 
laboratories, Bad Bocklet, Germany, and characterised as 95% of values from a normal 
population. Some probands had an increased or decreased level of some bacteria or fungi. 
Importantly, the quantity of bacteria or fungi was out of the normal range what means not 
automatically, that this is caused by illness. In connection with the incubation studies with 
faeces samples the data were compared. 
 
4.2 Amounts of chlorogenic acids quantities in the coffee samples 
The coffee used for the study was dissolved in boiled water and after cooling samples were 
centrifuged. Thereafter, the supernatant was filtered, diluted and 20 µL was injected to the 
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HPLC-DAD system. Parameters and solvent gradient are illustrated in Table 39 (Materials 
and methods) [Witt, 2012]. 
Figure 16 shows a representative HPLC-DAD chromatogram at 325 and 270 nm of an 
instant study coffee sample, used for the intervention study displaying the respective 
chlorogenic acids. 
Table 8 and Figure 17 show the amounts of chlorogenic acids [%] in the instant coffee 
sample used for the intervention study. The contents corresponded well with the denoted 
information on the original product label. There was 9.2 g of CGA per 100 g of instant coffee 
(compared to 8.7 g of CGA per 100 g of instant coffee as denoted information on the original 
product label). The different quantities were caused by the additional quantification of 3-FQA 
and 3,5-DiCQA in the coffee compared to the information on the original product label. 
Caffeoylquinic acid was the most abundant CGA subclass in the coffee we studied, followed 
by feruloylquinic acid and di-caffeoylquinic acid.  
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Figure 16 HPLC-Chromatogram of a coffee sample (0.5g/50 ml) at 325.4 and 270.2 nm [Witt, 
2012]. 
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Table 8 Amounts of chlorogenic acids [%] determined in the instant coffee used in the human 
intervention study (n = 3). 
 amount [%] SD [%] 
3-CQA 1.32* 0.05* 
4-CQA 1.41* 0.06* 
5-CQA 3.86* 0.13* 
3-FQA 0.23* 0.03* 
4-FQA 0.23* 0.02* 
5-FQA 0.73* 0.03* 
3,4-DiCQA 0.58* 0.08* 
3,5-DiCQA 0.35* 0.03* 
4,5-DiCQA 0.46* 0.06* 
QA 1.12 0.04 
* [Witt, 2012] 
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Figure 17 Amounts of chlorogenic acids (sum: sum of all chlorogenic acids) and quinic 
acid [%] in the instant study coffee used in the human intervention study (n = 3); modified 
according to [Witt, 2012] 
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4.3 Systemic availability of instant coffee clorogenic acids and 
metabolites in plasma 
 
In general, we observed large interindividual variation in AUC, Cmax, and tmax of all determined 
56 metabolites in plasma (data not shown). For the statistical calculations, 20 of these 56 
plasma metabolites were selected. These data modifications were agreed during a blind data 
review meeting by the project manager (Mathieu Renouf), biostatisticians (Julien Sauser and 
Sharam Émady-Azar) and involved parties (Isabelle Cristiani, Samir Dahbane, Laure Poquet, 
Elke Richling and Denise Scherbl). Table 9 shows the structures of the selected metabolites 
except 3- and 4-FQA (isomers of 5-FQA, which are esterified on position 3 or 4 with quinic 
acid). Additionally to the statistical analysis for single metabolites, the metabolites were 
divided into groups, according to similarity and chemical properties, which were then 
compared to observe any possible differences (see Table 10). Additionally metabolites were 
further classified into three groups according to their physical structure and predicated from 
the area of appearance: directly from coffee (quinics - 5-CQA, 3-FQA, 4-FQA and 5-FQA), 
after first degradation and metabolism (phenolics - CA3S, CA4S, FA4G, FA4S, iFA, iFA3G, 
iFA3S, MeFA) as well as colonic degradation and metabolism (colonics - DHCA, DHCA3S, 
DHFA, DHFA4G, DHFA4S, DHiFA, DHiFA3G, mDHCoA, mDHCoAS).  
 
Table 9 Structures of the selected 20 metabolites in plasma for the statistical calculations. 
  R 
 
5-CQA 
5-FQA 
H 
CH3 
  R1 R2 
 
CA3S 
CA4S 
FA4G 
FA4S 
iFA 
iFA3G 
iFA3S 
MeFA 
SO2H 
H 
CH3 
CH3 
H 
Gluc* 
SO2H 
CH3 
H 
SO2H 
Gluc* 
SO2H 
CH3 
CH3 
CH3 
CH3 
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  R1 R2 
 
DHCA 
DHFA 
DHCA3S 
DHFA4G 
DHFA4S 
DHiFA 
DHiFA3G 
mDHCoA 
mDHCoAS 
H 
OCH3 
SO2H 
CH 
CH3 
H 
Gluc* 
OH 
OSO3
- 
OH 
OH 
OH 
O-Gluc* 
OSO2H 
OCH3 
OCH3 
H 
H 
*Gluc:    
 
Table 10 Plasma sample grouping for the different derivatives according to similarity and 
chemical properties. 
Chlorogenics Phenolics Colonics Ferulics Caffeics 
5CQA CA3S DHCA 5FQA 5CQA 
5FQA CA4S DHCA3S 3FQA CA3S 
3FQA FA4G DHFA 4FQA CA4S 
4FQA FA4S DHFA4G FA4G iFA 
 iFA DHFA4S FA4S iFA3G 
 iFA3G DHiFA DHFA iFA3S 
 iFA3S DHiFA3G DHFA4G DHiFA 
 MeFA mDHCoA DHFA4S DHiFA3G 
  mDHCoAS MeFA  
     
Coumarics Sulfates Glucuronides Aglycons Methylated 
mDHCoA CA3S FA4G 5CQA iFA 
mDHCoAS CA4S iFA3G 5FQA MeFA 
 FA4S DHFA4G 3FQA DHiFA 
 iFA3S DHiFA3G 4FQA DHFA 
 DHCA3S  DHFA  
 DHFA4S  DHCA  
 mDHCoAS    
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Figure 18 to Figure 21 show the time-dependent peak detections (in samples taken after 0, 
0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 15 h after coffee consumption) for selected subjects 
(S02 and S05) and treatments (T1: COFFEE and T3: FAT).  Data were obtained with 
MultiQuantTM Software (version 3.0.2, Sciex, Darmstadt, Germany) using the MQ4 
integration algorithm. For integration details see 6 Material and methods.   
The figures show clear inter-individual differences, but also an influence on tmax and Cmax of a 
fat-rich meal consumed at the same time with the coffee beverage (Figure 19 and Figure 21) 
is visible compared to the consumption of pure coffee bavarage (Figure 18 and Figure 20). 
 
 
Figure 18 Time-dependent peak detection of FA4S in serum of subject 02 after consumption of 
pure instant coffee (T1: COFFEE). 
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Figure 19 Time-dependent peak detection of FA4S in serum of subject 02 after consumption of 
coffee with a fat-rich meal (T3: FAT). 
 
 
Figure 20 Time-dependent peak detection of FA4S in serum of subject 05 after consumption of 
pure instant coffee (T1: COFFEE). 
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Figure 21 Time-dependent peak detection of FA4S in serum of subject 05 after consumption of 
coffee with a fat-rich meal (T3: FAT). 
 
Figure 22 to Figure 41 show the plasma kinetics of the selected 20 metabolites as mean data 
of the values of single subjects. Error bars are for the sake of clarity not shown in these 
figures. 
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Figure 22 Time kinetics of 3-FQA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 23 Time kinetics of 4-FQA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 24 Time kinetics of 5-CQA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 25 Time kinetics of 5-FQA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 26 Time kinetics of CA3S from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 27 Time kinetics of CA4S from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 28 Time kinetics of DHCA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 29 Time kinetics of DHCA3S from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 30 Time kinetics of DHFA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 31 Time kinetics of DHFA4G from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 32 Time kinetics of DHFA4S from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 33 Time kinetics of DHiFA from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
4 Results and discussion 
62 
 
 
Figure 34 Time kinetics of DHiFA3G from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 35 Time kinetics of FA4G from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
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Figure 36 Time kinetics of FA4S from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 37 Time kinetics of iFA from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
FA4S 
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Figure 38 Time kinetics of iFA3G from 0 up to 15 h. Data are means [nM] of the plasma values 
of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 39 Time kinetics of mDHCoA from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
mDHCo
A 
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Figure 40 Time kinetics of mDHCoAS from 0 up to 15 h. Data are means [nM] of the plasma 
values of single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
 
Figure 41 Time kinetics of MeFA from 0 up to 15 h. Data are means [nM] of the plasma values of 
single volunteers. T1: COFFEE, T2: CARB, T3: FAT 
MeFA 
mDHCoS
A 
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Table 11 shows the number of detected metabolites in plasma samples by subject and 
treatment. In addition, Table 12shows the number of subjects with a specific detected 
metabolite in plasma depending on the treatment. The data modifications were agreed during 
the above-mentioned blind data review meeting and included following: For iFA3S, almost all 
data were very close to the LOQ (see Appendix, Table 60), hence this metabolite was 
removed from all the analysis. Subject 07 had for all colonic metabolites inconsistent and 
incoherent kinetics for the treatment with pure coffee (COFFEE) and was removed for all 
metabolites. Subject 08 was removed from FA4G analysis, based on inconsistent kinetics 
between treatments. For 5-CQA, subject 02 had strong outliers, which were excluded and 
replaced by the LOQ (see Appendix, Table 60) value. For mDHCoA and mDHCoAS, the 
kinetics were incomplete for the most of the data. Accordingly, Cmax and tmax were not 
relevant and were not computed. 
 
Table 11 Number of detected metabolites in plasma; samples of each subject and depending 
on treatments (total n = 20). Data modifications deviant from the norm were agreed during the 
blind data review meeting (see page 64). NE: not evaluated. 
subject COFFEE CARB FAT 
01 20 18 19 
02 20 19 19 
03 20 20 20 
04 20 20 19 
05 19 18 17 
06 20 19 20 
07 NE 18 20 
08 19 17 18 
09 20 20 19 
10 20 20 20 
11 20 20 20 
12 19 18 18 
13 20 20 20 
14 20 18 19 
Details of the different 20 structures see Table 9. 
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Table 12 Number of subjects with specific detected metabolites in plasma samples depending 
on treatments (total n = 14). Data modifications deviant from the norm were agreed during the 
blind data review meeting (see page 64). 
metabolite COFFEE CARB FAT 
3-FQA 13 13 14 
4-FQA 11 9 12 
5-CQA 13 14 14 
5-FQA 13 14 14 
CA3S 13 12 13 
CA4S 13 9 9 
DHCA 13 14 13 
DHCA3S 13 13 14 
DHFA 13 14 14 
DHFA4G 13 14 14 
DHFA4S 13 14 14 
DHiFA 13 14 14 
DHiFA3G 13 14 14 
FA4G 12 13 13 
FA4S 13 14 14 
iFA 13 14 14 
iFA3G 13 14 14 
mDHCoA 13 14 13 
mDHCoAS 13 14 13 
MeFA 13 14 14 
 
Area under the curve (AUC) 
AUCs were calculated as described in chapter 6.4.5 Area under the curve (AUC).  
The individual sum of AUC for plasma metabolites by treatment showed strong varying 
values (see Table 13), both interindividual and intraindividual. For instance, the lowest value 
was 315 µM*min for subject 14 (FAT) and the highest value 1,706 µM*min for subject 05 
(COFFEE). Examples for strong intraindividual differences were subject 05 and subject 09. 
For subject 05 sum of AUC for plasma metabolites was 606 µM*min (FAT) compared to 
1,706 µM*min (COFFEE). For subject 09 it was 353 µM*min (FAT) compared to 953 µM*min 
(COFFEE).  
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Table 13 Individual sum of AUC for plasma metabolites by subject and by treatment [nM*min]. 
Data modifications deviant from the norm were agreed during the blind data review meeting 
(see page 64). NE: not evaluated. 
subject COFFEE CARB FAT 
01 974,862 700,417 852,199 
02 1,046,453 788,510 720,931 
03 673,906 749,112 821,840 
04 622,874 820,865 606,084 
05 1,705,997 950,539 605,720 
06 794,508 388,212 662,454 
07 NE 856,833 727,578 
08 447,583 466,914 542,497 
09 952,887 717,541 353,312 
10 887,310 772,052 772,187 
11 1,688,207 1,142,593 1,047,529 
12 357,267 299,743 520,925 
13 503,516 829,744 626,276 
14 367,366 455,847 314,538 
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Figure 42 Sum of AUCs by treatment shown for single subjects as geometric mean. T1: 
COFFEE, T2: CARB, T3: FAT (n = 2; lower and upper bounds are hidden for a better overview)  
Table 14 shows the summary statistics on sum of AUCs with lower and upper bounds by 
treatments and Figure 42 the barplot related to the AUCs of single subjects as well as 
summary statistics. The geomeans of summary statistics in sum of AUCs were 
approximately 752 µM*min for COFFEE treatment, 669 µM*min for CARB treatment and 
626 µM*min for FAT treatment. The three treatments did not show any statistically significant 
differences among themselves, when comparing the sum of AUCs of all metabolites 
determined (see Table 15). Indeed, the ratio between the mean of CARB with respect to 
COFFEE was 0.876 with 95% CI equals to [0.713, 1.076] with an associated p-value of 
0.0207. Comparing FAT to COFFEE showed a mean ratio of 0.825 and a 95% CI of [0.672, 
1.014] with a p-value of 0.067. In tendency, intake of coffee in combination with a meal may 
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cause a decreased sum of plasma AUC. Whereas, the comparison of FAT treatment to 
CARB led to a mean ratio of 0.943 with a 95% CI of [0.770, 1.154] and a p-value of 0.566. 
The two treatments did not show differences even if the composition of ingredients varied. 
Breakfast had no significant effect on CGA absorption when calculated as summary statistics 
on sum of plasma metabolite AUCs. A detailed observation of the metabolic profiles of the 14 
study subjects demonstrated that there is no consistent influence of a food matrix on the 
bioavailability of CGAs from coffee. Only for a few metabolites exceptions were observed. 
Table 14 Summary statistics on sum of plasma AUCs with lower and upper bounds [nM*min]. 
Data modifications deviant from the norm were agreed during the blind data review meeting 
(see page 52). 
 n geomean lower upper 
COFFEE 13 751,791 451,021 1,253,133 
CARB 14 669,009 459,058 974,983 
FAT 14 626,070 451,913 867,343 
 
Table 15 Model-based treatments effect on sum of plasma AUCs with 95% confidence intervals. 
 estimate lower upper p-value 
CARB / COFFEE 0.876 0.713 1.076 0.207 
FAT / COFFEE 0.825 0.672 1.014 0.067 
FAT / CARB 0.943 0.770 1.154 0.566 
 
Overall, for the single metabolites and COFFEE treatment, the highest AUCs were observed 
for mDHCoA (142,728 nM*min; correspond to 25.8% of sum of all determined metabolites), 
DHFA (117,846 nM*min; correspond to 21.3%), DHCA3S (74,525 nM*min; correspond to 
13.5%) and DHiFA (61,695 nM*min; correspond to 11.2%) (see Table 16). Thus, 71.8% of 
the sum of the plasma AUCs for all metabolites identified comprised of these four 
metabolites. 
In addition, our initial analysis of metabolites by group showed that for all three treatments, 
plasma contained low levels of quinics and high levels of colonics, based on their AUC 
values. For example, we observed higher quantities of phenolics (48,253 nM*min, 8.7%: 
CA3S, CA4S, FA4G, FA4S, iFA, iFA3G, iFA3S, MeFA) and colonics (501,840 nM*min, 
90.8%: DHCA, DHCA3S, DHFA, DHFA4G, DHFA4S, DHiFA, DHiFA3G, mDHCoA, 
mDHCoAS) than for chlorogenics (2,842 nM*min, 0.5%: 5-CQA, 3-FQA, 4-FQA, 5-FQA) (all 
COFFEE data). 
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Table 16 Summary statistics on plasma AUC for each metabolite and treatment with lower and 
upper bounds [nM*min]. Data modifications deviant from the norm were agreed during the 
blind data review meeting (see page 52 and Table 12). 
metabolite n geomean lower upper 
3-FQA        
COFFEE 13 290.8 136.8 617.9 
CARB 14 63.8 3.2 1280.1 
FAT 14 316.6 130.9 765.9 
4-FQA     
COFFEE 13 81.7 1.3 5171.3 
CARB 14 9.0 0.1 1772.6 
FAT 14 93.4 1.7 5106.2 
5-CQA     
COFFEE 13 1232.5 570.1 2664.6 
CARB 14 720.1 276.9 1872.6 
FAT 14 1515.2 746.7 3074.8 
5-FQA     
COFFEE 13 1236.6 629.1 2430.7 
CARB 14 817.7 452.1 1479.0 
FAT 14 932.2 529.4 1641.6 
CA3S     
COFFEE 13 6927.3 1550.2 30955.5 
CARB 14 2053.8 11.4 369739.5 
FAT 14 4440.1 99.9 197291.3 
CA4S     
COFFEE 13 97.7 21.9 437.0 
CARB 14 2.3 0.0 175.9 
FAT 14 3.3 0.0 342.1 
DHCA     
COFFEE 13 24010.1 13824.3 41700.9 
CARB 14 15994.3 8205.6 31176.3 
FAT 14 5466.5 116.2 257065.3 
DHCA3S     
COFFEE 13 74524.8 37649.7 147516.1 
CARB 14 19917.4 285.1 1391615.0 
FAT 14 48627.4 22000.4 107481.3 
DHFA     
COFFEE 13 117846.3 59374.9 233899.4 
CARB 14 115717.9 62402.1 214586.3 
FAT 14 101955.4 64952.5 160038.6 
DHFA4G        
COFFEE 13 33193.9 13982.0 78803.4 
CARB 14 33671.2 15091.6 75124.5 
FAT 14 30455.1 15472.4 59946.2 
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Isomers (CA3S and CA4S, DHCA3S and DHCA4S, DHFA snd DHiFA, DHFA3G and 
DHFA4G) showed preferential regions for conjugation, if comparing the formation rates. For 
example, both metabolites, CA3S (6927.3 nM*min, COFFEE) and DHCA3S 
metabolite n geomean lower upper 
DHFA4S     
COFFEE 13 26796.5 4298.7 167041.1 
CARB 14 29088.4 6340.0 133458.8 
FAT 14 22702.7 5605.5 91947.6 
DHiFA     
COFFEE 13 61695.0 30292.9 125648.8 
CARB 14 54884.2 35671.6 84444.8 
FAT 14 56745.8 31619.8 101837.4 
DHiFA3G     
COFFEE 13 12239.0 5192.9 28845.8 
CARB 14 11544.0 4861.3 27413.3 
FAT 14 9900.5 4912.3 19954.0 
FA4G     
COFFEE 12 5939.4 3247.8 10861.7 
CARB 13 7806.9 3715.2 16404.9 
FAT 13 7273.5 2815.0 18793.0 
FA4S     
COFFEE 13 3963.7 1244.1 12628.7 
CARB 14 5297.8 1812.2 15487.2 
FAT 14 5215.7 1826.2 14895.8 
iFA     
COFFEE 13 1324.5 516.8 3395.0 
CARB 14 1673.7 830.4 3373.5 
FAT 14 1048.6 336.9 3264.4 
iFA3G     
COFFEE 13 14955.4 9623.1 23242.2 
CARB 14 17164.0 11021.4 26730.0 
FAT 14 14782.6 9667.8 22603.5 
mDHCoA     
COFFEE 13 142728.1 37515.5 543010.1 
CARB 14 121833.4 44070.5 336809.8 
FAT 13 166986.3 78657.7 354503.6 
mDHCoAS        
COFFEE 13 33193.9 13982.0 78803.4 
CARB 14 33671.2 15091.6 75124.5 
FAT 13 30455.1 15472.4 59946.2 
MeFA     
COFFEE 13 26796.5 4298.7 167041.1 
CARB 14 29088.4 6340.0 133458.8 
FAT 14 22702.7 5605.5 91947.6 
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(74524.8 nM*min, COFFEE), were preferred structures compared to the corresponding 4-
isomers (CA4S: 97.7 nM*min, COFFEE, DHCA4S: N/A). We observed a similar structural 
preference also for methylation, as we found greater AUCs for DHFA (117846.3 nM*min, 
COFFEE) and DHFA4G (33193.9 nM*min, COFFEE), as for DHiFA (61695.0 nM*min, 
COFFEE) and DHiFA3G (12239.0 nM*min, COFFEE), respectively. If glucuronidation would 
be the favored conjugation, DHiFA3G would be preferred. In addition, methylation seemed 
also favored. In our search for methylated metabolites, we found that the quantities of DHiFA 
and DHFA were three- and ten-times higher than the quantity of DHCA (24010.1  nM*min, 
COFFEE), respectively. Also high quantities of iFA (1324.5 nM*min, COFFEE) and MeFA 
(26796.5 nM*min, COFFEE), and not pure CA and FA (as aglycons), were detected. 
Furthermore, caffeic and coumaric acid derivatives seemed to be preferred sulfated, whereas 
FA and DHFA derivatives appeared to be preferred glucuronidated. For example, FA4G 
(5939.4 nM*min, COFFEE) was more abundant than FA4S (3963.7 nM*min, COFFEE) and 
DHFA4G (33193.9 nM*min, COFFEE) was more abundant than DHFA4S (26796.5 nM*min, 
COFFEE). These effects were independent from treatment. 
Compounds are metabolized as soon as they enter the body. Liorach and coworkers, found 
glucuronidation take place faster and glucuronides appear ealier in urine of humans than 
sulfates [Liorach et al., 2010]. Erk and coworkers were able to specify this finding in more 
detail as results given from an ileostomists study, showed that CA and derivatives were 
predominantly sulfated, and FA and derivatives were to a greater extent glucuronidated and 
renally excreted [Erk et al., 2012, Guy et al., 2009]. This is in line with our data indicating that 
for ferulic acid and derivatives glucuronidation was preferred. Nevertheless, as caffeic and 
coumaric acid and derivatives seemed to be preferred sulfated, also the pH-value, the 
stabilization by a π-electron system, and the steric influence of the methyl group of FA, may 
play a role which final conjugation step is occurring. In addition, Wen and Walle investigated 
the hepatic metabolic stability and intestinal absorption of either methylated or non-
methylated polyphenols in vitro. For the non-methylated polyphenols a rapidly elimination 
was observed when a human liver S9 fraction including the appropriate cofactors for 
conjugation and oxidation was used. In contrast, methylation indicated to give a higher 
resistance to hepatic metabolism, and due to an increased stability. Additionally, a 5 – 8 
times larger uptake of methylated flavones than of the nonmethylated ones was observed 
[Wen and Walle, 2006].  
All these findings may explain the higher amounts of methylated compounds in humans, as 
well. 
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Figure 43 Plasma bioavailability as AUC by treatment and metabolites ploted as geometric 
means. T1: COFFEE, T2: CARB, T3: FAT. (n = 13 or 14 (see Table 16)) Data modifications 
deviant from the norm were agreed during the blind data review meeting (see page 52). Lower 
and upper bounds are hidden for a better overview. 
Table 17 and Figure 43 show the correlation of AUCs dependent on treatment (CARB / 
COFFEE, FAT / COFFEE and FAT / CARB) with a detectable treatment effect on AUC with 
95% confidence interval for selected metabolites. All the quinic acid esters showed no 
significance between FAT and COFFEE treatment, except 5-FQA. However, they showed a 
strong significance between CARB and COFFEE as well as FAT and CARB treatment, 
except 5-FQA which showed no significance between FAT and CARB. The only phenolics 
giving significance were CA4S for CARB and COFFEE as well as FAT and COFFEE (see 
definition of quinics, phenolics, colonics, caffeics, ferulics, sulfates, glucuronides, aglycons 
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and methylated in Table 10), iFA for FAT and CARB, iFA3G for CARB and COFFEE and 
MeFA for CARB and COFFEE. None of the colonics gave significance. 
In summary, only for the early metabolites (compare tmax values in Table 25) a treatment 
effect on AUC could be observed, even if the effects are not consistent between the 
treatments. To investigate, if this effect was compound dependent, a higher number of data 
would be useful to get statistical significances.   
 
Table 17 Model-based treatments effect on plasma AUCs for each metabolite with 95% 
confidence intervals. 
metabolite estimate lower upper p-value 
3-FQA     
CARB / COFFEE 0.269 0.088 0.818 0.021 
FAT / COFFEE 1.332 0.437 4.059 0.614 
FAT / CARB 4.961 1.672 14.716 0.004 
4-FQA     
CARB / COFFEE 0.137 0.026 0.706 0.018 
FAT / COFFEE 1.424 0.276 7.350 0.673 
FAT / CARB 10.411 2.107 51.449 0.004 
5-CQA     
CARB / COFFEE 0.590 0.358 0.971 0.038 
FAT / COFFEE 1.220 0.738 2.018 0.437 
FAT / CARB 2.069 1.270 3.370 0.003 
5-FQA     
CARB / COFFEE 0.645 0.494 0.843 0.001 
FAT / COFFEE 0.736 0.563 0.961 0.024 
FAT / CARB 1.140 0.879 1.479 0.324 
CA3S     
CARB / COFFEE 0.260 0.040 1.705 0.160 
FAT / COFFEE 0.551 0.082 3.715 0.540 
FAT / CARB 2.119 0.339 13.239 0.422 
CA4S     
CARB / COFFEE 0.018 0.002 0.156 0.000 
FAT / COFFEE 0.026 0.003 0.224 0.001 
FAT / CARB 1.435 0.183 11.279 0.731 
DHCA     
CARB / COFFEE 0.709 0.131 3.831 0.690 
FAT / COFFEE 0.222 0.041 1.193 0.079 
FAT / CARB 0.313 0.060 1.640 0.169 
DHCA3S     
CARB / COFFEE 0.288 0.042 1.953 0.202 
FAT / COFFEE 0.556 0.081 3.816 0.551 
FAT / CARB 1.932 0.287 13.008 0.499 
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metabolite estimate lower upper p-value 
DHFA     
CARB / COFFEE 0.984 0.737 1.313 0.912 
FAT / COFFEE 0.859 0.646 1.142 0.295 
FAT / CARB 0.873 0.659 1.156 0.342 
DHFA4G     
CARB / COFFEE 0.999 0.751 1.327 0.992 
FAT / COFFEE 0.906 0.682 1.204 0.496 
FAT / CARB 0.907 0.688 1.197 0.491 
DHFA4S     
CARB / COFFEE 1.116 0.796 1.564 0.525 
FAT / COFFEE 0.862 0.618 1.202 0.381 
FAT / CARB 0.772 0.558 1.069 0.119 
DHiFA     
CARB / COFFEE 0.868 0.589 1.279 0.474 
FAT / COFFEE 0.897 0.609 1.321 0.581 
FAT / CARB 1.033 0.707 1.509 0.867 
DHiFA3G     
CARB / COFFEE 0.911 0.621 1.336 0.632 
FAT / COFFEE 0.781 0.532 1.145 0.204 
FAT / CARB 0.857 0.593 1.238 0.411 
FA4G     
CARB / COFFEE 1.267 0.793 2.024 0.323 
FAT / COFFEE 1.180 0.738 1.886 0.490 
FAT / CARB 0.931 0.595 1.457 0.756 
FA4S     
CARB / COFFEE 1.192 0.902 1.575 0.216 
FAT / COFFEE 1.214 0.922 1.598 0.167 
FAT / CARB 1.018 0.778 1.333 0.895 
iFA     
CARB / COFFEE 1.172 0.796 1.724 0.421 
FAT / COFFEE 0.765 0.526 1.115 0.163 
FAT / CARB 0.653 0.449 0.951 0.026 
iFA3G     
CARB / COFFEE 1.182 1.012 1.380 0.035 
FAT / COFFEE 1.019 0.872 1.190 0.816 
FAT / CARB 0.862 0.741 1.002 0.054 
mDHCoA     
CARB / COFFEE 0.832 0.477 1.453 0.518 
FAT / COFFEE 1.176 0.659 2.100 0.583 
FAT / CARB 1.413 0.805 2.482 0.229 
mDHCoAS     
CARB / COFFEE 0.861 0.156 4.756 0.864 
FAT / COFFEE 0.288 0.051 1.607 0.156 
FAT / CARB 0.334 0.062 1.807 0.203 
MeFA     
CARB / COFFEE 0.749 0.582 0962 0.024 
FAT / COFFEE 0.860 0.669 1105 0.238 
FAT / CARB 1.148 0.900 1466 0.266 
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The above-mentioned findings are summarized in Table 18 as statistical significant 
differences for AUC for each metabolite and each treatment. 
 
Table 18 Summary of statistical significant differences observed for individual metabolite 
plasma AUC. “>1” means the numerator is higher. “<1” means the denominator is higher. 
 CARB / COFFEE FAT / COFFEE FAT / CARB 
3-FQA <1  >1 
4-FQA <1  >1 
5-CQA <1  >1 
5-FQA <1 <1  
CA4S <1 <1  
iFA   <1 
iFA3G >1   
MeFA >1   
    
 
Additionally to the statistical analysis for single metabolites, the metabolites were divided into 
groups, according to similaries and chemical properties, which were then compared to 
determine any possible differences (see Table 10). 
Table 19 shows the summary statistics on sum of AUCs for quinics, phenolics, colonics, 
caffeics, ferulics, sulfates, glucuronides, aglycons and methylated with lower and upper 
bounds by treatments (see also Figure 44). For all three treatments, our initial analysis of the 
metabolites by main groups (quinics, phenolics and colonics) showed very low sums of 
AUCs from plasma after only coffee consumption for the quinics, and high sums for the 
colonics.  
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Table 19 Summary statistics on sum of plasma AUCs for quinics, phenolics, colonics, ferulics, 
sulfates, glucuronides, aglycons and methylated with lower and upper bounds [nM*min]. 
  n geomean lower upper 
quinics 
    
COFFEE 13 3,414 1,826 6,383 
CARB 14 2,263 1,290 3,968 
FAT 14 3,419 1,911 6,117 
phenolisc 
    
COFFEE 13 58,020 40,983 82,138 
CARB 14 63,832 43,215 94,285 
FAT 14 61,827 43,968 86,939 
colonics 
    
COFFEE 13 678,482 386,128 1,192,192 
CARB 14 595,412 392,430 903,384 
FAT 14 552,352 378,628 805,786 
caffeics 
    
COFFEE 13 112,489 698,28 181,215 
CARB 14 106,115 778,43 144,654 
FAT 14 105,239 765,12 144,750 
ferulics     
COFFEE 13 259365 110039 611331 
CARB 14 250560 119811 523994 
FAT 14 224745 132393 381519 
sulfates     
COFFEE 13 181427 76256 431647 
CARB 14 154480 65667 363410 
FAT 14 134077 65284 275359 
glucuronides     
COFFEE 13 72318 41530 125931 
CARB 14 75231 42765 132343 
FAT 14 66874 40415 110655 
aglycons     
COFFEE 13 148379 79507 276910 
CARB 14 136054 74984 246862 
FAT 14 121122 77630 188980 
methylated     
COFFEE 13 207110 115228 372258 
CARB 14 189808 112683 319721 
FAT 14 184298 123553 274908 
 
 
4 Results and discussion 
79 
 
 
 
 
Figure 44 Sum of plasma AUCs for chlorogenic, phenolic, colonic, caffeic, ferulic, sulfated, 
glucuronided, aglycon and methylated compounds by treatment plotted as geometric means. 
T1: COFFEE, T2: CARB, T3: FAT. (n = 13 or 14 (see Table 19)); Data modifications deviant from 
the norm were agreed during the blind data review meeting (see page 52). Lower and upper 
bounds are hidden for a better overview. 
In the plasma samples of the 14 healthy volunteers, we determined approximately 0.5% 
(3,414 nM*min) as quinics of the sum of the AUCs of all metabolites identified, 8.7% 
(58,020 nM*min) as phenolics and the highest quantity (approximately 90.8% 
(678,482 nM*min)) revealed the ones formed in the colon (colonics). The single metabolites 
which were related to the three groups may be subjected to varying amounts. To point it out, 
the geomeans were between 9.0 nM*min (4-FQA, CARB) and 1,236.6 nM*min (5-FQA, 
COFFEE) for the quinics, between 2.3 nM*min (CA4S, CARB) and 29,088.4 nM*min (MeFA, 
CARB) for the phenolics and between 5,466.5 nM*min (DHCA, FAT) and 117,846 nM*min 
(DHFA, COFFEE) for the colonics. For all treatments, the four colonics with the highest 
plasma concentrations were mDHCoA (142,728 nM*min; 25.8%)), DHFA (117,846 nM*min; 
21.3%), DHCA3S (74,525 nM*min; 13.5%), and DHiFA (61,695 nM*min; 11.2%). Noticeable 
for these compounds was a slow distribution phase followed by a much slower terminal 
elimination phase, giving a long time period with relatively high plasma concentrations (cp. 
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Figure 41). Thus, 71.8% of the sum of the plasma AUCs for all metabolites identified 
comprised of these four metabolites.  
Calculating the amounts as percent of sum of AUC of all determined metabolites (COFFEE 
treatment) gave 15.2% for the caffeics, 35.0% for the ferulics, 24.5% for the sulfates, 9.8% 
for the glucuronides, 20.1% for the aglycons and 28.0% for the methylated compounds. 
Table 20 shows the effects of treatments on AUC with 95% confidence interval for grouped 
derivatives. For quinic derivatives, significant statistical differences were observed between 
CARB and COFFEE as well as between FAT and CARB treatment. For phenolic, colonic, 
caffeic and ferulic derivatives, the three treatments do not show any statistically significant 
differences among themselves. For sulfated derivatives, a significant statistical difference 
was observed between FAT and COFFEE treatment. For remaining derivatives, that is 
glucuronide, aglycons and methylated derivatives, the three treatments did not show any 
statistically significant differences among themselves. 
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Table 20 Model-based effects of treatments on sum of plasma AUCs for chlorogenics, 
phenoloics, colonics, ferulics, sulfates, glucuronides, aglycons and methylated with 95% 
confidence intervals. 
  estimate lower upper p-value 
chlorogenics 
    
CARB / COFFEE 0.673 0.503 0.9 0.008 
FAT / COFFEE 1.016 0.759 1.36 0.914 
FAT / CARB 1.511 1.137 2.007 0.004 
phenolics 
    
CARB / COFFEE 1.08 0.96 1.216 0.202 
FAT / COFFEE 1.046 0.929 1.177 0.455 
FAT / CARB 0.969 0.863 1.087 0.587 
colonics 
    
CARB / COFFEE 0.868 0.689 1.093 0.228 
FAT / COFFEE 0.805 0.639 1.014 0.065 
FAT / CARB 0.928 0.741 1.162 0.513 
caffeics 
    
CARB / COFFEE 0.937 0.723 1.215 0.625 
FAT / COFFEE 0.93 0.717 1.205 0.581 
FAT / CARB 0.992 0.769 1.278 0.949 
ferulics 
    
CARB / COFFEE 0.965 0.769 1.21 0.757 
FAT / COFFEE 0.865 0.69 1.086 0.211 
FAT / CARB 0.897 0.719 1.118 0.334 
sulfates 
    
CARB / COFFEE 0.834 0.68 1.023 0.082 
FAT / COFFEE 0.724 0.591 0.888 0.002 
FAT / CARB 0.868 0.712 1.058 0.162 
glucuronides 
    
CARB / COFFEE 1.021 0.856 1.219 0.814 
FAT / COFFEE 0.908 0.761 1.084 0.286 
FAT / CARB 0.889 0.748 1.056 0.181 
aglycons 
    
CARB / COFFEE 0.913 0.704 1.185 0.494 
FAT / COFFEE 0.813 0.627 1.055 0.119 
FAT / CARB 0.89 0.691 1.147 0.369 
methylated 
    
CARB / COFFEE 0.906 0.698 1.175 0.456 
FAT / COFFEE 0.879 0.678 1.141 0.333 
FAT / CARB 0.971 0.753 1.252 0.82 
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According to previous studies, intact CGA were determined only at low levels in plasma, and 
3-, 4-, and 5-CQA could not be detected after coffee consumption at all [Matsui et al., 2007, 
Nardini et al., 2002, Stalmach et al., 2009]. Our results confirmed these findings, as only 
0.5% of all the metabolites we detected were quinic conjugates. For the quinics, we only 
identified 5-CQA in measureable amounts in plasma, but we were able to detect all FQA 
isomers in the same plasma samples. This is in contrast to the total amount of CGA in the 
instant coffee that was consumed, in which the CQA were detected at much higher 
concentrations as the FQA (5-CQA: 46%, 3-CQA: 12%, 4-CQA: 16%, 5-FQA: 9%, and 4-
FQA: 2%). Finally, the mechanisms of absorption of FQA and CQA are not fully investigated. 
Erk et al. also observed that FQA were absorbed  in vivo to a higher extent than CQA. They 
speculated that this finding is related to the different chemical structures of the compounds. 
The increasing molecular size and higher lipophilicity of FQA might lead to a better 
absorption. Additionally, the increasing permeation of FQA may be explained by absorption 
mechanisms, presumably active transport as discussed by Erk et al. [Erk et al., 2013]. Due to 
high concentrations of CA3S, CQA from coffee may be cleaved into CA, and then further 
sulfated. It is reported that FQA seem to be more stable against metabolism and/or 
hydrolysis [Farrell et al., 2011] but it is also conceivable, that CQA are methylated to FQA. 
Moreover, Konishi and coworkers showed that FA has a higher affinity for the 
monocarboxylic transporter (MCT) than CA [Konishi et al., 2006]. If we transfer this 
knowledge to FQA and CQA, CQA may not be a good MCT substrate, which could explain 
the lower absorption of CQA compared to FQA in our study. Even if metabolite transport 
might occur via passive diffusion, less CQA would be absorbed [Konishi et al., 2005, 
Murota&Terao, 2003] because CQA have a lower predicted octanol-water partition coefficient 
(logP) and are thus more polar than FQA [ChemSpider a&b]. In detail, the logP value is a 
partition coefficient which indicates the ratio of the concentration of a chemical in a two-
phase system of n-octanol and water. The logP value of 5-CQA is lower than the one of 5-
FQA meaning that 5-CQA is more hydrophil than 5-FQA. The different chemical structures, 
monoisotopic masses and logP values of 5-CQA and 5-FQA are shown in Table 21. 
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Table 21 Molecular formula, monoisotopic masses and logP values of 5-CQA and 5-FQA 
[ChemSpider a&b] 
 
 
 5-CQA (R = H) 5-FQA (R = CH3) 
molecular formula C16H18O9 C17H20O9 
monoisotopic mass 354.095 Da 368.111 Da 
logP -0.36 -0.14 
 
As described, in our study, we observed higher amounts of phenolics (8.7%: CA3S, CA4S, 
FA4G, FA4S, iFA, iFA3G, iFA3S, MeFA) and colonics (90.8%: DHCA, DHCA3S, DHFA, 
DHFA4G, DHFA4S, DHiFA, DHiFA3G, mDHCoA, mDHCoAS) than for chlorogenics (0.5%: 
5-CQA, 3-FQA, 4-FQA, 5-FQA). Notably, these compounds were subject to a slow 
distribution phase followed by an even slower terminal elimination phase. Thus for an 
extended time period, the plasma concentrations of these metabolites, i.e. 78% of all the 
metabolites we investigated, were relatively high. Stalmach and coworkers identified 
DHFA4S, DHCA3S, FA4S, DHFA, and CA3S as the most abundant metabolites in eleven 
healthy volunteers after ingestion of a single cup of instant coffee containing 412 µmol of 
CGA [Stalmach et al., 2009].  
Also coumaric acid derivatives were determined as abundant metabolites in our study. For 
example mDHCoAS was detected as metabolite circulating in high concentrations in the 
plasma samples after coffee consumption. Researchers should investigate whether these 
compounds are responsible for the beneficial effects of coffee. Literature data suggests that, 
for example, DHCA has photo-protective effects – it interferes with biological events that 
initiate after UV exposure in HaCaT cells [Poquet et al., 2008]. Another beneficial effect, a 
higher scavenging effect than that of α-tocopherol and CA, has been reported [Lekse et al., 
2001, Silva et al., 2000]. However, limited data on biological effects of DHFA, mDHCoA, 
DHCA3S and DHiFA are available, and these metabolites should be investigated in the 
future. 
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Higher AUCs for the quinics and early metabolites were detectable when only a single dose 
of coffee was ingested. Fasting conditions led to lower gastric pH-values (pH 1.5 – 3) as 
during meal intake (pH > 5). That may have a stabilizing effect on the CGA. The meals may 
trigger impaired absorption, but only for early metabolites. This finding may be explained by a 
longer resting time in the stomach and upper GIT based on the food matrix. This delay in 
absorption in the stomach and GIT may cause longer presence in the GIT and therefore an 
increased degradation by intestinal enzymes and bacteria. This is notably for the quinics, 
except for 5-FQA. In addition, Price and coworkers have observed a fasting-induced 
suppression of glucuronidation in rats [Price and Jollow, 1989]. We cannot confirm this effect 
with data of our human intervention study, in which no significant differences were detected 
regarding sum of AUCs of glucuronides between all treatments. However, an additional 
fasting-induced suppression cannot be ruled out as the results received after treatment of 14 
participants gave an overview but no verified data. Comparing the results for the two 
treatments with either carbohydrate-rich (CARB) or fat-rich (FAT) food, the trend showed 
higher quinics AUCs after FAT treatment than after CARB treatment. The approximate 33 g 
additional fat ingested by the fat-rich (FAT) food, (compared to high-carb food treatment 
(CARB)) may have allowed better partitioning, or better access to the membrane or 
transporter, as mentioned by Jacobsen et al. before [Jacobsen et al., 1999]. These trends 
were not detected for 5-FQA, and also iFA showed the opposite effect. Nevertheless, only 
low fat-induced effects on AUC were observed. The reason may be the hydrophilicity of 
CGA, meaning that dietary lipids have a limited influence on the absorption and 
bioavailability on this kind of polyphenols. This finding was confirmed by an in vitro digestion 
model, which showed no higher bioaccessibility of phenolic acids from lipid-rich cacao liquor 
(45% fat) in comparison to cacao powder (15% fat) [Ortega et al., 2009].  
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Maximum plasma concentration (Cmax) 
As secondary outcome the effect of the different treatments on the plasma kinetics other than 
the AUCs and sum of AUCs were investigated. 
Table 22 shows the summary statistics on plasma Cmax with lower and upper bounds by 
treatments for each metabolite (see also Figure 45). The geomeans were between 7.6 nM 
(3-FQA, CARB) and 19.2 nM (5-CQA, COFFEE) for the quinics, between 5.8 nM (CA4S, 
CARB) and 60.7 nM (MeFA, COFFEE) for the phenolics and 40.1 nM (DHiFA3G, FAT) and 
449.2 nM (DHFA, COFFEE) for the colonics.  
Table 22 Summary statistics on plasma Cmax for each metabolite and treatment with lower and 
upper bounds [nM]. Data modifications deviant from the norm were agreed during the blind 
data review meeting (see page 52 and Table 12). 
metabolite n geomean lower upper 
3-FQA     
COFFEE 13 10.7 8.6 13.5 
CARB 14 7.6 5.4 10.6 
FAT 14 9.9 7.4 13.2 
4-FQA     
COFFEE 13 9.5 6.4 13.9 
CARB 14 7.4 5.2 10.4 
FAT 14 9.4 6.2 14.2 
5-CQA     
COFFEE 13 19.2 12.9 28.5 
CARB 14 13.6 8.5 21.6 
FAT 14 18.4 11.7 28.9 
5-FQA     
COFFEE 13 17.5 13.2 23.0 
CARB 14 12.0 9.5 15.3 
FAT 14 14.1 10.9 18.1 
CA3S     
COFFEE 13 57.1 28.1 116.0 
CARB 14 46.2 17.3 123.1 
FAT 14 49.9 22.7 109.9 
CA4S     
COFFEE 13 9.8 7.0 13.8 
CARB 14 5.8 4.5 7.3 
FAT 14 6.2 4.9 7.9 
DHCA     
COFFEE 13 88.5 56.3 139.4 
CARB 14 62.7 35.6 110.6 
FAT 14 50.5 20.6 124.3 
DHCA3S     
COFFEE 13 240.3 126.4 456.8 
CARB 14 149.4 43.2 516.4 
FAT 14 169.4 76.9 373.3 
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metabolite n geomean lower upper 
DHFA     
COFFEE 13 449.2 262.8 767.9 
CARB 14 416.4 236.9 732.2 
FAT 14 399.0 229.7 693.0 
DHFA4G        
COFFEE 13 120.0 62.6 22985.0 
CARB 14 117.2 59.1 23267.0 
FAT 14 110.5 58.2 21001.0 
DHFA4S     
COFFEE 13 111.8 23.1 54154.0 
CARB 14 106.5 25.9 43892.0 
FAT 14 95.4 26.9 33782.0 
DHiFA     
COFFEE 13 279.6 174.4 44830.0 
CARB 14 212.3 137.4 32812.0 
FAT 14 234.1 139.9 39183.0 
DHiFA3G     
COFFEE 13 47.9 24.6 9301.0 
CARB 14 41.6 22.4 7738.0 
FAT 14 40.1 20.6 7801.0 
FA4G     
COFFEE 12 30.5 22.5 4155.0 
CARB 13 30.2 19.1 4770.0 
FAT 13 28.8 18.3 4540.0 
FA4S     
COFFEE 13 37.0 20.8 6583.0 
CARB 14 25.8 14.7 4543.0 
FAT 14 29.2 17.2 4952.0 
iFA     
COFFEE 13 23.0 16.1 3283.0 
CARB 14 17.2 12.1 2444.0 
FAT 14 16.5 10.6 2545.0 
iFA3G     
COFFEE 13 51.3 37.3 7046.0 
CARB 14 49.2 33.5 7241.0 
FAT 14 47.0 32.6 6787.0 
MeFA     
COFFEE 13 60.7 36.7 10030.0 
CARB 14 44.1 28.1 6918.0 
FAT 14 44.2 27.6 7058.0 
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Figure 45 Plasma Cmax by treatment and metabolites plotted as geometric means. T1: COFFEE, 
T2: CARB, T3: FAT. (n = 13 or 14 (see Table 22)); Data modifications deviant from the norm 
were agreed during the blind data review meeting (see page 52 and). Lower and upper bounds 
are hidden for a better overview. 
Table 23 shows the correlation of Cmax dependent on treatment with a detectable treatment 
effect on Cmax with 95% confidence interval for selected metabolites. The Cmax variable was 
noticeably affected by breakfast consumption. For all quinics, there were significant 
correlations in Cmax between CARB and COFFEE as well as FAT and CARB. Five of eight 
phenolics also showed significant correlations between treatments: CA3S for 
CARB / COFFEE and CA4S, FA4S, iFA and MeFA for CARB / COFFEE as well as 
FAT / COFFEE. Only two colonics, DHCA for FAT and COFFEE and DHiFA for CARB and 
COFFEE, showed significant correlations between treatments. 
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Table 23 Model-based treatments effect on Cmax for each metabolite with 95% confidence 
intervals. 
metabolite estimate lower upper p-value 
3-FQA     
CARB / COFFEE 0.715 0.630 0.811 0.000 
FAT / COFFEE 0.936 0.825 1.062 0.303 
FAT / CARB 1.309 1.157 1.480 0.000 
4-FQA     
CARB / COFFEE 0.794 0.717 0.879 0.000 
FAT / COFFEE 1.014 0.916 1.123 0.786 
FAT / CARB 1.277 1.157 1.410 0.000 
5-CQA     
CARB / COFFEE 0.740 0.633 0.865 0.000 
FAT / COFFEE 1.044 0.892 1.222 0.591 
FAT / CARB 1.410 1.211 1.643 0.000 
5-FQA     
CARB / COFFEE 0.681 0.598 0.775 0.000 
FAT / COFFEE 0.796 0.699 0.906 0.001 
FAT / CARB 1.168 1.030 1.325 0.016 
CA3S     
CARB / COFFEE 0.779 0.630 0.964 0.021 
FAT / COFFEE 0.835 0.673 1.036 0.102 
FAT / CARB 1.072 0.872 1.317 0.510 
CA4S     
CARB / COFFEE 0.604 0.513 0.712 0.000 
FAT / COFFEE 0.651 0.553 0.767 0.000 
FAT / CARB 1.078 0.923 1.259 0.345 
DHCA     
CARB / COFFEE 0.729 0.490 1.084 0.118 
FAT / COFFEE 0.571 0.385 0.849 0.006 
FAT / CARB 0.784 0.531 1.158 0.222 
DHCA3S     
CARB / COFFEE 0.632 0.359 1.110 0.110 
FAT / COFFEE 0.631 0.358 1.114 0.112 
FAT / CARB 0.999 0.569 1.756 0.998 
DHFA     
CARB / COFFEE 0.967 0.731 1.278 0.812 
FAT / COFFEE 0.878 0.666 1.158 0.357 
FAT / CARB 0.908 0.692 1.193 0.490 
DHFA4G     
CARB / COFFEE 0.962 0.760 1.217 0.746 
FAT / COFFEE 0.892 0.705 1.129 0.342 
FAT / CARB 0.928 0.738 1.167 0.521 
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metabolite estimate lower upper p-value 
DHFA4S     
CARB / COFFEE 1.037 0.786 1.369 0.795 
FAT / COFFEE 0.881 0.670 1.158 0.363 
FAT / CARB 0.849 0.650 1.109 0.230 
DHiFA     
CARB / COFFEE 0.760 0.577 0.999 0.049 
FAT / COFFEE 0.838 0.637 1.103 0.207 
FAT / CARB 1.103 0.844 1.442 0.472 
DHiFA3G     
CARB / COFFEE 0.865 0.662 1.130 0.286 
FAT / COFFEE 0.833 0.638 1.088 0.180 
FAT / CARB 0.963 0.745 1.245 0.775 
FA4G     
CARB / COFFEE 1.042 0.871 1.246 0.653 
FAT / COFFEE 0.996 0.833 1.191 0.965 
FAT / CARB 0.956 0.807 1.133 0.603 
FA4S     
CARB / COFFEE 0.690 0.604 0.789 0.000 
FAT / COFFEE 0.767 0.672 0.876 0.000 
FAT / CARB 1.112 0.977 1.266 0.109 
iFA     
CARB / COFFEE 0.722 0.647 0.806 0.000 
FAT / COFFEE 0.700 0.629 0.779 0.000 
FAT / CARB 0.969 0.871 1.079 0.569 
iFA3G     
CARB / COFFEE 0.979 0.859 1.116 0.755 
FAT / COFFEE 0.933 0.818 1.064 0.298 
FAT / CARB 0.952 0.838 1.082 0.451 
MeFA     
CARB / COFFEE 0.731 0.673 0.795 0.000 
FAT / COFFEE 0.733 0.674 0.797 0.000 
FAT / CARB 1.002 0.925 1.087 0.955 
 
The above-named findings are summarized in Table 24 as statistical significant differences 
for Cmax for each metabolite and each treatment. 
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Table 24 Summary of statistical significant differences observed for individual metabolite 
plasma Cmax. “>1” means the numerator is higher. “<1” means the denominator is higher. 
 CARB / COFFEE FAT / COFFEE FAT / CARB 
3-FQA <1  >1 
4-FQA <1  >1 
5-CQA <1  >1 
5-FQA <1 <1 >1 
CA3S <1   
CA4S <1 <1  
DHCA  <1  
DHiFA <1   
FA4S <1 <1  
iFA <1 <1  
MeFA <1 <1  
 
We observed that there were significant differences in Cmax between treatments for quinics 
and phenolics (see Table 23 and Table 24). Except for the two metabolites DHCA and 
DHFA, there were no significant differences in Cmax between treatments for the colonics. As 
previously shown for the plasma AUCs of our study, Cmax values detected for most 
metabolites measured after consumption of coffee without a meal were significantly higher 
than for metabolites measured after consumption of coffee with a meal. This may be due to 
faster metabolite absorption, resulting in a fast distribution phase and followed by an even 
faster terminal elimination phase (sharper but shorter curves). Additionally, we observed 
significant correlations of Cmax, only for the quinics, and carbohydrate (CARB) and fat-rich 
(FAT) treatments. A fat-rich meal led to higher amounts of quinic metabolites in plasma than 
a high-carb meal. This result suggests that there is a substantial influence of treatments on 
Cmax for the quinics. 
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Time at which Cmax is observed (tmax) 
The reported influence of threatments on Cmax also affected the time at which Cmax occured. 
Therefore, we also investigated the of tmax in relation to the different treatments. 
Table 25 shows the summary statistics on plasma tmax with lower and upper bounds by 
treatments (see also Figure 46). The first appearing metabolite was iFA with a tmax of 
15.8 min, when only coffee was ingested. However, all metabolites defined in the quinic or 
phenolic group ahowed at latest a tmax value of 41.7 min (for iFA3G, COFFEE). A fat rich 
meal led to a delay up to 118.9 min for FA4G. In contrast to this, the defined group of colonic 
metabolites showed an accordingly delayed tmax compared to the metabolites of the quinic 
and phenolic groups, respectively. The range of tmax was between 396.5 min (DHFA; 
COFFEE) and 612.3 min (DHiFA3G, CARB). For most of the dihydro metabolites, excepted 
DHFA4S and DHiFA, did not reach a baseline value, even after 15 h (see Figure 28 Figure 
31, and Figure 34, Figure 39, Figure 40). It is conceivable that we showed probably only the 
beginning of the colonic metabolites entering in the bloodstream. 
After initial detection at 6 h post-treatment, the metabolites FA4S and MeFA were detected a 
second time at 12 h (see Figure 36 and Figure 41). Also, after COFFEE there was an early 
increase in detection of the DH compounds in plasma, when compared to the other 
treatments (see for examples Figure 28, 30 and 34). 
 
Table 25 Summary statistics on plasma tmax for each metabolite ad treatment with lower and 
upper bounds [min]. Data modifications deviant from the norm were agreed during the blind 
data review meeting (see page 52 and Table 12). 
metabolite n geomean lower upper 
3-FQA     
COFFEE 13 28.4 20.2 40.0 
CARB 13 68.6 44.7 105.2 
FAT 14 69.4 49.4 97.3 
4-FQA     
COFFEE 11 36.2 23.2 56.7 
CARB 9 93.5 70.3 124.2 
FAT 12 83.3 67.3 103.2 
5-CQA     
COFFEE 13 30.0 20.1 44.8 
CARB 14 71.4 46.1 110.5 
FAT 14 65.5 47.4 90.3 
5-FQA     
COFFEE 13 37.1 24.0 57.5 
CARB 14 95.3 71.9 126.2 
FAT 14 75.6 53.7 106.5 
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metabolite n geomean lower upper 
CA3S     
COFFEE 13 27.0 16.7 43.5 
CARB 12 112.8 73.8 172.2 
FAT 13 85.7 49.3 149.0 
CA4S     
COFFEE 13 16.7 12.9 21.7 
CARB 9 89.4 38.2 209.2 
FAT 9 48.3 24.3 95.6 
DHCA     
COFFEE 13 398.5 275.0 577.4 
CARB 14 483.7 369.7 632.9 
FAT 13 483.5 411.3 568.4 
DHCA3S     
COFFEE 13 454.7 318.7 648.8 
CARB 13 536.9 449.1 641.9 
FAT 14 509.3 439.4 590.2 
DHFA     
COFFEE 13 396.5 246.3 638.3 
CARB 14 493.7 393.7 619.1 
FAT 14 473.4 397.7 563.6 
DHFA4G        
COFFEE 13 464.9 328.0 658.8 
CARB 14 546.7 446.0 670.1 
FAT 14 497.4 412.0 600.6 
DHFA4S     
COFFEE 13 444.7 310.0 637.9 
CARB 14 520.3 419.5 645.3 
FAT 14 479.6 393.3 584.9 
DHiFA     
COFFEE 13 437.2 307.9 620.7 
CARB 14 508.2 396.9 650.8 
FAT 14 507.8 430.7 598.6 
DHiFA3G     
COFFEE 13 507.4 377.5 682.2 
CARB 14 612.3 512.9 730.9 
FAT 14 531.1 439.3 642.0 
FA4G     
COFFEE 12 26.7 14.0 51.2 
CARB 13 89.6 55.5 144.5 
FAT 13 118.9 61.7 229.3 
FA4S     
COFFEE 13 21.8 15.2 31.2 
CARB 14 67.9 36.0 128.3 
FAT 14 71.4 35.2 144.7 
iFA     
COFFEE 13 15.8 13.1 19.2 
CARB 14 56.9 31.3 103.3 
FAT 14 52.6 25.7 107.6 
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metabolite n geomean lower upper 
iFA3G     
COFFEE 13 41.7 19.2 90.7 
CARB 14 109.2 73.3 162.6 
FAT 14 118.1 77.8 179.3 
MeFA     
COFFEE 13 16.7 12.9 21.7 
CARB 14 55.3 35.7 85.6 
FAT 14 59.3 29.6 118.6 
 
Table 26 shows the correlation of tmax dependent on treatment with a detectable treatment 
effect on tmax with 95% confidence interval for selected metabolites. Most metabolites we 
measured showed significant differences in tmax between CARB and COFFEE as well as 
between FAT and COFFEE treatment. However, four metabolites, namely DHCA3S, 
DHFA4G, DHFA4S and DHiFA, showed no significant correlation between FAT and 
COFFEE treatament. Additionally, CA4S and DHiFA3G revealed significance between FAT 
and CARB (pc. Figure 41). 
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Figure 46 Plasma tmax by treatment and metabolites plotted as geometric means. T1: COFFEE, 
T2: CARB, T3: FAT. (n = 13 or 14 (see Table 25)); Data modifications deviant from the norm 
were agreed during the blind data review meeting (see page 52). Lower and upper bounds are 
hidden for a better overview. 
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Table 26 Model-based treatments effect on plasma tmax for each metabolite with 95% 
confidence intervals. 
metabolite estimate lower upper p-value 
3-FQA     
CARB / COFFEE 2.412 1.813 3.207 0.000 
FAT / COFFEE 2.438 1.843 3.226 0.000 
FAT / CARB 1.011 0.764 1.338 0.939 
4-FQA     
CARB / COFFEE 2.574 1.931 3.431 0.000 
FAT / COFFEE 2.298 1.760 3.000 0.000 
FAT / CARB 0.893 0.673 1.183 0.430 
5-CQA     
CARB / COFFEE 2.378 1.765 3.204 0.000 
FAT / COFFEE 2.178 1.615 2.938 0.000 
FAT / CARB 0.916 0.684 1.227 0.557 
5-FQA     
CARB / COFFEE 2.564 1.963 3.350 0.000 
FAT / COFFEE 2.036 1.559 2.660 0.000 
FAT / CARB 0.794 0.611 1.032 0.085 
CA3S     
CARB / COFFEE 4.108 2.916 5.788 0.000 
FAT / COFFEE 3.200 2.282 4.488 0.000 
FAT / CARB 0.779 0.555 1.093 0.148 
CA4S     
CARB / COFFEE 5.549 3.323 9.264 0.000 
FAT / COFFEE 3.028 1.814 5.055 0.000 
FAT / CARB 0.546 0.317 0.940 0.029 
DHCA     
CARB / COFFEE 1.203 1.026 1.412 0.023 
FAT / COFFEE 1.196 1.016 1.408 0.032 
FAT / CARB 0.994 0.846 1.168 0.941 
DHCA3S     
CARB / COFFEE 1.183 1.027 1.363 0.020 
FAT / COFFEE 1.111 0.967 1.278 0.137 
FAT / CARB 0.940 0.816 1.082 0.388 
DHFA     
CARB / COFFEE 1.253 1.056 1.487 0.010 
FAT / COFFEE 1.195 1.009 1.415 0.039 
FAT / CARB 0.953 0.807 1.126 0.574 
DHFA4G     
CARB / COFFEE 1.176 1.038 1.332 0.011 
FAT / COFFEE 1.065 0.940 1.207 0.320 
FAT / CARB 0.906 0.802 1.023 0.112 
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metabolite estimate lower upper p-value 
DHFA4S     
CARB / COFFEE 1.174 1.016 1.357 0.029 
FAT / COFFEE 1.078 0.933 1.244 0.308 
FAT / CARB 0.918 0.797 1.056 0.230 
DHiFA     
CARB / COFFEE 1.161 1.013 1.331 0.032 
FAT / COFFEE 1.160 1.012 1.330 0.033 
FAT / CARB 0.999 0.875 1.141 0.991 
DHiFA3G     
CARB / COFFEE 1.212 1.071 1.370 0.002 
FAT / COFFEE 1.051 0.929 1.189 0.429 
FAT / CARB 0.867 0.770 0.977 0.019 
FA4G     
CARB / COFFEE 3.503 2.326 5.274 0.000 
FAT / COFFEE 4.658 3.093 7.015 0.000 
FAT / CARB 1.330 0.895 1.975 0.158 
FA4S     
CARB / COFFEE 2.999 2.018 4.455 0.000 
FAT / COFFEE 3.242 2.190 4.798 0.000 
FAT / CARB 1.081 0.735 1.590 0.692 
iFA     
CARB / COFFEE 3.637 2.495 5.301 0.000 
FAT / COFFEE 3.351 2.318 4.843 0.000 
FAT / CARB 0.921 0.637 1.332 0.663 
iFA3G     
CARB / COFFEE 2.611 1.716 3.971 0.000 
FAT / COFFEE 2.810 1.846 4.277 0.000 
FAT / CARB 1.076 0.713 1.625 0.726 
MeFA     
CARB / COFFEE 3.325 2.331 4.744 0.000 
FAT / COFFEE 3.565 2.500 5.086 0.000 
FAT / CARB 1.072 0.758 1.517 0.694 
 
The above-mentioned findings are summarized in Table 27 as statistical significant 
differences for tmax for each metabolite and each treatment. 
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Table 27 Summary of statistical significant differences observed for individual metabolite 
plasma tmax. “>1” means the numerator is higher. “<1” means the denominator is higher. 
 CARB / COFFEE FAT / COFFEE FAT / CARB 
3-FQA >1 >1  
4-FQA >1 >1  
5-CQA >1 >1  
5-FQA >1 >1  
CA3S >1 >1  
CA4S >1 >1 <1 
DHCA >1 >1  
DHCA3S >1   
DHFA >1 >1  
DHFA4G >1   
DHFA4S >1   
DHiFA >1 >1  
DHiFA3G >1  <1 
FA4G >1 >1  
FA4S >1 >1  
iFA >1 >1  
iFA3G >1 >1  
MeFA >1 >1  
 
As shown in our study, also other research groups reported that the dihydro compounds, 
found with the highest plasma concentrations, are typical colonic metabolites, since more 
extensive hydrolysis occurs in colon and less in the small intestine [Plumb et al., 1999]. This 
means microbiota is responsible for degradation to DHFA and DHCA derivatives [Williamson 
et al., 2011], which circulated later in plasma and had a delayed tmax in comparison to the 
other metabolites from the quinic or phenolic groups [Renouf et al., 2010a, Renouf et al., 
2010b, Renouf et al., 2010c]. Finally, in accordance to published data [Renouf et al., 2010b, 
Lang et al., 2013a], the metabolites detected in this study could be separated into two 
groups: early metabolites, with a tmax occurring between 0 - 2 h, and late metabolites, with a 
tmax occurring between 7 - 10 h post-ingestion of the instant coffee we studied. Some 
metabolites had tmax values that occur really early in the plasma after coffee consumption. 
These results corroborates previous findings for phenolic acids that some compounds could 
be absorbed or metabolized by the stomach and/or in the upper part of the small intestine 
[Poquet et al., 2008, Zhao et al., 2004, Konishi et al., 2006]. In a previous study, metabolites 
that were detected later in plasma such as FA, no return to baseline was observed for most 
healthy subjects 12 h after coffee consumption [Renouf et al., 2010b]. Our study 
demonstrated that even after 15 h the metabolite concentrations did not reach to baseline 
and this showed probably only the beginning of the colonic metabolites entering in the 
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bloodstream. Plasma collection at time points up to 24 h, as performed in other studies [Guy 
et al., 2009],  or even up to 48 h, seem to be meaningful. Nevertheless, for such late time 
points, sample collection should be performed with shorter time intervals, e.g. every two 
hours. In this line, it might be possible that even a 48 h polyphenol free diet prior coffee 
intake was not sufficient to reach a full wash out of the colonic CGA metabolites circulating in 
the blood of the volunteers.  
Comparable to the findings described by Farrell and coworkers, we determined methylated 
compounds like iFA and MeFA, but no CA, directly (~16 min) after coffee consumption. 
Additionally, we found that only the phase II conjugates FA4S and FA4G appear early post-
coffee consumption in plasma. No FA was detected. We confirmed the hypothesis of Farrell 
and members, that the stomach can be an important site for absorption of pharmacologically 
active compounds, such as polyphenols from coffee. Furthermore, the ability of the human 
gastric mucosal cells (apart from the liver) to form methylate conjugates as well as execute 
biotransformation reactions by SULT and UGT was shown, as also previously observed in 
vitro [Farrell et al., 2011, Poquet et al., 2008]. 
We also identified two tmax for MeFA and FA4S in plasma, as described by other authors for 
other metabolites [Renouf et al., 2010b, Guy et al., 2009]. This biphasic behavior suggests 
that absorption occurs both in the stomach/small intestine (first peak) and in the colon 
(second peak). It may also suggest that plasma appearance is influenced by the 
enterohepatic circulation. 
The tmax for all metabolites were strongly affected by treatment. Ingestion of the coffee 
beverage in combination with the food matrix led to enhanced absorption, probably already in 
the stomach or in the upper part of the small intestine. For example, FA4G reached tmax 
27 min after consumption of coffee only, and 119 min after consumption of coffee with a fat-
rich meal. Overall, the delay in tmax seemed to be more pronounced for the earlier 
metabolites as for the colonic once. Presumably, CGA may bind to digestive proteins, lipids 
and carbohydrates. This would reduce the possibility for enzymes such as esterases to 
cleave the CGA to release the free acids. Additionally, this would increase gastrointestoinal 
bulk and may also reduce the availability of the coffee CGA, at least in the stomach and 
small intestine. On the way down to the colon, CGA and the released free acids are 
absorbed and transformed into their corresponding dihydro derivatives. Thus, the arrival into 
the colon was delayed, which explains the later tmax for the colonics in plasma in general. 
This delay was also caused by the food matrix, but not as much as for the earlier metabolites 
such as FA4G.  
It seemed that a CARB treatment had a stronger effect on tmax than FAT treatment. At a very 
early stage in research of others groups, in vitro experiments with isolated brush border 
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membrane vesicles (150 – 200 µg protein) demonstrated that low levels of selected phenolic 
acids (CQA, CA, FA at concentrations of 1 mM) can effectively reduce NA+-dependent 
glucose uptake from a reaction mixture containing 50 µM D-[3H]-glucose determined by a 
liquid scintillation spectrometer. At 1 mM, CQA reduced glucose uptake by approximately 
81%, while only a slight reduction of 35 and 38% respectively was observed in the presents 
of CA and FA [Welsch et al., 1989a&b]. At the present time, it is assumed that several 
polyphenols inhibit glucose uptake transporters, such like MCTs, SGLT1 and GLUTs, but 
also the opposite effect, including reduction of polyphenol uptake by sugar-rich ingredients, 
may have a meaningful impact [Peng et al., 2015, Shimizu et al., 2010, Williamson, 2013]. 
This interdependence influence may explain the stronger effects on tmax between COFFEE 
and CARB in comparison to COFFEE and FAT as well as the significant differences of CA4S 
and DHiFA3G when comparing CARB and FAT treatment.  
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4.2 Availability of instant coffee chlorogenic acids and metabolites 
in urine  
For the statistical calculations, Table 28 shows the number of subjects where specifically 
detected metabolites in urine where detected after each treatment. The data modifications 
were agreed during a blind data review meeting and included following: For urinary excretion, 
absolute values were used instead of expressing them as a percentage ingested dose, 
except for QA, which was determined as µmol QA/g creatinine. Moreover, when the 
measurements were below the LOQ for a given time period, the contribution was set to 0. 
Table 28 Number of subjects with a specific detected metabolite in urine samples (0 - 24 h) by 
treatment. NA: not available. Data modifications deviant from the norm were agreed during the 
blind data review meeting (see page 52). 
metabolite COFFEE CARB FAT 
3CQA 14 14 14 
3FQA 14 14 14 
4CQA 14 14 14 
4FQA 14 14 14 
5CQA 14 14 14 
5CQA4S 7 7 7 
5FQA 14 14 14 
CA 14 14 14 
CA3G 1 NA 1 
CA3S 14 14 14 
CA4G 12 13 13 
CA4S 14 14 14 
CQA3G 5 1 5 
CQA3S 9 9 9 
CQL 14 13 14 
CQLG 14 13 14 
DHCA 14 14 14 
DHCA3G 14 14 14 
DHCA3S 14 14 14 
DHCA4G 13 13 13 
DHCA4S 14 14 14 
DHFA 13 13 13 
DHFA4G 14 14 14 
DHFA4S 14 14 14 
DHIFA NA 1 NA 
DHIFA3G 14 14 14 
DHIFA4S 13 12 13 
FA 10 12 11 
FA4S 14 13 14 
FAG 14 14 14 
FQA4G 10 13 12 
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metabolite COFFEE CARB FAT 
FQA4S 14 14 14 
IFA 3 4 3 
IFA3G 14 14 14 
IFA3S 14 14 14 
Quinic acid 14 14 14 
 
The total 24 h urine as well as the time spans (0 – 6 h, 6 – 12 h and 12 – 24 h) for urinary 
excretion summary statistics for the sum of the metabolites concentrations are shown in 
Table 29 and Figure 47. In total, as geomean of the 14 urinary samples and dependent from 
treatment between 354.2 – 406.2 nmol/mL of the detected metabolites were excreted. In the 
time period from 0 to 6 h, we detected 63.2 – 95.4 nmol/mL, which was increasing up to 
186.8 – 237.0 nmol/mL in the time period from 6 to 12 h. From 12 to 24 h, between 61.2 –
 75.3 nmol/mL of all quantified metabolites were excreted. This is almost in the range of the 
first time period.  
Table 29 Summary statistics on sum of metabolites in urine samples (0 – 24 h, 0 – 6 h, 6 – 12 h 
and 12 – 24 h) with lower and upper bounds [nmol/mL]. Data modifications deviant from the 
norm were agreed during the blind data review meeting (see page 52). 
  n geomean lower upper 
0 - 24 h 
    
COFFEE 14 406.2 210 785.6 
CARB 14 396.8 207.1 760.3 
FAT 14 354.2 200.2 626.6 
0 - 6 h 
    
COFFEE 14 95.4 45.0 202.4 
CARB 14 63.2 39.1 102.1 
FAT 14 87.7 55.1 139.5 
6 - 12 h 
    
COFFEE 14 204.8 97.1 431.9 
CARB 14 237.0 105.5 532.2 
FAT 14 186.8 87.9 397.0 
12 – 24 h 
    
COFFEE 14 65.0 26.7 157.8 
CARB 14 75.3 37.6 150.5 
FAT 14 61.2 34.9 107.3 
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Figure 47 Sum of metabolites in urine samples (0 – 24 h, 0 – 6 h, 6 – 12 h and 12 – 24 h) by 
treatment plotted as geometric means. T1: COFFEE, T2: CARB, T3: FAT (n = 14; Lower and 
upper bounds are hidden for a better overview) 
Table 30 shows the correlation of sum of metabolites in urine samples dependent on 
treatment as well as time periods of urine collection. No statistical significant differences 
were observed in the sum of 24 h urinary excretion for each of the three treatments. For the 
0 – 6 h period, statistical significant differences with 95% confidence interval between CARB 
and COFFEE as well as between FAT and CARB treatment were observed. No other time 
periods or comparisons showed significant differences between treatments. Summation of 
the metabolite concentrations after each treatment from time periods 0 – 6 h and 6 – 12 h 
showed equal values, meaning we observed no differences in total excretion between 0 –
 12 h (data not graphically shown). 
 
 
 
4 Results and discussion 
103 
 
Table 30 Model-based treatments effect on sum of metabolites in urine samples (0 – 24 h, 0 –
 6 h, 6 – 12 h and 12 – 24 h) with 95% confidence intervals. 
  estimate lower upper p-value 
0 - 24 h 
    
CARB / COFFEE 0.977 0.771 1.238 0.845 
FAT / COFFEE 0.872 0.688 1.105 0.256 
FAT / CARB 0.893 0.704 1.131 0.347 
0 - 6 h 
    
CARB / COFFEE 0.662 0.539 0.813 0.000 
FAT / COFFEE 0.919 0.748 1.128 0.419 
FAT / CARB 1.388 1.13 1.704 0.002 
6 - 12 h 
    
CARB / COFFEE 1.157 0.802 1.67 0.435 
FAT / COFFEE 0.912 0.632 1.317 0.624 
FAT / CARB 0.788 0.546 1.138 0.204 
12 – 24 h 
    
CARB / COFFEE 1.158 0.787 1.706 0.456 
FAT / COFFEE 0.943 0.64 1.388 0.765 
FAT / CARB 0.814 0.553 1.198 0.296 
 
There were no significant differences between treatments in the sum of metabolites in urine 
samples collected 24 h after treatment. It has to be mentioned that the interindividual 
variance in the urine samples was high, thus a larger number of volunteers would be 
required to investigate the possible effects of treatments on bioavailability. Additionally, 
shorter collection intervals (e.g. time periods with two or three hours per period) would 
provide a more useful pharmacokinetic profile with a stronger validity.  
For the 0 – 6 h time period, we observed statistically significant differences between the 
CARB and COFFEE groups, as well as between the FAT and CARB groups. There were no 
other significant differences in the sum of metabolites in urine samples between treatments 
or time periods. A summation of the metabolite concentrations after each treatment over the 
time periods 0 – 6 h and 6 – 12 h produced equal values  
The return of the concentrations in the last periode of time (12 – 24 h) to the level determined 
in the first time period (-24 – 0 h) indicated that the most metabolites were excreted between 
the first 24 h.  
 
Figure 47 shows the detailed kinetics, and it seems that the excretion of the summarized 
amount of metabolites for CARB treatment was delayed in comparison to the other both 
treatments. This is in line with the results for plasma, which showed also a delayed tmax for 
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every metabolite determined after CARB treatment. Also for the FAT treatment a delayed tmax 
for metabolites in plasma was observed, what we could not confirm for urinary excretion. It 
should be kept in mind that time periods of six hours revealed no clear full pharmacokinetic 
profile.  
Based on an evaluated and validated HPLC-ESI-MS/MS method using isotopically labeled 
QA for quantification [Erk et al., 2009], QA kinetics in urine samples were investigated in 
more detail. Figure 48 shows the boxplots related on sum of time spans (-24 – 0 h, 0 – 6 h, 
6 – 12 h and 12 – 24 h) of urinary excretion by treatment. In addition, the summary statistics 
of AUCs are figured. Comparing the AUCs, the three treatments did not show any statistically 
significant differences among themselves. Indeed, between time period 0 – 6 h and 6 – 12 h 
for CARB and FAT treatment significant differences on tmax with an associated p-value of 
< 0.001 and < 0.05 respectively were determined. 
The data obtained for quinic acid were in line with the overall findings of summarized 
excreted urine metabolites as described before. QA as well as the polyphenols in the 
beverage alone passes faster through the GIT as the same amount of QA as well as 
polyphenols in the beverage in combination with a food matrix, which gave a retarded 
emptying of stomach and thus a time-delayed metabolization and excretion of the 
polyphenols under study [Biesalski and Grimm, 2007]. Especially for CARB treatment, strong 
significant differences in urinary excretion were observed between time period 0 – 6 h and 
6 – 12 h, whereas the effect for FAT was significant but marginal.  
Table 31 shows the amounts of ingested coffee and corresponding QA contents in relation to 
urinary excreted QA values by subjects and treatments. Additionally, the statistics 
summarized as means ± SD and corresponding percentage of excreted QA relating to the 
ingested amounts are specified. Approximately 60% relating to the ingested QA was renal 
excreted, whereas no statistically significant differences were determined among the three 
treatments. 
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Figure 48 Model-based effects of treatments as boxplots related on sum of time spans (-24 –
 0 h, 0 – 6 h, 6 – 12 h and 12 – 24 h) of urinary excretion [µmol/g creatinine] for quinic acid. 
n = 14; normal distribution according to Anderson and Darling, one-sided, pared t-test; 
*: < 0.05; ***: < 0.001. T1: COFFEE, T2: CARB, T3: FAT 
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In a human intervention study reported in literature, Adamson and coworkers detected 20 -
60% of the ingested QA as hippuric acid in urine and the remaining percentage was mostly 
excreted as unmetabolized QA [Adamson et al., 1970]. Unfortunately, we did not detect 
hippuric acid in the urine samples, but the determined 60% of QA were in line with these 
data. Nevertheless, we have to keep in mind that the in the body circulating QA was not only 
free QA from coffee but might be liberated from different QA esters, such as CQA and FQA. 
High amounts of QA may be released from QA esters after cleavage by esterases during the 
GIT passage. Hence, it was not possible to define the percentage of excreted QA referred to 
the free QA from coffee but. It is always the sum of free QA and released QA from QA 
esters, which is ingested, metabolized and excreted.  
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Table 31 Amounts of ingested coffee [g] and corresponding QA contents [mg] in addition to urinary excreted QA values [mg] by subjects and 
treatments. Summary statistics as means ± SD and corresponding percentage of excreted QA relating to the ingested amounts. 
subject COFFEE 
 
CARB 
 
FAT 
  
ingested 
coffee [g] 
ingested 
QA [mg] 
excreted 
QA [mg] 
 
ingested 
coffee [g] 
ingested 
QA [mg] 
excreted 
QA [mg] 
 
ingested 
coffee [g] 
ingested 
QA [mg] 
excreted 
QA [mg] 
01 2.6 29.4 15.2 
 
2.6 29.6 17.6 
 
2.7 29.8 18.9 
02 2.1 23.7 6.9 
 
2.1 23.7 13.2 
 
2.1 23.7 11.5 
03 2.9 32.5 21.8 
 
2.9 32.0 20.0 
 
2.9 32.5 18.2 
04 2.6 29.3 13.3 
 
2.6 28.9 14.2 
 
2.7 29.8 22.5 
05 2.3 25.3 16.2 
 
2.3 25.7 13.6 
 
2.3 26.1 17.6 
06 2.2 24.6 15.7 
 
2.1 23.7 10.5 
 
2.1 23.9 14.6 
07 2.8 31.7 23.1 
 
2.8 31.7 18.0 
 
2.8 31.7 18.1 
08 2.9 32.2 13.5 
 
2.9 32.5 27.0 
 
2.8 31.8 17.4 
09 2.0 22.0 12.9 
 
2.0 22.0 25.0 
 
2.0 22.5 12.9 
10 2.1 23.9 19.6 
 
2.2 24.5 16.8 
 
2.1 23.7 14.3 
11 2.4 26.5 16.8 
 
2.4 26.8 16.5 
 
2.3 26.2 17.8 
12 3.1 35.3 25.6 
 
3.2 35.4 18.8 
 
3.1 35.3 21.2 
13 2.4 26.8 14.2 
 
2.4 26.4 11.5 
 
2.4 26.5 11.9 
14 2.8 31.3 23.1 
 
2.8 30.9 24.3 
 
2.8 30.9 22.2 
mean 
 
28.2 17.0 
  
28.1 17.6 
  
28.2 17.1 
SD 
 
3.9 4.9 
  
3.9 4.9 
  
3.9 3.5 
percentage excreted 
relating to ingested 
amount 
 
60.3% 
  
62.7% 
  
60.6% 
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4.3 Correlation between plasma AUC and 24 h urinary excretion 
After the evaluation of the plasma AUC and 24 h urinary excretion, in Table 32 the 
correlation between plasma metabolite AUCs and metabolites from 24 h urine samples is 
described. The inverse correlations for DHFA (only CARB treatment), DHFA4S and FA4S 
(only COFFEE treatment) were not significant. The positive correlations for CA3S, DHCA, 
DHCA3S, DHFA (COFFEE and FAT treatment), DHFA4G and FA4S (CARB and FAT 
treatment) were not significant either. However, apparent data trends suggested that 
increased plasma metabolite AUCs led to increased metabolite concentrations in the urine 
samples. Interindividual differences hindered the emergence of any significance in the data 
from only 14 healthy subjects.  
Table 32 Correlation between plasma AUC and 24 h urinary excretion of CA3S, DHCA, 
DHCA3S, DHFA, DHFA4G, DHFA4S, FA4S depending on the treatment. 
 correlation 
CA3S   
COFFEE 0.238 
CARB 0.339 
FAT 0.073 
DHCA  
COFFEE 0.570 
CARB 0.499 
FAT 0.680 
DHCA3S  
COFFEE 0.469 
CARB 0.533 
FAT 0.251 
DHFA  
COFFEE 0.218 
CARB −0.044 
FAT 0.215 
DHFA4G  
COFFEE 0.477 
CARB 0.526 
FAT 0.445 
DHFA4S  
COFFEE −0.062 
CARB −0.163 
FAT −0.184 
FA4S  
COFFEE −0.261 
CARB 0.319 
FAT 0.075 
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The possibility to evaluate the plasma and urinary data was limited due to the low amount of 
subjects in this study. Caused by this, also the correlation of the plasma AUC and 24 h 
urinary excretion gave no clear trend. Up to now, just limited data are published. Farah and 
coworkers found a negative correlation between apparent bioavailability and urinary recovery 
of CGA (r = −0.76; P = 0.01). The group tried to explain this behavior by interindividual 
differences in metabolic rates and/or preferential excretion routes [Farah et al., 2008]. 
Further investigations are needed to produce reliable data which give the possibility to have 
a clear conclusion on any correlations between plasma AUCs and urinary excretion. 
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4.4 Investigation of the colonic metabolism of food intrinsic in vitro 
Interindividual variability in absorbability and metabolism also depends on individual gut 
microbiota and therefore microbal degradation. Finally this degradation affects the efficacy of 
CGAs. Further investigations might accelerate progress in understanding the role of human 
gut bacteria in the bioavailability of CGAs. In our study, after a 48 h polyphenol-free diet we 
collected fecal samples of each subject. Incubations of commercially available 5-CQA with 
these fecal samples of individual volunteers were performed under anaerobic conditions. 
Afterwards 5-CQA and metabolites were determined and quantified by HPLC CoulArray™ to 
investigate the degradation and metabolism efficancy of the gut bacteria. The achieved 
results are shown in Table 33 as well as Figure 49 to Figure 62 and were corrected for 
endogenous levels of 5-CQA, CA and DHCA which were detected in very low levels in the 
control fermentations of the fecal samples. We were able to observe that the degradation of 
5-CQA was depending on the fecal samples of the subjects following a very interindividual 
kinetic. Both extremes, full degradation of 5-CQA (see results for subject 04 (Figure 52 and 
Table 33)) and very limited degradation (see results for subject 13 (Figure 61 and Table 33)) 
were observable. The results of all other incubations of the other subjects showed varying 
degradation efficiency in between. As example for the strong interindividual differences, the 
degradation of 5-CQA and the appearance of the degradants CA, and DHCA for subject 4 
and 13 observed for 4 h are shown in Figure 52 and Figure 61. As noticeable for subject 4, a 
fast degradation of 5-CQA was determined accompanied with the appearance of CA until 
2 h. Already after 30 minutes, DHCA was detectable with a clear increase up to 4 h. The 5-
CQA incubated with fecal sample of subject 13, showed no distinct cleavage. After 1 h, a 
decreasing shift was observed in combination with a small increase of CA up to 2 µM until 
4 h. Over the whole incubation time, no DHCA was detectable in the incubation from subject 
13. As an overview of the 14 subjects, 10.0 ± 2.3 µM determined as sum of 5-CQA, CA and 
DHCA after 4 h incubation were detectable. Regarding the individual values as sum of 5-
CQA, CA and DHCA after 4 h incubation, the lowest value is 6.0 µM (subject 7) and the 
highest value 13.3 µM (subject 13). The subject were divided into two groups regarding the 
seven subjects with the lowest DHCA concentration after 4 h and the seven subjects with the 
highest DHCA concentration after 4 h. Subjects 5, 7, 9, 10, 11, 12 and 13 degraded 5-CQA 
into the DHCA to a low extend, whereas subjects 1, 2, 3, 4, 6, 8 and 14 degraded 5-CQA into 
DHCA to a high extend. In Table 34 both groups are listed showing the individual amounts of 
summarized plasma AUCs [µmol*min] of all dihydro compounds (DHCA, DHCA3S, DHFA, 
DHFA4S, DHiFA, DHiFA3G, DHiFA3S, MeDHFA) determined. The mean of dihydro 
compounds for the group with low DHCA formation was 952 µM*min, for the group with high 
DHCA formation 636 µM*min.  
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Table 33 Amounts of 5-CQA, CA, and DHCA after 4h anaerobic incubations of 5-CQA (10 
µM) with fecal samples of 14 volunteers (S01 – S14). The concentrations were determined 
as mean ± SD of three separate incubations. 
  
5-CQA  
[µM ± SD] 
CA  
[µM ± SD] 
DHCA 
 [µM ± SD] 
 
  
5-CQA  
[µM ± SD] 
CA  
[µM ± SD] 
DHCA  
[µM ± SD] 
S01 
   
 
S08 
   
0 h 4.29 ± 0.48 1.83 ± 0.27 0.55* 
 
0 h 5.06 ± 0.64 2.33 ± 0.14 0.04 ± 0.00 
0.5 h 3.47 ± 0.30 4.15 ± 0.15 0.66 ± 0.02 
 
0.5 h 1.43 ± 0.06 5.71 ± 1.05 0.59 ± 0.16 
1 h 1.75 ± 0.62 4.85 ± 1.49 0.76 ± 0.08 
 
1 h 0.01 7.00 ± 0.47 1.15 ± 0.01 
2 h 0.59 ± 0.05 7.20 ± 1.59 1.12± 0.19 
 
2 h n. d. 7.37 ± 0.28 2.23 ± 0.09 
4 h 0.50 ± 0.04 7.76 ± 1.11 2.03 ± 0.15 
 
4 h n.d. 5.25 ± 0.63 3.38 ± 0.06 
S02 
   
 
S09 
   
0 h 6.55 ± 0.31 n. d. n. d. 
 
0 h 6.05 ± 0.34 0.48 ± 0.06 n. d. 
0.5 h 7.47 ± 0.35 0.22* n. d. 
 
0.5 h 4.27 ± 0.41 1.52 ± 0.10 0.32* 
1 h 6.44 ± 0.19 1.12 ± 0.40 n. d. 
 
1 h 3.38 ± 0.16 3.00 ± 0.56 0.44* 
2 h 5.58 ± 1.91 3.31 ± 0.98 0.04* 
 
2 h 2.09 ± 0.28 5.49 ± 0.71 0.65 ± 0.44 
4 h 1.32 ± 0.70 5.43 ± 0.99 2.22 ± 0.48 
 
4 h 0.4* 5.79 ± 1.27 1.34 ± 0.65 
S03 
   
 
S10 
   
0 h 5.81 ± 0.29 1.26 ± 0.10 0.89 ± 0.03 
 
0 h 7.60 ± 0.63 0.41 ± 0.11 0.14 ± 0.06 
0.5 h 5.64 ± 0.69 2.56 ± 0.22 1.19 ± 0.02 
 
0.5 h 8.23 ± 0.51 1.22 ± 0.06 0.21 ± 0.00 
1 h 3.69 ± 0.02 3.03 ± 0.20 1.45 ± 0.09 
 
1 h 7.99 ± 0.18 2.10 ± 0.07 0.26 ± 0.00 
2 h 2.58 ± 0.28 5.89 ± 0.21 2.44 ± 0.05 
 
2 h 7.18 ± 0.35 3.90 ± 0.36 0.36 ± 0.03 
4 h 0.77 ± 0.03 6.95 ± 1.37 3.91 ± 0.42 
 
4 h 4.48 ± 0.63 6.45 ± 0.24 0.66 ± 0.03 
S04 
   
 
S11 
   
0 h 7.06 ± 0.59 0.28 ± 0.04 n. d. 
 
0 h 4.64 ± 0.24 n. d. n. d. 
0.5 h 4.55 ± 0.28 1.44 ± 0.24 0.94 ± 0.14 
 
0.5 h 4.78 ± 0.21 n. d. n. d. 
1 h 2.86 ± 0.15 2.79 ± 0.40 2.45 ± 0.24 
 
1 h 5.13 ± 0.67 0.86 ± 0.20 0.47 ± 0.00 
2 h 0.36 ± 0.11 3.63 ± 0.14 5.08 ± 0.18 
 
2 h 4.57 ± 0.11 4.04 ± 1.19 0.62 ± 0.04 
4 h n. d. n. d. 8.47 ± 0.63 
 
4 h 2.46 ± 1.17 9.89 ± 3.15 0.90 ± 0.16 
S05 
   
 
S12 
   
0 h 9.42 ± 0.73 n. d. n. d. 
 
0 h 7.74 ± 1.59 n. d. n. d. 
0.5 h 12.0 ± 2.80 0.32 ± 0.08 n. d. 
 
0.5 h 7.85 ± 0.47 1.17 ± 0.14 0.26* 
1 h 14.4 ± 3.43 0.94 ± 0.30 n. d. 
 
1 h 6.65 ± 0.18 2.64 ± 0.02 0.29 ± 0.00 
2 h 14.1 ± 3.43 2.04 ± 0.82 n. d. 
 
2 h 4.43 ± 0.40 4.95 ± 0.62 0.34 ± 0.02 
4 h 9.17 ± 1.81 2.69 ± 0.47 n. d. 
 
4 h 1.62 ± 0.18 7.01 ± 1.35 0.46 ± 0.03 
S06 
   
 
S13 
   
0 h 7.15 ± 0.11 1.60 ± 0.23 0.87 ± 0.41 
 
0 h 14.75 ± 0.33 n. d. n. d. 
0.5 h 6.37 ± 0.26 2.63 ± 0.51 0.98 ± 0.01 
 
0.5 h 14.73 ± 1.59 n. d. n. d. 
1 h 5.28 ± 0.32 3.64 ± 0.97 1.08 ± 0.06 
 
1 h 14.69 ± 0.67 0.02* n. d. 
2 h 4.04 ± 0.65 5.31 ± 0.79 1.62 ± 0.17 
 
2 h 13.45 ± 0.88 0.82 ± 0.36 n. d. 
4 h 1.28 ± 0.04 5.99 ± 0.61 4.50 ± 0.55 
 
4 h 11.21 ± 0.38 2.13 ± 0.14 n. d. 
S07 
   
 
S14 
   
0 h 6.51 ± 2.46 n. d. n. d. 
 
0 h 6.01 ± 1.07 2.45 ± 0.78 0.04* 
0.5 h 7.94 ± 0.74 n. d. n. d. 
 
0.5 h 2.15 ± 0.60 7.33 ± 2.09 0.46 ± 0.20 
1 h 8.46 ± 1.89 0.54 ± 0.40 n. d. 
 
1 h 0.44* 6.85 ± 0.78 0.80 ± 0.17 
2 h 5.86 ± 1.38 1.13 ± 0.35 n. d. 
 
2 h n. d. 6.45 ± 1.31 1.56 ± 0.33 
4 h 3.88 ± 0.67 1.80 ± 0.31 0.31 ± 0.16 
 
4 h n. d. 5.02 ± 0.80 3.11 ± 0.53 
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Figure 49 Incubations of 5-CQA (10 µM) with fecal samples of subjects S01. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 50 Incubations of 5-CQA (10 µM) with fecal samples of subjects S02. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 51 Incubations of 5-CQA (10 µM) with fecal samples of subjects S03. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 52 Incubations of 5-CQA (10 µM) with fecal samples of subjects S04. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 53 Incubations of 5-CQA (10 µM) with fecal samples of subjects S05. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 54 Incubations of 5-CQA (10 µM) with fecal samples of subjects S06. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 55 Incubations of 5-CQA (10 µM) with fecal samples of subjects S07. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 56 Incubations of 5-CQA (10 µM) with fecal samples of subjects S08. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 57 Incubations of 5-CQA (10 µM) with fecal samples of subjects S09. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 58 Incubations of 5-CQA (10 µM) with fecal samples of subjects S10. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 59 Incubations of 5-CQA (10 µM) with fecal samples of subjects S11. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 60 Incubations of 5-CQA (10 µM) with fecal samples of subjects S12. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 61 Incubations of 5-CQA (10 µM) with fecal samples of subjects S13. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Figure 62 Incubations of 5-CQA (10 µM) with fecal samples of subjects S14. Degradation and 
appearance (of 5-CQA, CA and DHCA) within 4 h (0, 30, 60, 120, and 240 min). The results are 
means of three separate incubations with SD in all cases ≤1.59 µM. 
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Table 34 Plasma AUC [µM*min] of dihydro compounds determined (DHCA, DHCA3S, DHFA, 
DHFA4G, DHFA4S, DHiFA, DHiFA3G, DHiFA3S, MeDHFA) for each individual subject after 
ingestion of one cup of coffee (3.1 mg CGA/kg bw). Subjects were separated into two groups 
split by the final DHCA concentration being above or below 2 µM in incubated fecal sample 
medium after 4 h. 
  low DHCA formation   high DHCA formation 
  subject 
respective 
DHCA 
amounts 
[µM]  
plasma  
concentrations  
[µM*min] 
subject 
respective 
DHCA 
amounts 
[µM] 
Plasma 
 concentrations 
[µM*min] 
 
S05 n.d.  1603 
 
S01 2.03 ± 0.15 890 
 
S07 0.31 ± 0.16 N/A 
 
S02 2.22 ± 0.48 953 
 
S09 1.34 ± 0.65 910 
 
S03 3.91 ± 0.42 601 
 
S10 0.66 ± 0.03 849 
 
S04 8.47 ± 0.63 585 
 
S11 0.90 ± 0.16 1630 
 
S06 4.50 ±0.55 734 
 
S12 0.46 ± 0.03 284 
 
S08 3.38 ± 0.06 404 
 
S13  n.d. 439 
 
S14 3.11 ± 0.53 291 
average 
[µM*min] 
  
 
953 ± 630     
 
637 ± 242 
  
Overall, metabolism of different food ingredients can take place in all the different tissues of 
an organism with variable occurrences of the possibilities of metabolism according to the 
availability of special enzymes or bacteria. Different studies tried to investigate which part of 
an organism is responsible for which metabolic steps. Investigations of metabolism in the 
stomach in addition to the small intestine can be performed using ileostomy subjects (for 
example as investigated by [Erk et al., 2012, Erk et al., 2013b]). Investigations on the 
metabolism of the large intestine are rather difficult due to the impossibility to use an isolated 
part of the organism such as the large intestine. Hence, the comparison of results received 
by studies with ileostomy subjects and healthy subjects delivered first knowledge information 
of the metabolism occurring in the colonic part as shown by Stalmach and coworkers 
[Stalmach et al., 2009, Stalmach et al., 2010]. For detailed information on the metabolising 
ability of typical human microbiota, only in vitro investigations are mostly possible and should 
be interpreted with caution. In the past, it was showed that the microbiota is responsible for 
metabolism of CGA to DHFA and DHCA derivatives [Williamson et al., 2011], with 
subsequent formation of a wide range of metabolites including 3-hydroxyphenylpropionic 
acid, benzoic acid and hippuric acid [Gonthier et al., 2006, Gonthier et al., 2003, Ludwig et 
al., 2013]. Due to a confined experiment, we had only the possibility to determine DHCA 
formation by fecal microbiota as final metabolite. Our results confirmed the findings of the 
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other working groups detecting DHCA as one of the metabolites formed by the fecal bacteria 
from CQA.  
In our study, the individual summation of 5-CQA, CA, and DHCA values after 4 h from the 
incubation of 5-CQA with fecal samples of single probands were in a range between 6.0 and 
13.3 µM. Smaller amounts as the expected total of 10 µM indicated on one hand binding 
effects of phenolic acids to fecal components. On the other hand, a much more detailed 
catabolic pathway as proposed by Ludwig and coworkers [Ludwig et al., 2013], could also 
explain the lower values determined. In this case, CA is the direct product of CQA hydrolysis, 
whereat FA and IFA might be tissulare formed in gastric mucosal cells as well as the liver by 
COMT methylation of CA [Farrell et al., 2011, Poquet et al., 2008]. The microbiota and 
tissues formed broader metabolites of CA, such as mCoA and hydroxylated derivatives of 
phenylpropionic, benzoic, and hippuric acids. To this, mCoA can be formed by 
dehydroxylation, and 3,4-hydroxyphenylpropionic and 3-hydroxyphenylpropionic acids by 
hydrogenation and dehydroxylation. Finally benzoic acid is formed by dehydroxylation and 
subsequent β-oxidation in tissue. A conjugation of benzoic acid with glycine leads to the 
formation of hippuric acid [Booth, 1963, Chesson et al., 1999, Griffiths, 1964, Gumbinger et 
al., 1993, Perez-Silva, 1966, Quick&Cooper, 1931, Scheline, 1968]. In our in vitro 
experiment, only the non-tissual metabolism steps were possible due to the experimental 
setting. This limitation could explain the lower amounts determined as the expected 10 µM, 
because we did not determin other metabolites except CA and DHCA. Findings of more than 
10 µM may be explained by the release of already on fecal compounds bounded 5-CQA, CA 
or DHCA. No studies on binding effects of CGA and fecal compounds are available, but 
interactions of phenolics with other moleculs of human origin were investigated. For example, 
Adzet and coworkers showed the interactions of phenolics with bovin serum albumin in an in 
vitro experiment by determining the binding ratio. They observed CA coupled with bovine 
serum albumin by a binding ratio between 61 to 95%. In contrast, the binding capacity of FA 
and p-CoA to bovine serum albumin was shown to have a binding ratio of less than 10% 
[Adzet et al., 1988]. The strength of binding affinity to human serum albumin follows the order 
CA >> CQA >>> QA [Muralidhara&Prakash, 1995]. These results confirm the possibility of 
interactions from CGA and fecal components. 
The devision of subjects into two groups split by the final DHCA concentration after 4 h being 
above or below 2 µM showed no correlation between low plasma AUCs of dihydro 
compounds and a limited degradation of 5-CQA and appearance of CA and DHCA. 
Concluding, the bioavailability of coffee chlorogenic acids and its derivatives depend not only 
on the structure, molecular size and active or passive transport ability of the tissular 
composition of the organism, rather or also on individual differences, which are difficult to 
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assess and to forecast. We strongly recommend that future investigations include conduct 
metabolism experiments that focus on microbiota genotyping of individual subjects.  
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5 Final discussion  
The influence of a food matrix on the bioavailability of coffee chlorogenic acids (CGA) in 
humans was investigated in an exploratory human intervention study. Taking the limited 
number of subjects into account, the effects of food matrix on the bioavailability of CGA from 
coffee and further metabolism only allowed us to observe tendencies. Nevertheless, no clear 
conclusion can be drawn, as the study with 14 participants revealed no reliable statistical 
data. 
Strong interindividual variations could be observed for area under the curve (AUC), 
maximum plasma concentration (cmax), and time needed to reach maximum plasma 
concentration (tmax). Based on these interindividual variations and given the limited number of 
subjects no significant effects on the sum of plasma metabolite AUCs were detectable. A 
detailed observation of the metabolic profiles of the 14 study subjects definitely demonstrated 
that there is no consistent influence of the food matrix consumed in this study on the 
bioavailability of CGA from coffee. However, a few metabolites were found to contradict this 
observation. 
Our results confirmed findings of previous studies, in which intact CGA were measured only 
at low plasma levels [Matsui et al., 2007, Nardini et al., 2002, Stalmach et al., 2009]. We 
were able to quantify 5-CQA, but no 3- and 4-CQA in measurable amounts in plasma. In 
contrast to the total sum of CGA in the instant study coffee, in which the CQA were detected 
at much higher concentrations as compared to FQA, we found all FQA isomers in our study 
in comparatively high amounts. It is already known that FQA may be absorbed in a higher 
quantity as compared to CQA, but the underlying mechanism of absorption is not yet fully 
investigated [Erk et al., 2013]. It is assumed, that these findings are based on the different 
chemical structures, the increased molecular size and lipophilicity of FQA. A lower predicted 
log octanol-water partition coefficient (logP) of CQA might explain a lower absorption of CQA, 
even if transport of the metabolites would occur via passive diffusion, as described for in vitro 
monolayer experiments [Konishi et al., 2005, Murota&Terao, 2003, ChemSpider a&b]. In 
addition, FQA are known to be relatively chemically stable, whereas CQA from coffee may 
be cleaved into CA, and then further metabolized [Farrell et al., 2011]. In addition, it is 
conceivable, that CQA is methylated to FQA. It is known that FA has a higher affinity for the 
monocarboxylic transporter (MCT) than CA [Konishi et al., 2006]. If this hold also true for 
FQA and CQA, CQA may not be a good MCT substrate.   
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The main metabolites found in our intervention study were colon-metabolized and conjugated 
compounds, such as DHCA, DHCA3S, DHFA, DHFA4G, DHFA4S, DHiFA, DHiFA3G, 
mDHCoA, and mDHCoAS (colonics), with approximately 90.8% of all statistically interpreted 
metabolites. Phenolic compounds accounted for 8.7% in form of CA3S, CA4S, FA4G, FA4S, 
iFA, iFA3G, iFA3S and MeFA (phenolics), but only for 0.5% as quinic compounds (5-CQA, 3-
FQA, 4-FQA and 5-FQA (quinics)) representing the direct instant coffee constituents without 
any transformation. In the 14 healthy participants we identified DHFA, mDHCoA, DHCA3S 
and DHiFA as the most abundant metabolites, with 78% of all metabolites investigated. 
Interestingly, these compounds were subject to a slow distribution phase followed by an even 
slower terminal elimination phase. Thus, the plasma concentrations of these metabolites 
were relatively high for an extended period of time, what may explain the comparably higher 
quantities than for all other compounds detected. Since coumaric acid derivatives have not 
been much investigated in previous studies yet, these results suggest, that there should be a 
further examination, whether these compounds are also capable to be responsible for the 
beneficial effects of coffee. The same applies to the other three abundant metabolites after 
study coffee consumption – DHFA, DHCA3S and DHiFA – of which only limited data for the 
biological effects in humans are available.  
The ingested meals may trigger impaired absorption relating to single metabolite AUCs, but 
only for the early metabolites. A possible reason for the impaired bioavailability may be a 
delay in absorption resulting in an increased degradation by intestinal enzymes and bacteria. 
We observed for quinics and phenolics, and additionally for DHCA and DHFA, significant 
differences in Cmax between treatments. Detected Cmax values determined after pure coffee 
consumption were significantly higher than for metabolites measured after ingestion of coffee 
with a meal. After coffee consumption alone, a faster CGA and metabolite absorption, 
resulting in a fast distribution phase and followed by an even faster terminal elimination 
phase. This assumption is reflected by sharper, but compressed curves as compared to 
consumption of coffee with a meal. According to this finding, we did not observe differences 
in the sum of the AUC between treatments, reflecting the constant exposure of coffee 
polyphenols, even though there is a substantial influence of treatment on Cmax.  
Depending on the region where the metabolites are formed and/or absorbed, they can be 
divided into two groups: The early metabolites, such as quinics or phenolics, with a tmax 
between 0 and 2 h post-ingestion of the coffee and the late ones, the colonics, with a tmax 
between 7 and 10. Some of the early metabolites occurred really early (already 15 min post-
dose) in the plasma what may indicate an absorption or metabolization by the stomach 
and/or in the upper part of the small intestine as already published before [Poquet et al., 
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2008, Zhao et al., 2004, Konishi et al., 2006]. The appearance of FA4S, FA4G, iFA and 
MeFA directly after coffee consumption confirmed previous hypothesis, that the stomach can 
be an important site for absorption of pharmacologically active compounds [Farrell et al., 
2011]. Furthermore, these data provided an argument for the ability of human gastric 
mucosal cells (apart from the liver) to perform methylation as well as biotransformation 
reactions by SULT and UGT [Farrell et al., 2011, Poquet et al., 2008]. The late metabolites, 
which were found with the highest concentrations in plasma, are typically dihydro compounds 
formed by the microbiota via hydrolysis in the colon. Additionally, after 15 h no return to 
baseline was observed for most of the latest metabolites. Therefore, plasma collection at 
time points up to 24 h, or even up to 48 h, and within shorter intervals, e.g. every two hours, 
seemed to be meaningful, providing a full pharmacokinetic profile. Nevertheless, this showed 
probably only the beginning of the colonic metabolites entering in the bloodstream. In this 
line, it might be possible that even a 48 h polyphenol free diet prior coffee intake was not 
sufficient to reach a full wash out of the colonic CGA metabolites circulating in the blood of 
the volunteers.  
For two compounds, MeFA and FA4S, we identified two Cmax in plasma (6 and 12 h). This 
biphasic behavior suggests that absorption occurs both in the stomach/small intestine (first 
peak) and in the colon (second peak). It may also suggest that plasma kinetic is influenced 
by the enterohepatic circulation which causes reabsorption in the small intestine.  
The tmax values for all metabolites were strongly affected by treatment, as observed for FA4G 
for example, which had a delayed tmax of about 1.5 h when coffee was consumed in 
combination with uptake of a fat-rich meal. Ingestion of the coffee beverage in combination 
with the food matrix led to an enhanced absorption, probably in the upper part of the small 
intestine. Esterases in the small intestine are capable to cleave the CGA releasing the free 
acids and QA, respectively. On the way up to the colon, the acids are absorbed and 
transformed into their corresponding dihydro derivatives, the colonics. However, the time of 
arrival to the colon is delayed, which explains the later tmax for the colonics. 
The metabolites were further classified into groups according to published knowledge about 
their physical structure and/or on whether the metabolites originated directly from the coffee, 
or whether they sustained initial or colonic degradation and metabolism: Quinics, phenolics, 
colonics, caffeics, ferulics, glucuronides, sulfates, aglycons and methylated compounds. No 
significant differences in the sums of AUCs were detected for all groups, except for the 
quinics and sulfates. In contrast to the quinics, for which the sum of AUCs of metabolites 
collected after coffee consumption with a CARB meal was significantly lower than other 
metabolites collected after pure coffee consumption, the sulfates showed a significantly lower 
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sum of metabolite AUCs collected after treatment with coffee with a FAT meal. These 
findings may be explained by a longer transition period of metabolites in the gut, caused by 
the presence of food matrix. This longer transition time potentially increased metabolite 
degradation or reduced sulfation. The data we collected cannot explain the reduced sulfation. 
However, it may have been caused by the direct inhibition of SULT conjugation, or by 
increased degradation due to longer storage in the gut. 
There were no significant between-treatment differences in the metabolite concentrations of 
urine samples collected 24 h after coffee consumption. However, there was high inter-
individual variance in the urine samples, and thus, a larger group of volunteers is required to 
investigate how the different treatments affect bioavailability. Additionally, shorter collection 
intervals could have provided a more useful pharmacokinetic profile. Nevertheless, there 
were differences in the urine samples collected during the 0 – 6 h period. The concentrations 
of metabolites were significantly higher in urine samples of individuals who had only 
consumed coffee than in the urine samples of indivudals who had consumed coffee with a 
carbohydrate-rich meal. Furthermore, the treatment that included coffee consumption in 
combination with a fat-rich meal resulted in significantly higher concentrations of metabolites 
in urine samples than the treatment that included coffee consumption with a carbohydrate-
rich meal. There were no differences in the amounts of urinary metabolites between samples 
collected from 6 – 12 h and from 12 – 24 h. In addition, we determined quinic acid (QA) in 
urine samples and correlated the quantity to the amount ingested via the study coffee. We 
determined 60% QA of the given dosage, but we have to keep in mind, that circulating QA in 
the body was not only free QA directly from coffee. Moreover, QA may also be released from 
different QA esters, such as CQA and FQA, after cleavage by esterases during the colonic 
passage. On the basis of these data, a clear statement concerning the excreted amount of 
QA related to the ingested amount is not possible. We have to consider the sum of free QA 
and released QA from QA esters always as a result of ingestion, metabolism, as well as 
excretion.  
The comparison of plasma metabolite concentrations to urinary metabolite concentrations 
showed no significant differences. The reason for this may be explained by strong 
interindividual differences and the low number of volunteers, which hindered a clear 
significance in the data. However, apparent data suggest a trend that higher plasma AUCs 
led to higher concentrations of urinary metabolites.  
Overall, metabolism of different food ingredients can take place in all tissues of an organism 
with varying metabolism depending on the presence of special enzymes or bacteria. The 
possibility to investigate the metabolic ability of typical human microbiota is and the results 
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should be interpreted with caution. We performed incubation experiments of 5-CQA with 
fecal samples of individual volunteers under anaerobic conditions to calculate the inter-
individual kinetics for each compound (reduced concentrations of 5-CQA as well as the 
appearance of CA and DHCA in the gut microbiota medium). As observed before for almost 
all data (plasma and urine samples), strong interindividual differences were also apparent for 
the degradation (5-CQA) and formation (CA and DHCA) efficiency of the individual fecal 
samples. The incubation of 10 µM 5-CQA with individual fecal samples has shown results 
(summations of 5-CQA, CA, and DHCA after 4 h), which varied in a wide range between 6.0 
and 13.3 µM. This suggested that additional degradation and metabolism steps occurred 
besides the simple degradation from 5-CQA to DHCA. The lower levels as the expected total 
of 10 µM may be explained by chemical reactions of phenolic acids with fecal components 
such as proteins, as shown in other in vitro experiment, in which phenolics were able to 
interact with bovin serum albumin. Furthermore, the binding capacities of different phenolics 
with bovine serum albumin varied strongly [Adzet et al., 1988]. In addition, the more 
branched catabolic pathway with further formation of different metabolites, such as mCoA 
and hydroxylated derivatives of phenylpropionic, benzoic and hippuric acids, could also 
explain the low values determined. Higher amounts as the expected may be caused by the 
initial release of fecal matrix bound 5-CQA, CA or DHCA.  
Final correlations between low plasma AUCs of dihydro compounds and a limited 
degradation of 5-CQA and appearance of CA and DHCA after 4 h in the incubation medium 
showed no significant difference for the individual fecal samples. 
This study and all the outcomes measured within were exploratory. Due to the limited 
number of subjects, we could only investigate tendencies for effects of food on the 
bioavailability of CGAs and metabolites from coffee and therefore the revealed results are 
only indicative. But despite of that limitation it is to highlight that the data show no influence 
of the breakfast on the total bioavailability of CGAs and metabolites from coffee (AUC), but a 
significant difference in their kinetics of the release demonstrated by Cmax and tmax. The co-
ingestion of breakfast favored a slow and continuous release of colonic metabolites in 
contrast to the non-metabolized coffee components appearing in the first hour after coffee 
consumption. This is a relevant result which needs further investigation as it might have 
important physiological consequence.  
In conclusion, the data of the human intervention study suggest that bioavailability of food 
ingredients depends not only on the chemical structure, molecular size and active or passive 
transport ability of the organisms, but rather or largely on individual differences. Therefore, 
we strongly recommend that future investigations should also include the conduction of 
metabolism experiments that focus on microbiota genotypes in individual subjects. The goal 
5 Final discussion 
128 
 
would be to identify a correlation between genotype and metabolic profiles after chlorogenic 
acid intake. 
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6 Material and methods 
6.1 General 
Chemicals used were of analytical grade. Those not specified were purchased from Fluka, 
Sigma Aldrich (Schnelldorf, Germany) and Toronto Research Chemicals Inc. (Toronto, 
Ontario, Canada), in highest purity. Feruloylglycine and 3-O-caffeoylquinic acid lactone were 
synthesized in the working group and were sufficient for sample analysis. For dilutions, 
solvents and solid phase extractions were operated and produced with fresh bidestilled water 
(waterbidest). 
6.2 General used consumables, chemicals and equipments 
6.2.1 Consumables 
reaction tube 2 ml und 1.5 ml, Greiner BIO ONE, 
Kremsmünster, Österreich 
fluted filter  Schleicher & Schuell Bioscience Inc., New 
Hampshire, United States 
Pasteur pipette disposable pipette og glas circa 150 mm, Brand 
GmbH & Co KG, Wertheim, Germany 
pH paper pH 9.0-13.0, Honeywell Riedel-de Haën AG, 
Seelze, Germany  
pH strips Spezialindikator pH 6,5-10,0, Merck,  
pipette tip 1000 µl, 100 μl,  Greiner BIO ONE, 
Kremsmünster, Österreich 
filter circle Schleicher & Schuell Bioscience Inc., New 
Hampshire, United States 
centrifuge tube Centrifugal Filter Devices, 1.6 ml, Amicon, 
Bioseparation Microcon®, MerckMillipore, 
Billerica, Massachusetts, United States 
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6.2.2 Chemicals 
compound abbrevation  
5-O-caffeoylquinic acid 5-CQA Extrasynthèse1 
genistein - Extrasynthèse1 
sodium chlorid NaCl Merck2 
calcium chlorid CaCl2 Sigma
3 
sodium hydrogencarbonate NaHCO3 Sigma
3 
vitamin K3 (menadione) - Sigma
3 
potassium hydrogen 
phosphate 
KH2PO4 Merck
2 
iron (II) sulfate heptahydrate FeSO4 (7 H2O) Sigma
3 
Tween 80 - BD4 
resazurin - Sigma3 
hemin - Sigma3 
acetic acid (glacial) CH3COOH Merck
2 
propionic acid - Fluka5 
valeric acid - Aldrich6 
isovaleric acid - Fluka5 
tryptycase peptone - BD4 
yeast Extract - BD4 
D-glucose - Sigma3 
L-cysteine - Sigma3 
cellobiose D+ - Calbiochem7 
maltose - Sigma3 
fructose - Sigma3 
meat extract - Fluka5 
magnesium sulfate 7 H2O MgSO4 (7 H2O) Serva
8 
ATCC Vitamin Mix - ATCC9 
ATCC Trace Mineral Mix - ATCC9 
Dubelco phosphate buffer 
saline 
PBS Sigma3 
glycerol - Merck2 
sodium hydroxide NaOH Merck2 
methanol Lichrosolv CH3OH Merck
2 
acetonitrile CH3CN J. T. Baker
10 
ortho-phosphoric acid 85% H3PO4 Merck
2 
sodium phosphate 
monobasic monohydrate 
NaH2PO4 H2O Sigma
3 
dimethyl sulfoxide DMSO Sigma3 
D-(-)quinic acid QA Sigma3 
U-13C-D-(-)-quinic acid U-13C-QA IsoLife11 
p-coumaric acid pCoA Sigma-Aldrich Chemie12 
3-phenylpeopionic acid 3PPA Sigma-Aldrich Chemie12 
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compound abbrevation  
Cinnamic acid CinAc Sigma-Aldrich Chemie12 
4-methoxycinnamic acid 4MCA Sigma-Aldrich Chemie12 
3-(4-
methoxyphenyl)propionic 
acid 
3,4MPPA Sigma-Aldrich Chemie12 
methylferulic acid MeFA Sigma-Aldrich Chemie12 
methyldihydroferulic acid MeDHFA Sigma-Aldrich Chemie12 
  Sigma-Aldrich Chemie12 
caffeic acid CA Extrasynthèse13 
ferulic acid FA Extrasynthèse13 
dihydrocaffeic acid DHCA Extrasynthèse13 
m-coumaric acid mCoA Extrasynthèse13 
o-coumaric acid oCoA Extrasynthèse13 
isoferulic acid iFA Extrasynthèse13 
dihydroferulic acid DHFA Fluka5 
3-caffeoylquinic acid 3-CQA 
Chengdu Biopurify 
Pytochemicals Ltd14 
4-caffeoylquinic acid 4-CQA 
Chengdu Biopurify 
Pytochemicals Ltd14 
3-feruloylquinic acid 3-FQA NRC15 
4-feruolquinic acid 4-FQA NRC15 
5-feruloylquinic acid 5-FQA NRC15 
dihydroisoferulic acid DHiFA NRC15 
m-dihydrocoumaric acid mDHCoA NRC15 
o-dihydrocoumaric acid oDHCoA NRC15 
p-dihydrocoumaric acid pDHCoA NRC15 
dihydroferulic-4-O-sulfate DHFA4S NRC15 
ferulic-4-O-sulfate FA4S NRC15 
caffeic-4-O-sulfate CA4S NRC15 
dihydrocaffeic-4-O-sulfate DHCA4S NRC15 
dihydrocaffeic-3-O-sulfate DHCA3S NRC15 
caffeic-3-O-sulfate CA3S NRC15 
isoferulic-3-O-sulfate iFA3S NRC15 
dihydroisoferulic-3-O-sulfate DHiFA3S NRC15 
5-caffeoylquininc-3-O-sulfate 5CQA3S NRC15 
5-caffeoylquininc-4-O-sulfate 5CQA4S NRC15 
5-feruloylquininc-4-O-sulfate 5FQA4S NRC15 
p-coumaric acid-4-O-sulfate pCoAS NRC15 
m-coumaric acid-3-O-sulfate mCoAS NRC15 
dihydro-m-coumaric acid-3-
O-sulfate 
mDHCoAS NRC15 
dihydro-p-coumaric acid-4-
O-sulfate 
pDHCoAS NRC15 
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compound abbrevation  
caffeic-4-O-glucuronide CA4G NRC15 
dihydrocaffeic-4-O-
glucuronide 
DHCA4G NRC15 
dihydroferulic-4-O-
glucuronide 
DHFA4G NRC15 
caffeic-3-O-glucuronide CA3G NRC15 
ferulic-4-O-glucuronide FA4G NRC15 
dihydrocaffeic-3-O-
glucuronide 
DHCA3G NRC15 
isoferulic-3-O-glucuronide iFA3G NRC15 
dihydroisoferulic-3-O-
glucuronide 
DHiFA3G NRC15 
5-feruloylquininc-4-O-
glucuronide 
5FQA4G NRC15 
m-dihydrocoumaric-3-O-
glucuronide 
mDHCoAG NRC15 
p-dihydrocoumaric-4-O-
glucuronide 
pDHCoAG NRC15 
p-coumaric-4-O-glucuronide pCoAG NRC15 
m-coumaric-3-O-glucuronide mCoAG NRC15 
D13C2-caffeic acid D
13C2-CA Orphachem
16 
Dihydroisoferulic-D2-3-O-
glucuronide 
D2-DHiFA3G TRC
17 
Dihydroisoferulic-D2-3-O-
sulfate 
D2-DHiFA3S TRC
17 
1
Extrasynthèse, Genay, France 
2
Merck, Darmstadt, Germany 
3
Sigma, a part of Merck, Darmstadt, Germany 
4
BD, Franklin Lakes, New Jersey, United States 
5
Fluka, a part of Merck, Darmstadt, Germany 
6
Aldrich, a part of Merck, Darmstadt, Germany 
7
Calbiochem, a part of Merck, Darmstadt, Germany 
8
Serva, Heidelberg, Germany 
9
ATCC, Teddington, Middlesex, United Kingdom 
10
 J. T. Baker, Avantor Performance Materials, Center Valley, Pennsylvania, United States 
11
IsoLife, Wageningen, The Netherlands
 
12
Sigma-Aldrich Chemie, Buchs, Switzerland 
13
Extrasynthèse, Lyon, France 
14
Chengdu Biopurify Phytochemicals Ltd, Chengdu, Sichuan, China 
15
NRC, Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland 
16
Orphachem S.A., Clermont.Ferrand Cedex, France 
17
TRC, Toronto Research Chemicals, Toronto, Canada 
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6.2.3 Equipments 
thermometer  LHU, LET-100/30, DIN 12778 
incubator  CB 210 WTB Binder GmbH, Tuttlingen, Germany 
ice machine  Wessamat, Perfect ice! Combi-Line, 
Kaiserslautern, Germany 
Eppendorf pipettes  Eppendorf Group, Hamburg, Germany 
hot air gun  Steinel HL 1800E; Herzebrock-Clarholz; 
Germany 
refrigerator  Privileg, Privileg *** (-20 °C) 
  Liebherr Comfort *** (-30 °C) 
  Liebherr Premium (5 °C and -20 °C) 
volumetric glassware  Schott Duran®, Mainz, Germany 
HPLC-ESI-MS/MS  mass spectrometer API 2000 AB Sciex, Concord, 
Canada 
  Perkin Elmer Series 2000, Waltham, United 
States 
mass spectrometer API 3200 AB Sciex, Concord, 
Canada 
  HPLC Jasco 2008, Groß-Umstadt, Germany 
  HPLC Agilent 1200 Series, Santa Clara, United 
States 
  mass spectrometer QTrap 5500 AB Sciex, 
Concord, Canada 
  HPLC Agilent 1260 Series, Santa Clara, United 
States 
magnetic stirrer  IKA COMBIMAG RCT, Staufen, Germany 
Nanodrop  NanoDrop®, ND-1000 Spectrophotometer; 
Wilmington, United States 
pipettes  Pipetten Abimed, Eppendorf, Pipettierhilfe 
Pipettus® Hirschmann Laborgeräte, Hamburg, 
Germany 
rotary evaporator  Büchi R110 Rotavapor, Essen, Germany 
thermo shaker  5436 Eppendorf, Hamburg, Germany 
ultrasonic bath  Bandelin Sonorex RK 102 H, Berlin, Germany 
analytical balance  Sartorius laboratory, Göttingen, Germany 
  Sartorius CP224S (Feinwaage) 
6 Material and methods 
134 
 
  Sartorius Type 1507 (Grobwaage) 
water quench  Köttermann Labortechnik, Uetze, Germany 
vacuum exhauster  Vacuubrand Drehschieber Ölpumpe, Wertheim, 
Germany 
vortex  MS1 Minishaker; IKA®, Staufen, Germany 
centrifuge  Eppendorf Zentrifuge 5415, Hamburg, Germany 
  Eppendorf Zentrifuge 5417R, Hamburg, 
Germany 
Eppendorf Zentrifuge 5804R, Hamburg, Germany 
anaerobic chamber  Don Whitley Anaerobic workstation MG 1000, 
Shipley, West Yorkshire, United Kingdom 
CoulArray Detector    Thermo Fisher, ESA CoulArray Detector model  
      5600A, Waltham, Massachusetts, United States 
Vortex  Genie 2, Scientific Industries, Bohemia, New 
York, United States 
SPE cartridges  Waters Oasis HLB 1 cc/3 mg, Milford, 
Massachusettts, United States 
SPE vacuum manifold   Supelco Visiprep™ 12 or 24, Bellefonte, 
Pennsylvania, United States 
disposable flow control liner   Supelco, Bellefonte, Pennsylvania, United States 
pH paper 0 – 14    Merck, Darmstadt, Germany 
Milli-Q  Millipore Coperations, a part of Merck, 
Darmstadt, Germany 
 
 
6.3 Synthesis and isolation of standards 
6.3.1 Nuclear magnetic resonance (NMR) 
Nuclear magnetic resonance (NMR) spectra were measured with DPX 400 und Avance 600, 
instruments of Bruker (Karlsruhe, Germany). For Evaluation, TOPSPIN 1.3 and 1D-WinNMR 
for graphical formation were used. 
The recorded 1H- und 13C-spectra were calibrated again the used solvent (Table 35). 
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Table 35 Calibration of chemical shift for evaluation of 
1H- and 13C-nuclear magnetic 
resonance spectra. 
 DMSO-d6 D2O 
1H-NMR 2.49 4.7 
13C-NMR 39.50 - 
 
Declaration of chemical shift was occurred in δ-scale in ppm. Multiplicities were specified 
with s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, as well as splitting patterns 
such like dt = doublet of triplet. 
 
6.3.2 Synthesis of feruloylglycine 
Feruloylglycine was synthesized to be used for optimization of compound-related parameters 
on the mass spectrometer and as a standard for quantification. The synthesis was adapted 
from Booth et al. with slight modifications [Booth et al., 1957] as shown in Figure 63. Ferulic 
acid and glycine ethyl ester hydrochloride were used as basic material, whereas the salt of 
glycine ethyl ester (glycine ethyl ester hydrochloride) had to be converted into glycine ethyl 
ester. This step was successfully simulated following a method described by Fischer 
[Fischer, 1902]. A solution of glycine ethyl ester hydrochloride was neutralized with sodium 
hydroxid solution and afterwards dried with calcium oxide. The filtrate was evaporated and 
an uncolored liquid occurred. In the first step, the glycinate and dicyclohexyl carbodiimide 
were dissolved in tetrahydrofurane. Afterwards ferulic acid was dissolved in tetrahydrofurane 
and added to the before mentioned solution. The reaction mixture was stirred at room 
temperature for three days and then dicyclohexyl urea was filtered. The filtrate was 
evaporated and dried, whereat a yellowish solid was achieved. Feruloylglycine ethyl ester 
was extracted with hot ethanol, filtered and hydrolyzed by being warmed up for about 15 
minutes with a slight excess of methanolic potassium hydroxide. Methanol was evaporated 
under reduced pressure, the residue was taken up in water and acidified to pH 4 with 
hydrochloric acid. Feruloylglycine was recyrstallized from water, precipitated and dried. A 
yellowish solid was achieved. 
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Figure 63 Synthesis scheme for feruloylglycine from ferulic acid and glycine ethyl ester, 
modified according to [Booth et al., 1957, Fischer, 1902] 
For the purification of feruloylglycine a preparative RP-HPLC system was used. Separation 
was performed on an analytical C18 HPLC column and detection was achieved at a 
wavelength of 325 nm (method see Materials and methods, Table 36). The yield was 60% 
corresponding 1.24 g (4.96 mmol) feruloylglycine. 
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Table 36 Preparative HPLC parameter for isolation and purification of feruloylglycine. 
Column                                                            Reprosil 100 
Material                                                  C18, 5 µm, 250x20 mm 
Mobile phase                                A: water (0.1% HCOOH) B: acetonitrile 
wave length                                                    325 nm 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 5 98 2 
20 5 10 90 
22 5 10 90 
25 5 98 2 
30 5 98 2 
 
The chemical characterization and identification of the structure was effected by NMR 
analysis and the mass to charge ratio (m/z) of feruloylglycine was verified by MS analysis. 
NMR analysis of feruloylglycine 
After dissolving the solid in d6-DMSO, the 
1H-NMR spectroscopy was performed using a DPX 
400 spectrometer (Bruker Biospin, Rheinstetten, Germany). The calibration was carried out 
of the d6-DMSO with a chemical shift at δ 2.49 ppm.  
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*** Current Data Parameters ***
NAME : FAG5H
EXPNO : 1
PROCNO : 1
*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :    400.1300000 MHz
BF2 :    400.1300000 MHz
BF3 :    400.1300000 MHz
BYTORDA :              0
CPDPRG :
CPDPRGB :
CPDPRGT :
DATE_t : 02:37:08
DATE_d : Jun 29 2011
DBP07 : edit
DBPNAM0 :
DBPNAM1 :
DBPNAM2 :
DBPNAM3 :
DBPNAM4 :
DBPNAM5 :
DBPNAM6 :
DBPNAM7 :
DE :            6.0 usec
DECBNUC : off
DECIM :             24
DECNUC : off
DECSTAT : DO
DIGTYP :              8
DP07 : edit
DPNAME0 :
DPNAME1 :
DPNAME2 :
DPNAME3 :
DPNAME4 :
DPNAME5 :
DPNAME6 :
DPNAME7 :
DR :             18
DS :              2
DSLIST : SSSSSSSSSSSSSSS
DSPFVS :             12
EXP : PROTON
F1LIST : 111111111111111
F2LIST : 222222222222222
F3LIST : 333333333333333
FL1 :             90 dB
FL2 :             90 dB
FL3 :             90 dB
FL4 :             90 dB
FOV :          20.00 cm
FW :      125000.00 Hz
GRDPROG :
HL1 :              1 dB
HL2 :             35 dB
HL3 :             16 dB
HL4 :             17 dB
INSTRUM : spect
LOCNUC : 2H
NBL :              1
NC :             -2
NS :             64
NUCLEUS : off
O1 :        2400.78 Hz
O2 :        2470.97 Hz
O3 :        2470.97 Hz
PAPS : QP
PARMODE : 1D
PHP :              1
PH_ref :          0.000 degree
POWMOD : low
PR : 11
PRGAIN : high
PROBHD : 5 mm PABBO BB-1H/D Z-GRD Z108618/0120
PROSOL : no
PULPROG : zg30
QNP :              1
RG :    128.0000000
RO :              0 Hz
SEOUT : HR
SFO1 :    400.1324008 MHz
SFO2 :    400.1324710 MHz
SFO3 :    400.1324710 MHz
SOLVENT : DMSO
SW :        16.0203 ppm
SW_h :       6410.256 Hz
TD :          32768
TE :          296.7 K
TP07 : edit
TPNAME0 :
TPNAME1 :
TPNAME2 :
TPNAME3 :
TPNAME4 :
TPNAME5 :
TPNAME6 :
TPNAME7 :
V9 :           5.00 sec
VCLIST : CCCCCCCCCCCCCCC
VD :      0.0000000 sec
VDLIST : DDDDDDDDDDDDDDD
VPLIST : PPPPPPPPPPPPPPP
VTLIST : TTTTTTTTTTTTTTT
WBST :           1024
WBSW :      4.0000000 MHz
XL :              0
YL :              0
YMAX_a : 1238459264.0000000
YMIN_a : -905321152.0000000
*** Processing Parameters ***
AUNMP : proc_1d
FT_mod : fqc
*** 1D NMR Plot Parameters ***
Height :          12.98 cm
Width :          21.30 cm
XOffset :           1.00 cm
YOffset :           3.50 cm
Start :          14.00 ppm
Stop :          -2.02 ppm
ppm_cm :           0.75
Hz_cm :         300.95
NUCLEUS : off
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the associated 1H-NMR spectrum (Figure 64), in the farthest upfield was the protons at 
position 3. There was a singlet at δ = 3.79 ppm with an integral of 3. The protons at position 
11 arose as doublet at δ = 3.85 ppm with an integral of 2 and a coupling constant of 
3JHH = 5.48 Hz. At a chemical shift of δ = 6.53 ppm, with an integral of 1 and 
3JHH = 15,.5 Hz 
was the proton at position 8 as doublet. In each case, there are doublets for the protons at 
position 5 and 6 of the aromatic ring, with a chemical shift of δ = 6.78 ppm and δ = 7.00 ppm 
respectively. Both with an integral of 1 and 3JHH = 8.22 Hz. The proton in position 2 was a 
singlet at δ = 7.14 ppm with an integral of 1. At a chemical shift of δ = 7.33 ppm with an 
integral of 1 and a coupling constant of 3JHH = 15.65 Hz, there is the proton at position 7. At 
δ = 8.20 ppm, there is a triplet for the proton at position 10 of the NH group with 
3JHH = 5.69 Hz and an integral of 1. In the farthest downfield, at a chemical shift of 
δ = 9.45 ppm was the proton at position 12 of the OH group as singlet with an integral of 1. 
Figure 64 
1
H-NMR of feruloylglycine in d6-DMSO at 293.5 K and 400 MHz. 
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MS characterization of feruloylglycine 
After dissolution of feruloylglycine (100 ng/ml) in ethanol/water/formic acid (30/69.9/0.1; v/v/v) 
the solution was directly injected via syringe pump into the ion source of a triple quad mass 
spectrometer (Applied Biosystems, API 3200). The flow rate was set at 10 µl/min and the 
polarity on the ESI source was negative. The compound was identified by the mass to 
charge ratio (m/z) of 250. After fragmentation in Q2 the compound-dependent parameters of 
the three fragments with the highest intensity (m/z 206, m/z 163, m/z 134) were optimized 
(see Figure 65). For the analyses the mass transition m/z 250  134 was used. 
Figure 65 ESI
-
 product ion scan of feruloylglycine ([M-H]
-
, m/z 250) at Q3 in mass range of m/z 90-
260. 
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6.3.3 Synthesis of 3-O-caffeoylquinic acid lactone  
3- and 4-O-caffeoylquinic acid lactones were synthesized to be used for mass spectrometry 
compound-related parameters optimization and as a standard for quantification. The first 
step of the synthesis was the isomerization of 5-O-caffeoylquinic acid to 3- and 4-O-
caffeoylquinic acid (3- and 4-CQA) adapted from Trugo and Macrae with slight modifications, 
briefly [Trugo&Macrae, 1984]. The intramolecular esterification to the lactones was 
performed by the synthesis of Steglich with some modifications [Neises&Steglich, 1978]. 
 
6.3.3.1 Isomerization of 5-O-caffeoylquinic acid to 3- and 4-O-
caffeoylquinic acid 
5-CQA was dissolved in waterbidest and pH value was adjusted to 8 with ammonia solution 
(1 N). For 30 min, the reaction mixture was stirred at 90 °C and the reaction was stopped by 
acidification with hydrochloric acid solution (adjusted pH-value of 2.5 – 3). The reaction was 
monitored by HPLC-DAD based on the retention times (3-CQA (4.9 min), 4-CQA (5.9 min), 
5-CQA (6.1 min). For the purification of 3-, 4- and 5-CQA a preparative RP-HPLC system 
was used. The separation was perforemed on an analytical C18 HPLC column at a 
wavelength of 325 nm. In Table 37 of chapter Materials and methods, the analytical 
parameters are shown. Separation of 3-CQA was successfully performed; 4- and 5-CQA 
were not separable. Water was evaporated under reduced pressure and 3-CQA was 
recrystallized from water/ethanol (1/1, v/v), precipitated and dried. An uncolored solid was 
achieved with a yield of 22% corresponding 111 mg (0.31 mmol). The synthesis scheme is 
shown in Figure 66. 
Table 37 Preparative HPLC parameter for isolation and purification of 3-O-caffeoylquinic acid. 
 
Column                                                            Reprosil 100 
Material                                                  C18, 5 µm, 250x20 mm 
Mobile phase                                A: water (0.1% HCOOH) B: acetonitrile 
wave length                                                    325 nm 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 8 98 2 
5 8 88 12 
20 8 70 30 
21 8 10 90 
24 8 10 90 
25 8 98 2 
29 8 98 2 
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Figure 66 Scheme of isomerization of 5-O-caffeoylquinic acid (5-CQA) to 3- and 4-O-
caffeoylquinic acid (3- and 4-CQA), modified according to [Trugo&Macrae, 1984] 
 
The chemical characterization and identification of the structure was effected by NMR 
analysis and the mass to charge ratio (m/z) of 3-CQA was verified by MS analysis. 
 
NMR analysis of 3-O-caffeoylquinic acid  
After dissolution of the solid in d6-DMSO, the 
1H-NMR spectroscopy was performed using a 
DPX 600 spectrometer (Bruker Biospin, Rheinstetten, Germany). The calibration was carried 
out of the d6-DMSO with a chemical shift by δ 2.49 ppm.  
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At the associated 1H-NMR spectrum (Figure 67), in the farthest upfield was the protons at 
position 12. There is a multiplet at δ = 1.86 ppm with an integral of 3. The protons at position 
11 arose as double doublet at δ = 1.99 ppm with an integral of 1 and a coupling constant of 
3JHHax-ax = 13.2 Hz and 
3JHHgeminal = 4.03 Hz. At a chemical shift of δ = 3.84 ppm, with an 
integral of 1 and 3JHHeq-eq = 8.81 Hz and 
3JHHeq-ax = 2.98 Hz was the proton at position 10 as 
double doublet. There is a singlet for the proton at position 9, the aliphatic hydroxyl group, 
with a chemical shift of δ = 4.90 ppm. The proton at position 8 was a triplet of a doublet at 
δ = 5.15 ppm with an integral of 1 and 3JHHdiaxial = 7.90 Hz, 
3JHHax-eq = 2,78 Hz and 
3JHHax-
eq = 2.70 Hz. At a chemical shift of δ = 6.19 ppm with an integral of 1 and a coupling constant 
of 3JHH = 15.77 Hz, there is the olefinic proton at position 7. At δ = 6.74 ppm, there is a 
doublet for the proton at position 6 with 3JHH = 8.07 Hz and an integral of 1. There is a double 
doublet at a chemical shift of δ = 6.94 ppm with an integral of 1 and 3JHH = 8.07 Hz and 
4JHH = 1.84 Hz for the proton at position 5. In each case, there are doublets for the protons at 
position 4 and 3, with a chemical shift of δ = 7.00 ppm and δ = 7.43 ppm respectively. Both 
Figure 67 
1
H-NMR spectrum of 3-O-caffeoylquinic acid (3-CQA) (d6-DMSO, 600 MHz, 293,5 K) 
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 -MS2 (353.05) CE (-50): 26 MCA scans from Sample 1 (TuneSampleName) of 3-CQA_InitProduct_Neg.wiff (Turbo Spray) Max. 1.9e5 cps.
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with an integral of 1 and 3JHH = 2.20 Hz and 
3JHH = 15.78 Hz, respectively. In the farthest 
downfield, at a chemical shift of δ = 9.24 ppm and δ = 9.58 ppm respectively, there were the 
protons at position 2 and 1 as singlet with an integral of 1. 
 
MS characterization of 3-O-caffeoylquinic acid  
After dissolving the sample (100 ng/ml) in ethanol/water/formic acid (30%/69.9%/0.1%; v/v/v) 
the solution was directly injected via syringe pump into the ion source of a triple quad mass 
spectrometer (Applied Biosystems, API 3200). The flow rate was set at 10 µl/min and the 
polarity at the ESI source was negative. The compound was identified by the mass to charge 
ratio (m/z) of 353 and the corresponding fragments (m/z 191 quinic acid, m/z 179 caffeic 
acid). After fragmentation in Q2 the compound-dependent parameters of the three fragments 
with the highest intensity were optimized (see Figure 68). For the analyses the mass 
transition 353  191 was used.  
 
 
 
Figure 68 ESI
-
 production scan of 3-O-caffeoylquinic acid ([M-H]
-
, m/z 353) at Q3 in mass 
range of m/z 40-360, fragmentation: m/z 191 quinic acid, m/z 179 caffeic acid 
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On the basis of the correlation of 1H-NMR spectrum by calculation of increment and in 
comparison with the literature [He et al., 2010] and in the comparison to the production ion 
scan of the precursor m/z 353, 3-CQA was identified in positive mode. 
 
6.3.3.2 Synthesis of 3-O-caffeoylquinic acid-1,5-lactone (3-CQA15L) 
To synthesize 3-O-caffeoylquinic acid lactone (3-CQA15L) 3-CQA was dissolved in 
tetrahydrofurane (THF) and transformed into the corresponding lactone with dicyclohexyl 
carbodiimide (DCC). For three hours, the reaction mixture was stired at room temperature. 
The reaction was monitored by HPLC-DAD based on the corresponding retention time. After 
evaporation, dicyclohexyl urea was filtered. For the purification of 3-CQA15L a preparative 
RP-HPLC system was used. The detection was effected on an analytical C18 HPLC column 
at a wavelength of 325 nm. In Table 38 of chapter Materials and methods, the analytical 
parameters are shown. Water was evaporated under reduced pressure and 3-CQA15L was 
precipitated and dried. An uncolored solid was achieved with a yield of 60% corresponding 
48 mg (0.14 mmol). The synthesis scheme is shown in Figure 69 [Neises&Steglich, 1978].  
 
 
Figure 69 Scheme for the synthesis of 3-O-caffeoylquinic acid-1,5-lactone (3-CQA15L)) from 3-
O-caffeoylquinic acid (3-CQA) modified according to [Neises&Steglich, 1978]; THF: 
tetrahydrofuran, DCC: N,N-dicyclohexylcarbodiimide 
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Table 38 Preparative HPLC parameter for isolation and purification of 3-O-caffeoylquinic acid 
lactone. 
Column                                                            Reprosil 100 
Material                                                  C18, 5 µm, 250x20 mm 
Mobile phase                                A: water (0.1% HCOOH) B: acetonitrile 
wave length                                                    325 nm 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 10 98 2 
3 10 84 16 
20 10 60 40 
21 10 10 90 
24 10 10 90 
25 10 98 2 
29 10 98 2 
 
The chemical characterization and identification of the structure was effected by NMR 
analysis and the mass to charge ratio (m/z) of 3-CQA15L was verified by MS analysis. 
 
NMR analysis of 3-O-caffeoylquinic acid-1,5-lactone 
After dissolution of the solid in d6-DMSO, the 
1H-NMR spectroscopy was performed using a 
DPX 400 spectrometer (Bruker Biospin, Rheinstetten, Germany). The calibration was carried 
out of the d6-DMSO with a chemical shift by δ 2.49 ppm.  
At the associated 1H-NMR spectrum (Figure 70), in the farthest upfield was the protons at 
position 8. There is a multiplet at δ = 1.93 ppm with an integral of 2. The protons at position 9 
arose as double doublet at δ = 2.21 ppm with an integral of 1 and a coupling constant of 3JHH 
= 13.2 Hz and 2JHH = 4.03 Hz. At a chemical shift of δ = 2.36 ppm, with an integral of 1 and 
3JHH = 11.49 Hz was the proton at position 10 as doublet. There is a triplet for the proton at 
position 7 with a chemical shift of δ = 4.13 ppm, an integral of 1 and a coupling constant of 
3JHH = 4,43 Hz. The proton at position 6 was a multiplet at δ = 4.69 ppm with an integral of 2. 
At a chemical shift of δ = 6.25 ppm with an integral of 1 and a coupling constant of 
3JHH = 15.910 Hz, there is the olefinic proton at position 4. At δ = 6.75 ppm, there is a doublet 
for the proton at position 5 with 3JHH = 8.07 Hz and an integral of 1. There is a double doublet 
at a chemical shift of δ = 6.99 ppm with an integral of 1 and 3JHH = 8.31 Hz and 
4JHH = 1.84 Hz 
for the proton at position 3. There is a singlet for the proton at position 2 with a chemical shift 
of δ = 7.04 ppm and an integral of 1. In the farthest downfield, at a chemical shift of 
δ = 7.52 ppm, there is the proton at position 1 as a doublet with an integral of 1 and a 
coupling constant of 3JHH = 15.78 Hz. 
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Figure 70 
1
H-NMR spectrum of 3-O-caffeoylquinic acid-1,5-lactone (d6-DMSO, 400 MHz, 293,5 K) 
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 -MS2 (335.00) CE (-50): 26 MCA scans from Sample 1 (TuneSampleName) of 3CQL_InitProduct_Neg.wiff (Turbo Spray) Max. 2.9e5 cps.
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MS characerizeation of 3-O-caffeoylquinic acid-1,5-lactone 
 
After dissolving of 3-O-caffeoylquinic acid-1,5-lactone (500 ng/ml) in ethanol/water/formic 
acid (30/69.9/0.1%; v/v/v) the solution was directly injected via syringe pump into the ion 
source of a triple quad mass spectrometer (Applied Biosystems, API 3200). The flow rate 
was set at 10 µl/min and the polarity at the ESI source was negative. The compound was 
identified by the mass to charge ratio (m/z) of 335 and the corresponding fragments (m/z 161 
caffeic acid derivative, m/z 133, m/z 93 phenol). After fragmentation in Q2 the compound-
dependent parameters of the three fragments with the highest intensity were optimized (see 
Figure 71). For the analyses the mass transition m/z 353  161 was used.  
On the basis of the correlation of 1H-NMR spectrum by calculation of increment and in 
comparison with the literature and in the contrast to the production scan, 3-CQA15L was 
positively identified. 
 
Figure 71 ESI
-
 production scan of 3-O-caffeoylquinic acid-1,5-lactone ([M-H]
-
, m/z 335) at 
Q3 in mass range of m/z 40-360 
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6.3.3.4 Synthesis of 4-O-caffeoylquinic acid-1,5-lactone (4-CQA15L) 
The alloy of 4- and 5-CQA was dissolved in THF and catalyzed by DCC. Theoretically, 4-
CQA should lactonize to 4-CQA15L whereat 5-CQA would be preserved. The aim was to 
separated 4-CQA15L and 5-CQA via preparative HPLC after lactonization. The above 
described intramolecular esterification was arranged like the synthesis of 3-CQA15L. For 
three hours, the reaction mixture was stirred at room temperature. The reaction was 
monitored by HPLC-DAD based on the retention time. The analysis showed a degradation of 
4- and 5-CQA, and unfortunately a reduced intramolecular esterification to the respective 
lactones. Next to a formation of by-products, an isomerization of 5-CQA was conductive to 
the formation of 3-CQA and 3-CQA15L, respectively. Frank and coworkers reported the 
appearance of 5-O-caffeoyl-epi-δ-quinic acid lactone as well as 5-O-caffeoyl-muco-δ-quinic 
acid lactone, 4-O-caffeoyl-epi-δ-quinic acid lactone and 4-O-caffeoyl-muco-δ-quinic acid 
lactone [Frank et al., 2006]. Due to the described findings, the separation of 4-CQA15L was 
not accomplishable. 
 
6.4 Human intervention study 
6.4.1 Study design and subjects  
This human intervention study was approved by the Ethics Committee of the 
Landesärztekammer Rheinland-Pfalz (837.014.11 (7556), 2011). The study was subdivided 
into five study days (shown in Figure 72); the first two study days were intended for 
screening and during the following three days the three different treatments were applied in 
random order. First (V0 – screening part 1), a general medical screening was conducted to 
exclude subjects with any known disorders. The body weight, height, and body mass index 
(BMI) of each participant was monitored, and body fat and body water were analyzed using 
bioimpedance measurements (BIA 101 analyzer, SMT medical GmbH, Wuerzburg, 
Germany). In addition, subcutaneous body fat was measured using calipometry (after 7-
crinkles-formula of Jackson-Pollock [Jackson et al., 1980]). During the medical screening, 
participants completed questionnaires on various illnesses together with the doctor.  
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Figure 72 Design of the whole human intervention study. 
 
Before visit 1 (V1 – screening part 2), volunteers followed a polyphenol-free diet for 48 h. On 
V1, an oral glucose tolerance test (oGTT) was performed. The volunteers consumed glucose 
syrup (75 g glucose in 200 mL) and peripheral blood glucose concentrations were measured 
from the fingertip after 0, 30, 60, 120, 180, 240, and 300 minutes. Additionally, the 
gastrointestinal transit time (GITT) for each subject was measured on a separate day. To 
determine GITT, subjects drank at least 100 mL of blueberry juice and were asked to note 
the time at which blue color appeared in their feces (should had been less than 24 h). A 
urinary pregnancy test was also conducted on the female volunteers (Screening visit). 
The study was conducted over three separate days (V2, V3, and V4) and the three different 
treatments were applied in a random order. Subjects received a polyphenol-free meal 48 h 
before breakfast time and then fasted for 8 h before breakfast consumption. On each day, 
the subjects consumed 200 mL of an instant coffee beverage prepared from a commercially-
available instant coffee product (3.1 mg chlorogenic acids/kg body weight). The method of 
instant coffee preparation, as well as consumption time and temperature, was selected 
according to our previous study [Erk et al., 2012]. The beverages were prepared with hot 
water (60 °C) and consumed without milk or sugar, as quickly as possible. Three different 
breakfasts were consumed in a cross-over design and in a randomized order. The three 
breakfasts consisted of: the coffee beverage only (COFFEE), the coffee beverage with a 
carbohydrate-rich breakfast (two bread rolls and honey; CARB), and the coffee beverage 
with a fat-rich breakfast (one bread roll and peanut butter; FAT). The carbohydrate-rich and 
the fat-rich breakfasts were designed to be equicaloric (~626 kcal, based on the nutrition 
facts of the products). During the progression from V2 to V4, the volunteers followed a 
Wash-out min 7 days Wash-out min 7 days Wash-out min 7 days 
Screening V1 V2 V3 V4 
Medical questionnaire 
Physical examination 
Anthropometry 
Check IC & EC 
 
Glucose tolerance test 
Blood collection 
Gastrointestinal transit 
time 
Polyphenol-free diet 
 
Test breakfast (3 different one in a cross-over 
design) 
Stool collection (V2 only) 
Blood collection 
Urine collection 
Polyphenol-free diet 
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polyphenol-free diet for 48 h before each treatment and at least seven days passed between 
each visit. For each visit on study days, subject tests were given the same standard 
polyphenol-free meal. After 5 hours, 2 bread rolls with cheese and after 10 hours, tortellini 
with cream sauce and yoghurt. See details in Figure 73. 
 
Figure 73 Study design of each visit (V2 to V4). 
Twelve blood samples, each a maximum of 7 mL, were collected during each visit at 0 h, 
0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h and 15 h after coffee consumption. 
Additionally, four urine samples were collected; one hours prior to coffee consumption (within 
the last 24h) and three after coffee consumption (between 0 – 6 h, 6 – 12 h, and 12 – 24 h, 
respectively). All samples were stored by -80 °C. 
Criterion for exclusion from the study was in the event of illnesses requiring medications 
other than the one authorized, as well as in the case of pregnancy. Moreover, participants 
who were renouncing for the required dietary restrictions or were intolerance to product 
consumption were withdrawn from the study. 
Finally, the subject collective consisted of seven health men and seven healthy women, 
29 ± 8 years old. GIT transit time was 17.4 ± 6.0 h and all other inclusion/exclusion criteria 
were also achieved. The average of BMI of all probands was 23.0 ± 1.6 kg/m2. 
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Bioimpedance measurements 
The body composition was determined by bioimpedance measurement of each proband. In 
order to determine percentage of total body fat and body water a physiological data analyzer 
(BIA 101 analyzer, SMT medical GmbH, Wuerzburg, Germany) was used and data analyses 
were carried out by the appropriate software (Bodygram Pro® Version 3.0, Akern 
bioresearch srl, Pontassieve, Florence, Italy).  
Appendixes, Table 51 to Table 53 show the physiological data of the 14 probands. The 
average of the percental fat free mass was 76.2 ± 7.5%, the average of percental total body 
water was 55.8 ± 5.5% and the average of percental fat mass was 17.4 ± 6.0 h. After 
determination of the kinetic data (urine and blood) there is the possibility to detect a relation 
between these measurements and the physiological data.  
Oral glucose tolerance test (oGTT) 
Oral glucose tolerance test (oGTT) was performed by a single intake of 75 g glucose. Blood 
glucose concentrations in the peripheral blood (fingertip) were determined after 0, 30, 60, 
120, 180, 240 and 300 minutes. The test is usually used to identify people with impaired 
glucose tolerance (IGT) (fasting plasma glucose: < 126 mg/dL; 2 h-plasma glucose1: 
>140 mg/dL and <200 mg/dL) [WHO, 2006].  
Appendix, Table 55 shows the blood glucose concentrations of each proband (01 – 14) up to 
300 min after intake of glucose. All probands´ fasting plasma glucose were less than 
126 mg/dL and the 2 h-plasma glucose lay between 140 mg/dL and 200 mg/dL. Only the 2 h-
plasma glucose of proband 14 was slightly increased in an acceptable magnitude. 
Baseline demographic table 
 n mean sd min max 
age [years] 14 29.36 8.06 20.0 44.0 
BMI [kg/m2] 14 22.95 1.72 19.5 25.3 
height [cm] 14 174.84 9.96 156.0 188.0 
weight [kg] 14 70.40 10.02 54.5 88.2 
 
 
                                               
 
1
 Venous plasma glucose 2 h after ingestion of 75 g oral glucose load 
if 2 h-plasma glucose is not measured, status is uncertain as diabetes or IGT cannot be excluded 
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6.4.3 Data collection, management and validation 
Data on CRFs 
Data were collected on paper CRFs and stored in locked office space. The CRFs are made 
of non carbon required paper providing two copies of each page. The original remained on 
site and a copy was sent to the sponsor for data management. 
Laboratory results obtained following blood, urine and stoic analyses were manually 
uploaded in the database. 
Computerized data 
Data were entered from the paper CRFs into a computer database (CLINTRIALTM) at the 
Nestlé Clinical Development Unit using double blind data entry by two different data entry 
operators. 
Data Management 
The data manager prepared a data validation plan and programmed the corresponding edit 
checks, at least on the primary outcome. The queries highlighted by the edit check were 
reviewed, and if necessary, sent on data clarification form to the investigator for treatment. 
 
6.4.3 Statistics 
The primary goal of the study was to evaluate the influence of breakfast consumption on the 
bioavailability of CGAs from coffee, because only few data was available. Therefore this 
study and the outcomes measured were considered exploratory. Based on other ongoing 
bioavailability studies, a sample size of 12 subjects was considered as sufficient to provide 
reliable estimates of parameters of interest. Finally 14 subjects were chosen to ensure the 
data collection of 12 subjects at the end of the study. No “normal power” analysis was done. 
The estimated effects were the differences between coffee alone or the two food matrix 
treatments in terms of AUC (area under curve), Cmax (maximum plasma concentration) and 
tmax (time needed to reach maximum plasma concentration) of the different metabolites in 
plasma and 24 h urinary excretion. A level of significance of 5% was used. AUCs were 
calculated using the trapezoidal rule from time 0 to the last time point. The sum of AUCs was 
then computed by adding the AUCs of all the metabolite by subject and treatment. A linear 
mixed model, with treatment and baseline as fixed effects and subject as a random effect, 
was used to analyze the sums of the AUCs. The baseline was computed as the sum of the 
individual subject´s baseline value. Normality assumptions were checked. A log-
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transformations were required and, thus, were applied to the data in order to fulfill statistical 
assumptions and perform appropriate hypothesis-testing procedures. Similar approaches 
were used for the plasma tmax and Cmax (for tmax, it was not needed to correct for baseline). 
For urine samples, no baseline correction was applied. For the 24 h urine excretion, values 
that fell below the detection limit (LOQ) for a given time period were set to zero. A majority of 
the data was skewed to the right; hence a log-transformation was applied. For this reason, 
the summary statistics presented show geometric mean defined as exp(mean(log(x))), the 
lower bound defined as exp(mean(log(x))-sd(log(x))) and the upper bound defined as 
exp(mean(log(x))+sd(log(x))). In our cases, the estimated treatment differences are 
presented as a ratio between the treatments. The related 95% confidence intervals define a 
confidence interval for the ratio. The Pearson correlation was used to compute the 
correlation between the plasma sample and the 24 h urinary excretion. Since the study is 
exploratory, no adjustments for multiplicity were performed. All the statistical analyses were 
done with R software (version 3.0.1, Lucent Technologies, Murray Hill, USA). 
A blind data review was executed to address and document the following points: 
- Protocol deviations, definition of minor and major ones, in order to define per protocol 
(PP) and intention to treat (ITT) data sets 
- Statistical analyses planned for the primary outcome abd main secondary outcomes
  
 
6.4.4 Randomization 
The subjects were randomly allocated to one of the six possible sequences. There were no 
stratification factors. The six sequences are given bye: 
    Treatment 1    Treatment 2    Treatment 3 
   A   B   C 
   A   C   B 
   B   A   C 
   B   C   A 
   C   A   B 
   C   B   A 
Where A is coffee (COFFEE), B is coffee + 2 bread rolls + honey (CARB) and C is coffee + 1 
bread roll + peanut butter (FAT). 
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6.4.5 Area under the curve (AUC) 
Area under the curves (AUCs) were calculated using the trapezoidal rule from time 0 to the 
last time point. The sum of AUCs was then computed by adding the AUCs of all the 
metabolites by subjects and treatments. A linear mixed model with treatment and baseline as 
fixed effects and subjects as random was used for the primary outcome (sum of AUCs). The 
baseline was computed as the sum of the individual baseline value. Normality assumptions 
were checked and the use of log-transformations were needed and applied to the data in 
order to fulfill statistical assumptions and perform appropriate hypothesis and testing 
procedures. 
 
6.5 Analysis of coffee 
0.5 g instant coffee used for the study was dissolved in 50 mL boiled water and after cooling 
samples were centrifuged for 5 min at 5,000 x g. Thereafter, 2 mL of supernatant was filtered 
(membrane filter 0.45 µm PFDV), diluted (20-fold, EtOH/H2O/HCOOH, 30/69.9/0.1, v/v/v) 
and 20 µL was injected to the HPLC-DAD system (Agilent Technologies 1200 Series). 
Parameters and solvent gradient are illustrated in Table 39. 
Table 39 HPLC parameters for determination of instant coffee chlorogenic acids [Witt, 2012]. 
Column                                                 Phenomenex Synergie Polar  
Material                                                  RP C18, 4 µm, 250x4.6 mm 
Mobile phase                                A: water (0.1% HCOOH) B:acetonitrile 
oven                                                                       40 °C 
wavelength                                                           325 nm 
Injection volume                                                     40 µl 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 0.8 98 2 
5 0.8 88 12 
20 0.8 70 30 
21 0.8 10 90 
24 0.8 10 90 
25 0.8 98 2 
29 0.8 98 2 
 
Limit of quantification (LOQ) 
For determination of 5-CQA, 3-CQA, 4-CQA, 3,4-diCQA, 3,5-diCQA, 4,5-diCQA, 4-FQA, 3-
FQA and 5-FQA using the HPLC-DAD, the LOQ was defined with the signal-to-noise ratio of 
1:10. Based on this, for 5-CQA a LOQ of 8.8 pg on column was calculated (same LOQ was 
assumed for 3- and 4-CQA). For 3,4-diCQA a LOQ of 8.5 pg on column was calculated 
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(same LOQ was assumed for 3,5- and 4,5-diCQA). For 4-FQA a LOQ of 9.8 pg on column 
was calculated (same LOQ was assumed for 3- and 5-FQA) [Witt, 2012]. 
 
6.6 Determination of chlorogenic acids in instant coffee 
(commercially available Nescafé® Green blend) and chlorogenic 
acids and metabolites in plasma 
All preparation steps and solutions were performed and prepared on ice to avoid any stability 
issue. The 1 mM solution of d13C2-CA was prepared by dissolving appropriate amounts of the 
compound in methanol and for 1 mM labeled DHiFA3S disodium salt and labeled DHiFA3G 
with water/acetonitrile (50/50, v/v). For obtaining of 200 µM standard solutions the stock 
solutions were diluted in 1% acetic acid in water/acetonitrile (1/49.5/49.5, v/v/v). A further 
dilution with mentioned solvent offer the working solution at the concentration of 2 µM. Stock 
solutions of CA, FA, iFA, DHCA, DHFA, MeFA and MeDHFA(10 mM) and 3-CQA, 4-CQA, 5-
CQA, 3-FQA, 4-FQA, 5-FQA (10 mM) were prepared by dissolving appropriate amounts of 
the compounds in methanol or 1% acetic acid water, respectively. Finally stock solutions of 
pCoA, mCoA, oCoA, 3PPA, CinAc, 4MCA, 34MPPA, DHiFA, mDHCoA, oDHCoA, pDHCoA, 
4CQA15L, 3CQA15L, 3FQA15L, 4FQA15L, DHFA4S, FA4S, CA4S, DHCA4S, DHCA3S, 
CA3S, iFA3S, DHiFA3S, 5CQA4S, 5CQA3S, 5FQA4S, pCoAS, mCoAS, mDHCoAS, 
pDHCoAS, CA4G, DHCA4G, DHFA4G, CA3G, FA4G, DHCA3G, iFA3G, DHiFA3G, 
5FQA4G, mDHCoAG, pDHCoAG, pCoAG and mCoAG (5 mM) were prepared by dissolving 
appropriate amounts of the compounds in 1% acetic acid water/acetonitrile (1/49.5/49.5, 
v/v/v). The intermediate dilution achieve a concentration of 250 µM by dilution of the stock 
solutions in appropriate amounts with 1% acetic acid in water (for phenolic acids and 
glucuronides) and of 1% acetic acid in water/acetonitrile (1/49.5/49.5, v/v/v) (for sulfates and 
lactones). These solutions were further diluted corresponding to 0.1, 0.2, 0.5, 1, 2, 5, 10, 15, 
20 µM and to yield the standard curves in plasma concentrations corresponding to 5, 10, 25, 
50, 100, 250, 500, 750 and 1000 nM were prepared. In order to compensate errors occurring 
during the extraction procedure and the matrix effect, also the standard curve samples were 
extracted in the same way as the plasma samples [Marmet et al., 2014]. 
Sample preparation was performed according to Marmet et al. [Marmet et al., 2014]. After 
spiking of 100 µl plasma with 5 µl labeled standard solution (2 µM) samples were vortexed 
and diluted with 500 µl ethanol for protein precipitation and mixed for 5 minutes. Samples 
were centrifuged (17,500 x g, 5 min, 4 °C), supernatants were transferred into 1.5 ml tubes 
and the solvent was evaporated under nitrogen gas. The residues were secondly extracted 
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and after centrifugation the supernatants were pooled. After evaporation of the solvent, the 
residue were added with 100 µl of water/acetonitrile/acetic acid (93/6/1, v/v/v) and 5 µl were 
injected into the LC-ESI-MS/MS system. The HPLC conditions and source parameters for 
determination of instant coffee ingredients and metabolites are shown in Table 40. 
 
Table 40 HPLC conditions and source parameters (API 5500 QTrap) for determination of 
chlorogenic acids in instant coffee (commercially available Nescafé
®
 Green blend) and 
chlorogenic acids and metabolites in plasma. CUR: curtain gas, CAD: collision gas, IS: ion 
spray voltage, TEM: temperature; GS1: gas 1, GS2: gas 2. 
Column                                                  Waters Acquity UHPLC BEH 
Material                                                    C18, 1.7 µm, 150x2.1 mm 
Mobile phase                     A: water (1% H3CCOOH) B:acetonitrile (1% H3CCOOH) 
Injection volume                                                        5 µl 
TCC                                                                         40 °C 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0 0.35 97 3 
2 0.35 976 3 
10 0.35 85 15 
20 0.35 70 30 
25 0.35 10 90 
30 0.35 10 90 
35 0.35 97 3 
40 0.35 97 3 
source    
CUR [psi] 45 
CAD medium 
IS [V] -4500 
TEM [°C] 550 
GS1 [psi] 70 
GS2 [psi] 80 
parameter quadrupol 
Dwell [msec] 40 
EP [V] -11 
 
MultiQuantTM integration algorithm details 
For integration and data processing MultiQuantTM (version 3.0.2, Sciex, Darmstadt, 
Germany) with the MQ4 integration algorithm was used. The integration parameters were as 
follows: Gauddian smooth width: 1.0 points, RT half window: 30.0 sec, min. peak width: 3 
points, min peak hight: 0.00 cps, noise percentage: 99%, baseline sub. window: 0.20 min, 
6 Material and methods 
 
157 
 
peak splitting factor: 2 points. Following regression options were used: Regression 
parameter: area, regression type: linear, weighting type: 1/x. 
Limit of quantification (LOQ) 
FDA defines the LOQ as the lowest concentration of an analyte in a sample that can be 
quantitatively determined with suitable precision and accuracy. According to the FDA, the 
lowest concentration of the calibration curve should be accepted as the LOQ if the analyte 
response is at least 5 times higher than the blank response and if this response is 
reproducible with a precision of at least 20% [FDA, 1996]. 
The LOQs of coffee ingredients and metabolites determined in plasma samples are shown in 
Appendix, Table 60. 
 
6.7 Determination of creatinine 
Creatinine is a product of a non-enzymatic reaction of creatinine phosphate in organism and 
is preferred excreted via kidney. In this context, a direct relationship between muscular mass 
and creatinine coefficient in adult is observed and the daily creatinine excretion for a given 
individual is constant. The daily output is not influenced by the food intake and independent 
of diuresis [Hobson, 1939]. 
Thus the metabolites in urine could be determined and compared independent of the 
excreted urine volume. 
Creatinine in study samples was determined according to an established method of Watzek 
and coworkers [Watzek et al., 2012]. Urine samples were diluted (1:1000) and spiked with 
10 µL of isotope stable standard solution of D3-creatinine (100 µg/mL) for stable isotope 
dilution analysis (SIDA). An aliquot of 50 µL was directly injected into a HPLC-ESI-MS/MS 
system (Perkin Elmer Series 200 HPLC system coupled to a SCIEX API 2000 triple 
quadrupole mass spectrometer). Determination was performed using single ion monitoring 
(SIM) mode in positive ionization mode, the mass to charge (m/z) ratio measured for D3- 
creatinine was 116.9 and for creatinine 114.0. Solvent gradient and optimized source and 
compound dependent parameters are illustrated in Table 41 and 42. 
6 Material and methods 
158 
 
Table 41 HPLC conditions for determination of creatinine according to [Watzek et al., 2012] 
Column                                                        Phenomenex Luna 
Material                                                  C8, 3 µm, 150x4.6 mm 
Mobile phase                                A: water (0.05% HCOOH) B:methanol 
Injection volume                                                    50 µl 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 0.3 99 1 
1 0.3 99 1 
20 0.3 80 20 
22 0.3 99 1 
25 0.3 99 1 
 
Table 42 Source and compound dependent parameter for determination of creatinin in urine of 
humans via SIDA (API 2000) [Watzek et al., 2012]. DP: declustering potential, FP: focusing 
potential, EP: entrance potential, CEP: cell entrance potential, CUR: curtain gas, IS: ion spray 
voltage, TEM: temperature; GS1: gas 1, GS2: gas 2 
 creatinine D3-creatinine 
Q1 [amu] 114.0 116.9 
Dwell[ms] 200 200 
parameter quadrupole   
DP [V] 31 21 
FP [V] 250 370 
EP [V] 11 10 
CEP [V] 8 9 
source   
CUR [psi] 20 
IS [V] 5000 
TEM [°C] 200 
GS1 [psi] 30 
GS2 [psi] 30 
 
Table 43 shows the ratios of amounts of creatininev to D3-creatinine as well as the ratios of 
the corresponding areas. Figure 74 shows the corresponding standard curve. The data offer 
a clear proportionality between creatinine and D3-creatinine with a correlation factor of 
R > 0.999. Due to the determined linearity, the standard curve is usable for quantification of 
creatinine. 
 
 
 
6 Material and methods 
 
159 
 
Table 43 Concentrations and quotients for calculation of the standard curve of creatinine 
(analyte) and D3-creatinine (IS) [Watzek et al., 2012]. 
creatinine 
[ng/ml] 
7.5 10 12.5 25 50 75 100 250 500 750 
D3-creatinine 
[ng/ml] 
100 100 100 100 100 100 100 100 100 100 
area analyte / 
area IS 
0.10 0.13 0.15 0.22 0.33 0.64 0.77 2.01 3.76 5.23 
amount analyt / 
amount IS 
0.08 0.10 0.13 0.26 0.51 0.77 1.03 2.56 5.13 7.69 
 
 
Figure 74 Standard curve for quantification of creatinine via SIDA [Watzek et al., 2012] 
Limit of quantification (LOQ) and intraday/interday variability 
Using the regression line of plotting the concentration of creatinine against the peak high 
(y = 6934.4666 x; R = 0.996) and subsequent transposition to x with the corresponding 
background gives the ability to calculate the LOQ [Watzek et al., 2012]: 
𝐿𝑂𝑄 =  𝑥 =  
6 · 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑔𝑟𝑎𝑑𝑖𝑒𝑛𝑡
=  
60
6934.4666
= 8.65 
𝑛𝑔
𝑚𝑙
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Calculating with a injection volume of 50 µl standard solution, the absolute quantifiable 
amount was 2.8 pmol [Watzek et al., 2012]. 
For the intraday variability < 2% and for the interday < 1% was determined [Watzek et al., 
2012]. 
 
6.8 Determination of chlorogenic acids in instant coffee 
(commercially available Nescafé® Green blend) and chlorogenic 
acids and metabolites in urine 
 
6.8.1 Validation of the determination method for chlorogenic acids 
in instant coffee (commercially available Nescafé® Green blend) 
and chlorogenic acids and metabolites in urine 
For determination of the linearity the standard curves with the correlation factors were used 
[Qualitätssicherung, 2004]. 
For determination of the accuracy/recovery three different concentrations of standard 
solution (25, 50 and 75 ng/ml) were used. All solutions were prepared three times and each 
solution was injected three times (see) [Qualitätssicherung, 2004]. 
For determination of the interday and intraday variability different standard solutions (25, 50 
and 75 ng/ml) were at different days and serially injected (see) [Qualitätssicherung, 2004]. 
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Table 44 Accuracy/recovery [%] as well as interday and intraday variability [%] of determined 
coffee ingredients and metabolites in urine samples. 
 
recovery [%] (n = 3) 
interday variability 
(n = 2) 
intraday variability 
(n = 3) 
 
25 ng/ml 50 ng/ml 75 ng/ml average variation coefficient [%] variation coefficient [%] 
5CQA 95 94 95 95 3,69 3,52 
3CQA 98 98 101 99 2,08 4,27 
4CQA 96 97 99 97 1,91 3,43 
CA 96 97 97 96 3,06 2,01 
FA 97 97 100 98 2,08 2,69 
DHCA3G 90 82 73 82 2,12 6,96 
FAG 101 99 98 99 1,63 2,59 
FA4S 102 97 95 98 2,65 4,00 
DHCA 98 97 95 96 3,77 4,86 
DHIFA 96 96 95 96 2,50 1,41 
IFA 97 95 95 96 2,49 2,93 
4FQA 96 98 99 97 2,07 2,92 
CQA3S 85 76 63 75 3,71 4,99 
 
 recovery [%] (n = 3) 
interday variability 
(n = 2) 
intraday variability 
(n = 3) 
 25 ng/ml 50 ng/ml 75 ng/ml average 25 ng/ml 50 ng/ml 
FQA4G 85 76 73 78 3,58 5,99 
FQA4S 88 78 73 80 3,64 4,26 
CA3G 84 76 77 79 2,38 5,57 
3FQA 96 100 104 100 2,21 2,50 
5FQA 98 96 95 96 2,03 2,47 
CA4G 98 100 103 100 2,36 4,99 
CA4S 88 79 73 80 2,91 4,91 
DHCA3S 98 85 77 86 2,89 6,93 
DHCA4S 103 101 101 102 3,92 4,84 
IFA3G 96 96 96 96 1,66 2,66 
IFA3S 102 96 95 98 2,40 3,89 
DHFA4S 99 97 96 97 2,38 4,15 
CA3S 98 96 96 96 2,79 3,98 
DHFA4G 99 98 99 98 1,68 3,98 
DHIFA3G 100 102 103 102 2,43 4,44 
DHFA 96 95 95 96 2,69 1,48 
5CQA4S 86 77 61 75 3,32 4,80 
DHCA4G 98 82 76 85 3,23 4,33 
CQL 94 97 98 97 3,55 3,51 
CQLG 96 95 97 96 1,79 2,54 
CQA3G 98 96 86 93 6,13 15,39 
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Using the regression line of plotting the concentration of analyte against the peak high and 
subsequent transposition to x with the corresponding background gives the ability to 
calculate the LOQs: 
𝐿𝑂𝑄 =  𝑥 =  
6 · 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝑔𝑟𝑎𝑑𝑖𝑒𝑛𝑡
 
The LOQs of coffee ingredients and metabolites determined in urine samples are shown in 
Appendix, Table 61 to Table 63. 
6.8.2 Sample preparation for determination of chlorogenic acids in 
instant coffee (commercially available Nescafé® Green blend) and 
chlorogenic acids and metabolites in urine 
All preparation steps and solutions were performed on ice to avoid any stability issue. The 
1 mg/ml solutions of D13C2-CA, D3-DHiFA3S and D3-DHiFA3G were prepared by dissolving 
appropriate amounts of the compounds in methanol. For obtaining of 10 µg/ml standard 
solutions the stock solutions were diluted in 1% acetic acid in water/acetonitrile (1/49.5/49.5, 
v/v/v). A further dilution with mentioned solvent offer the working solution at the concentration 
of 1 µg/ml. Stock solutions of 3CQA, 4CQA, 5CQA, 3FQA, 4FQA, 5FQA, CA, CA3G, CA4G, 
CA3S, CA4S, CQA3G, CQA3S, CQA15L, CQA15LG, DHCA, DHCA3G, DHCA4G, DHCA3S, 
DHCA4S, DHFA, DHFA4G, DHFA4S, DHiFA, DHiFA3G, DHiFA3S, FA, FA4S, FAG, 
5FQA4G, 5FQA4S, iFA, iFA3G and iFA3S (1 mg/ml) were prepared by dissolving 
appropriate amounts of the compounds in methanol. The intermediate dilution achieved a 
concentration of 10 µg/ml by dilution of the stock solutions in appropriate amounts with 1% 
acetic acid in water/acetonitrile (1/49.5/49.5, v/v/v). These solutions were further diluted to 
achieve 100 ng/ml and to prepare the standard curves in urine corresponding to 0.5, 1, 2.5, 
5, 10, 25, 40 and 50 ng/ml. In order to compensate errors occurring during the extraction 
procedure and the matrix effect, also the standard curve samples were extracted in the same 
way as the urine samples below-mentioned. 
After spiking of 100 µl plasma with 25 µl labelled standard solution (100 ng/ml) samples were 
vortexed and diluted with 500 µl ethanol for protein precipitation and mixed for 5 minutes at 
4 °C. Samples were centrifuged (17,500 x g, 5 min, 4 °C), supernatants were transferred into 
1.5 ml tubes and the solvent was evaporated in a vacuum centrifuge. The residues were 
afterwardsextracted and after centrifugation the supernatants were pooled. After evaporation 
of the solvent, the residue was added with 1 ml of water/acetonitrile/acetic acid (49.5/49.5/1, 
v/v/v) and 10 µl were injected into the LC-ESI-MS/MS system. The HPLC conditions and 
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source parameters for determination of chlorogenic acids and metabolites are shown in 
Table 45. 
Table 45 HPLC conditions and source parameters (API 5500 QTrap) for determination of 
chlorogenic acids in instant coffee (commercially available Nescafé
®
 Green blend) and 
chlorogenic acids and metabolites in urine. CUR: curtain gas, CAD: collision gas, IS: ion spray 
voltage, TEM: temperature; GS1: gas 1, GS2: gas 2. 
Column                                                  Phenomenex Synergie Polar 
Material                                                  RP C18, 4 µm, 250x4.6 mm 
Mobile phase                                A: water (0.1% H3CCOOH) B:acetonitrile 
Injection volume                                                    10 µl 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.05 0.9 95 5 
15 0.9 76 24 
21 0.9 72 28 
23 0.9 72 28 
23.1 0.9 1 99 
28 0.9 1 99 
28.1 0.9 95 5 
33 0.9 95 5 
source    
CUR [psi] 45 
CAD medium 
IS [V] -4500 
TEM [°C] 550 
GS1 [psi] 70 
GS2 [psi] 80 
parameters quadrupol 
Dwell [msec] 40 
EP [V] -10 
 
MultiQuantTM integration algorithm details 
For integration and data processing MultiQuantTM (version 3.0.2, Sciex, Darmstadt, 
Germany) with the MQ4 integration algorithm was used. The integration parameters were as 
follows: Gauddian smooth width: 1.0 points, RT half window: 30.0 sec, min. peak width: 3 
points, min peak hight: 0.00 cps, noise percentage: 99%, baseline sub. window: 0.20 min, 
peak splitting factor: 2 points. Following regression options were used: Regression 
parameter: area, regression type: linear, weighting type: 1/x. 
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6.8.3 Sample preparation for determination of quinic acid (QA) in 
instant study coffee and urine 
The determination of QA was performed after a method developed by Erk and coworkers 
[Erk et al., 2009]. 
For determination of quinic acid (QA) in instant study coffee, coffee samples were dissolved 
in ethanol/water/formic acid (29.9/70/0.1, v/v/v) to obtain a final concentration of 1 mg/ml. 
After subsequent centrifugation (5 min, 5000 rpm, RT), the solutions were filtered with a 
membrane filter (0.45 µm PVDF), diluted 400-fold with an ethanol/water/formic acid 
(29.9/70/0.1, v/v/v) solution, and 50 µl of each sample were spiked with 50 µl of the labeled 
standard (200 ng/ml) and analyzed by HPLC-ESI-MS/MS in the MRM method. 
For determination of QA in urine, urine samples were dissolved 20-fold with 
ethanol/water/formic acid (29.9/70/0.1, v/v/v). Subsequent, 40 µl of each sample was spiked 
with 56 µl of the labeled standard (200 ng/ml) and acidified with 16 µl of methanolic 
hydrochloric acid (0.25 M). Finally, the samples were analyzed by HPLC-ESI-MS/MS in the 
MRM method. 
Table 46 HPLC conditions for determination of quinic acid modified according to [Erk et al., 
2009] 
Column                                                             Waters Atlantis 
Material                                                  RP C18, 3 µm, 150x4.6 mm 
Mobile phase                                A: water (0.05% HCOOH) B:acetonitrile 
Injection volume                                                    20 µl 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 0.8 95 5 
6 0.8 95 5 
6.1 0.8 1 99 
11 0.8 1 99 
11.1 0.8 95 5 
16 0.8 95 5 
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Table 47 Source and compound dependent parameter for determination of Quinic acid in 
instant study coffee and urine of humans via SIDA (API 3200) [Erk et al., 2009]. DP: 
declustering potential, CE: collision energy, EP: entrance potential, CEP: cell entrance 
potential, CUR: curtain gas, CAD: collision gas, IS: ion spray voltage, TEM: temperature; GS1: 
gas 1, GS2: gas 2. 
 D-(-)-quinic acid U-13C-D-(-)-quinic acid 
Q1 [amu] 191 198 
Q3 [amu] 85 89 
Dwell[ms] 150 150 
parameter quadrupole   
DP [V] -55 
CE [V] -30 
EP [V] -10.5 
CEP [V] -28 
CXP [V] 0 
source   
CUR [psi] 30 
CAD 6 
IS [V] -4500 
TEM [°C] 450 
GS1 [psi] 60 
GS2 [psi] 50 
 
Limit of quantification (LOQ) 
For determination of QA using the LC-MS/MS, the LOQ was defined with the signal-to-noise 
ratio of 1:10. Based on this, a LOQ of 195.4 pg (on column) was calculated [Erk et al., 2009].  
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6.9 Fecal sample incubation 
6.9.1 Preparation of reagents 
6.9.1.1 PBS – 0.1% L-cystein and 10% glycerol 
L-cysteine 100 mg 
glycerol 100 mL 
Final volume in PBS 1 L 
Autoclaved at 121 °C for 15 min. This solution was stable 3 months at room temperature. 
 
6.9.1.2 Growth medium: gut microbiota medium (GMM) 
Preparation of stock solutions of ingredients for the preparation of the GMM was as follows. 
 Potassium dihydrogen phosphate: stock solution at 1 M, pH 7.2 
KH2PO4 68.1 g 
Adjust pH with NaOH at 2 
Final volume in distilled water 1 L 
 
 calcium chloride: stock solution at 0.8% 
CaCl2 0.8 g 
Final volume in distilled water 100 mL 
 
 vitamin K3 (menadione): stock solution at 1 mg/mL 
menadione 10 mg 
Volume final ethanol 95% 10 mL 
Can be kept one month in a dark flask at 4 °C. 
 
 iron(II)-sulfate: stock solution at 0.4 mg/mL 
FeSO4 4 mg 
Final volume in distilled water 10 mL 
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 Tween 80: stock solution at 25% 
Tween 80 25 g 
Final volume in distilled water 100 mL 
The solution was warmed up slowly to mix the ingredients. 
 
 resazurin: stock solution at 0.25 mg/mL 
resazurin 25 mg 
Final volume in distilled water 100 mL 
 
 hemin: stock solution at 1 mg/mL 
hemin 25 mg 
NaOH 1 N 5 mL 
Final volume in distilled water 25 mL 
 
 VFA mix: stock solution 
acetic acid (glacial) 100% 17 mL 
propionic acid 6 mL 
valeric acid 1 mL 
isovaleric acid 1 mL 
isobutyric acid 1 mL 
The 5 acids were mixed and adjust to a pH of ± 6.7 with NaOH (drop directly pellets into the 
solution). 
Final volume in distilled water 50 mL 
 
Except vitamin K3, all these solutions were kept for one year at 4 °C. 
 Gut microbiota medium preparation (GMM) 
Ingredients for one liter medium. 
Component  Amount/L comments 
tryptycase peptone 2 g weigh 
yeast extract 1 g weigh 
D-glucose 0.4 g weigh 
L-cysteine 0.5 g weigh 
cellobiose D+ 1 g weigh 
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Component  Amount/L comments 
maltose 1 g weigh 
fructose 1 g weigh 
meat extract 5 g weigh 
KH2PO4 100 mL 
1 M stock solution 
pH 7.2 
MgSO4 (-7 H2O) 0.002 g weigh 
NaHCO3 0.4 g weigh 
NaCl 0.08 g weigh 
CaCl2 1 mL 
0.8 mg/100 mL stock 
solution 
vitamin K3 (menadione) 1 mL 
stock solution 
1 mg/mL 
FeSO4 1 mL 
stock solution 
0.4 mg/mL 
hemin 1 mL 
stock solution 
1 mg/mL 
Tween 80 2 mL stock solution 25% 
ATCC vitamin mix 10 mL commercial solution 
ATCC trace mineral mix 10 mL commercial solution 
acetic acid (glacial)  
5.5 mL VFA mix (p. 167) 
propionic acid 
valeric acid 
isovaleric acid 
isobutyric acid 
resazurin 4 mL 
0.25 mg/mL stock 
solution 
 
6.9.1.3 Stock and working solution of genistein (internal standard) 
Stock solution of 10 mM: 2.7 mg genistein was dissolved in 1 mL of DMSO. Storage of stock 
solution for maximal one year at -20 °C in aliquots of 25 µL in 0.5 mL Eppendorf tubes.  
Working solution of 100 µM: 10 µL of stock solution were diluted in 990 µL of buffer A for 
CoulArray. 
 
6.9.1.4 Faeces master mix preparation 
A pool of 0.6 g of faeces from the 14 different subjects was prepared in 30 mL of PBS 
supplemented with 0.1% L-cystein hydrochloride and 10% glycerol. 
Faeces were throughly mixed and stored at 4 °C for 2 h and then at -20 °C until further use. 
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6.9.1.5 Preparation of the solvents 
Solvent A – NaH2PO4 50 mM pH 1.5 
Initially, 6.9 g of NaH2PO4 were diluted in 0.75 L of Milli-Q water and the pH adjusted to 1.5 
using ortho-phosphoric acid (85%). Afterwards, the solution were filed up to a volume of 
1.0 L and filtered at filtration pyrex millipore (0.2 µm) system. 
Solvent B – Solution NaH2PO4/acetonitrile 50:50 
Solvent A was diluted with the same volume of acetonitrile and filter at filtration pyrex 
millipore (0.2 µm) system. 
Both solutions can be kept for one week at room temperature and should be filtered every 
two days. 
 
6.9.2 Incubation of the fecal samples, sample preparation and 
chromatographic conditions 
Incubations of the fecal samples of the 14 volunteers were operated as described in the 
scheme of incubation (Table 48).  
Table 48 Scheme of incubation. 
 Replicat 1 Replicat 2 Replicat 3 
Positive 
control 
Negative 
control 
GMM 19 mL 19 mL 19 mL 20 mL 19 mL 
Master Mix 1 mL 1 mL 1 mL - 1 mL 
 Allow the system to equilibrate for 1 min 
bioactive 
compound 
10 mM (5-
CQA) 
20 µL 20 µL 20 µL 20 µL 20 µL DMSO 
aliquots 1.5 mL at the timepoints 0, 0.5, 1, 2 and 4 h  
 
Centrifuged the aliquots at 17,400 x g for 5 min. Pipetted supernatant into 
separate 1.5 mL Eppendorf amber tubes. Stored the Eppendorf at -40 °C 
until further use. 
 
The standard curve was prepared using aliquots of the fecal negative control of each subject. 
The controls were spiked with standards to obtain final concentrations of 0.15, 0.3, 0.6, 1.25, 
2.5, 5, 10, 20 and 40 µM. Therefor, 4 µL of each stock solution (10 mM 5-CQA, 10 mM CA, 
10 mM DHCA) were pipetted to 988 µL of the fecal negative control. Thus a standard point of 
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40 µM was achieved. By following dilution steps of 350 µL of each standard point with 350 µL 
of fecal negative control the individual calibration curves were achieved. 
After incubation samples were prepared by solide phase extraction (Table 49) as performed 
in former studies [Renouf and Hendrich, 2011].The same solid phase extraction procedure 
was used to prepare the calibration curve.  
Table 49 Solide phase extraction of bioactive compounds. 
conditioning 1 mL methanol 
1 mL distilled water 
sample 300 µL acidified sample (pH 2) 
15 µL genistin (IS; at 100 µM) 
rinse 4 x 1 mL acidified water (pH 2) 
Dry the column using the vacuum. 
eluation 0.8 mL methanol 
Dry the column using the vacuum. 
evaporation 
Add the initial volume (315 µL) of solvent A 
 
Table 50 shows the chromatographic conditions which were used to determine either, 5-
CQA, CA or DHCA. 
Table 50 HPLC conditions for determination of bioactive compounds. 
Column                                             Macherey-Nagel, Nucleodur 
Material                                                  C18, 5 µm, 250x3 mm 
Mobile phase      A: NaH2PO4 (50 mM, pH 1.5); B: NaH2PO4 (50 mM)/acetonitrile (50/50, v/v) 
Injection volume                                                    50 µl 
Wavelength                                                          325 nm 
Time Flow [ml/min] Solvent A [%] Solvent B [%] 
0.1 0.5 85 15 
4 0.5 85 15 
12 0.5 80 20 
19 0.5 78 22 
40 0.5 0 100 
45 0.5 0 100 
48 0.5 85 15 
55 0.5 85 15 
 
For determination of the linearity the standard curves with the correlation factors were used 
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Limit of quantification (LOQ) 
For determination of redoxactive compounds using the CoulArray® detector, the LOQ was 
fitted to the lowest concentration of the standard curve (0.15 µM for 5-CQA, CA and DHCA). 
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Table 51 Anthropometric data determined for proband 01 – 05; RZ: resistance [Ω], Xc: 
reactance [Ω], FFM [kg]: fat free mass, TBW [L]: total body water, ECW [L]: extra cellular water, 
BCM [kg]: body cell mass, FM [kg]: fat mass, PA [degrees]: phase angle, FM [%]: percental fat 
mass, FFM [%]: percental fat free mass, TBW [%]: percental total body water, ECW [%]: 
percental extra cellular water, ICW [%]: percental intra cellular water, BCM [%]: percental body 
cell mass, BMI [kg/m
2
]: body mass index, ECM [kg]: extra cellular mass, ECM [%]: percental 
extra cellular mass. 
 Proband 01 02 03 04 05 
Gender f f m m f 
Body weight [kg] 74.0 58.7 80.7 73.7 64.5 
Age [a] 40 22 31 24 24 
Body hight [cm] 171.0 169.5 179.9 180.6 168.0 
RZ [Ω] 602 626 449 493 670 
Xc [Ω] 52 64 55 50 53 
FFM [kg] 48.3 44.5 66.8 61.6 43.2 
TBW [L] 35.3 32.5 48.9 45.1 31.6 
ECW [L] 18.1 15.1 20.3 21.0 17.0 
BCM [kg] 23.1 23.5 38.9 32.5 19.6 
FM [kg] 25.7 14.2 13.9 12.1 21.3 
PA [degrees] 4.9 5.8 7.0 5.8 4.5 
FM [%] 34.7 24.3 17.3 16.4 33.0 
FFM [%] 65.2 75.7 82.8 83.6 67.0 
TBW[%] 47.7 55.4 60.6 61.2 49.1 
ECW [%] 51.1 46.5 41.6 46.7 53.7 
ICW [%] 48.8 53.6 58.4 53.3 46.4 
BCM [%] 47.9 52.9 58.3 52.7 45.3 
BMI [kg/m2] 25.3 20.4 24.9 22.6 22.9 
ECM [kg] 25.1 20.9 27.8 29.2 23.7 
ECM [%] 52.1 47.1 41.7 47.3 54.7 
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Table 52 Anthropometric data determined for proband 06 – 10; RZ: resistance [Ω], Xc: 
reactance [Ω], FFM [kg]: fat free mass, TBW [L]: total body water, ECW [L]: extra cellular water, 
BCM [kg]: body cell mass, FM [kg]: fat mass, PA [degrees]: phase angle, FM [%]: percental fat 
mass, FFM [%]: percental fat free mass, TBW [%]: percental total body water, ECW [%]: 
percental extra cellular water, ICW [%]: percental intra cellular water, BCM [%]: percental body 
cell mass, BMI [kg/m
2
]: body mass index, ECM [kg]: extra cellular mass, ECM [%]: percental 
extra cellular mass. 
 Proband 06 07 08 09 10 
Gender f m m f f 
Body weight [kg] 60.6 78.7 80.2 54.5 60.8 
Age [a] 26 20 25 24 44 
Body hight [cm] 156.0 185.0 186.7 156.0 176.6 
RZ [Ω] 636 493 481 766 650 
Xc [Ω] 53 52 51 75 51 
FFM [kg] 41.1 64.7 66.8 35.4 46.1 
TBW [L] 30.1 47.4 48.9 25.9 33.7 
ECW [L] 15.7 21.6 22.2 12.4 18.2 
BCM [kg] 19.2 34.9 36.1 18.3 20.7 
FM [kg] 19.5 14 13.4 19.1 14.7 
PA [degrees] 4,8. 6 6.1 5.6 4.5 
FM [%] 32.2 17.7 16.7 35.0 24.3 
FFM [%] 67.8 82.3 83.3 65.0 75.8 
TBW[%] 49.6 60.2 61.0 47.6 55.5 
ECW [%] 52.2 45.6 45.5 47.6 53.9 
ICW [%] 47.8 54.4 54.5 52.4 46.1 
BCM [%] 46.8 53.9 54.0 51.5 45.0 
BMI [kg/m2] 24.0 23.0 23.0 22.4 19.5 
ECM [kg] 21.8 29.9 30.7 17.1 25.3 
ECM [%] 53.2 46.1 46.0 48.4 55.0 
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Table 53 Anthropometric data determined for proband 11 – 14; RZ: resistance [Ω], Xc: 
reactance [Ω], FFM [kg]: fat free mass, TBW [L]: total body water, ECW [L]: extra cellular water, 
BCM [kg]: body cell mass, FM [kg]: fat mass, PA [degrees]: phase angle, FM [%]: percental fat 
mass, FFM [%]: percental fat free mass, TBW [%]: percental total body water, ECW [%]: 
percental extra cellular water, ICW [%]: percental intra cellular water, BCM [%]: percental body 
cell mass, BMI [kg/m
2
]: body mass index, ECM [kg]: extra cellular mass, ECM [%]: percental 
extra cellular mass. 
 Proband 11 12 13 14 
Gender f m m m 
Body weight [kg] 66.3 88.1 67.2 77.0 
Age [a] 44 34 25 28 
Body hight [cm] 167 187 177.5 183.0 
RZ [Ω] 522 465 474 583 
Xc [Ω] 50 44 51 57 
FFM [kg] 49.6 70.4 60.0 57.4 
TBW [L] 36.3 51.5 43.9 42.0 
ECW [L] 17.5 25 19.8 20.0 
BCM [kg] 25.3 35.6 32.7 29.6 
FM [kg] 16.7 17.7 7.2 19.6 
PA [degrees] 5.5 5.4 6.1 5.6 
FM [%] 25.2 20.1 10.7 25.4 
FFM [%] 74.8 79.9 89.3 74.6 
TBW[%] 54.7 58.5 65.4 54.6 
ECW [%] 48.3 48.6 45.1 47.7 
ICW [%] 51.7 51.4 55.0 52.3 
BCM [%] 51.0 50.6 54.5 51.6 
BMI [kg/m2] 23.8 25.2 21.3 23.0 
ECM [kg] 24.3 34.8 27.3 27.8 
ECM [%] 49.0 49.3 45.6 48.4 
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Table 54 Microbiota analysis in faecal samples of each proband (01 - 14) presented in colony forming units per g faeces [CfU/g]. 
 Proband 01 02 03 04 05  06 07 08 09 10  11 12 13 14 
E. coli 5·107 1·106 3·103 3·103 2·103  3·107 1·106 2·103 3·105 3·103  <104 4·105 1·105 2·105 
E. coli-variant <104 <104 <104 <104 <104  <104 <104 <104 <104 2·105  <104 <104 1·103 4·103 
Enterobacteriaceae <104 <104 <104 <104 <104  <104 <104 <104 <104 <104  <104 <104 <104 <104 
Enterococcus sp. <104 3·107 <104 1·105 2·105  5·103 2·103 1·106 2·107 3·105  <104 <104 2·103 1·105 
other aerobic <104 104 <104 3·103 3·103  <104 <104 <104 <104 5·103  4·103 <104 x·10 <104 
Bacteroides sp. 1·109 2·109 3·103 <108 2·103  1·109 5·109 5·103 4·109 <108  1·103 1·103 <108 1·109 
Clostridium sp. <106 <106 <106 <106 <106  <106 <106 <106 3·103 <106  <106 <106 <106 <106 
Bifidobacterium sp. 1·109 1·109 1·108 3·107 2·103  1·105 1·109 3·107 1·108 2·106  1·107 1·107 1·108 1·109 
Lactobacillus sp. 1·106 1·106 1·105 1·104 2·105  1·105 1·106 5·105 5·105 <102  1·104 1·103 1·105 2·103 
other anaerobic <106 <106 <106 <106 <106  <106 <106 <106 <106 <106  <106 <106 <106 <106 
Candida sp. <102 <102 <102 <102 1·102  6·103 1·104 6·103 1·103 5·103  1·103 <102 1·102 <102 
Geotrichum sp. <102 <102 4·102 <102 <102  <102 <102 <102 <102 <102  <102 <102 <102 <102 
other fungi <102 <102 <102 <102 <102  <102 <102 <102 2·103 <102  <102 <102 <102 <102 
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Table 55 Data of oral glucose tolerance (oGTT) test (0 to 300 min) of each proband (01 – 14) after ingestion of 75 g glucose. 
Time point 0min 30min 60min 120min 180min 240min 300min 
 
AUC 
Proband [mg/dL] [mg/dL] [mg/dL] [mg/dL] [mg/dL] [mg/dL] [mg/dL] 
 
 
01 83 178 132 109 82 82 76 
 
31185 
02 59 101 106 90 81 83 59 
 
25695 
03 90 181 127 78 74 94 92 
 
30015 
04 89 173 182 58 87 86 89 
 
31245 
05 91 168 189 98 65 74 82 
 
31590 
06 84 167 168 113 70 78 81 
 
31920 
07 84 149 147 75 62 70 81 
 
27195 
08 90 165 156 58 79 78 87 
 
28830 
09 92 154 138 104 78 76 66 
 
29670 
10 98 171 135 112 74 82 95 
 
31605 
11 95 119 105 112 81 87 85 
 
29070 
12 72 154 127 56 85 83 84 
 
27375 
13 88 165 116 76 83 84 92 
 
28830 
14 86 155 231 117 95 84 89 
 
36765 
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Table 56 Amount of administered instant coffee dependent on body weight [mg/kg bw] of each 
proband (01 – 14) at the appropriate study days. 
 Gewicht Kaffee CGA CGA 
Proband [kg] [g] [mg] [mg/kg bw] 
V2 - 05.11.2011 
1 74.0 2.64 242 3.28 
2 58.7 2.11 194 3.30 
3 80.6 2.89 265 3.29 
4 73.7 2.65 243 3.30 
5 64.5 2.32 213 3.30 
6 60.6 2.19 201 3.32 
7 78.7 2.82 259 3.29 
8 80.8 2.89 265 3.28 
9 54.5 1.96 180 3.30 
10 60.8 2.18 200 3.29 
11 66.3 2.36 217 3.27 
12 88.2 3.14 288 3.27 
13 67.2 2.39 219 3.26 
14 77.0 2.75 252 3.28 
V3 - 19.11.2011 
1 73.6 2.65 243 3.31 
2 58.8 2.11 194 3.29 
3 80.3 2.85 261 3.26 
4 72.1 2.57 236 3.27 
5 63.4 2.25 207 3.26 
6 60.3 2.13 196 3.24 
7 79.2 2.82 259 3.27 
8 78.8 2.83 260 3.30 
9 54.7 1.96 180 3.29 
10 60.1 2.13 196 3.25 
11 65.3 2.33 214 3.28 
12 88.4 3.15 289 3.27 
13 66.1 2.35 216 3.26 
14 77.1 2.75 252 3.27 
V4 - 03.12.2011 
1 73.3 2.62 241 3.28 
2 58.8 2.11 194 3.29 
3 81.1 2.89 265 3.27 
4 73.3 2.61 240 3.27 
5 63.5 2.29 210 3.31 
6 59.2 2.11 194 3.27 
7 79.1 2.82 259 3.27 
8 79.6 2.87 263 3.31 
9 55.6 2.00 184 3.30 
10 59.0 2.11 194 3.28 
11 67.0 2.39 219 3.27 
12 88.4 3.14 288 3.26 
13 66.1 2.36 217 3.28 
14 77.5 2.79 256 3.30 
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Table 57 Data of creatinine [g/L] (mean ± SD) of each proband (1 - 14) of the three study days 
(V2 – V4) of four time periods (-24 – 0 h, 0- 6 h, 6 – 12 h, 12 – 24 h) (n = 2). 
Creatinine [g/L] 
(mean ± SD) 
V2 - 05.11.2011 
 
-24 - 0h 0 - 6h 6 - 12h 12 - 24h 
1 1.48 ± 0.32 0.69 ± 0.05 0.74 ± 0.01 1.13 ± 0.43 
2 0.28 ± 0.02 0.44 ± 0.16 0.41 ± 0.00 0.47 ± 0.09 
3 0.73 ± 0.00 0.88 ± 0.11 0.74 ± 0.06 1.23 ± 0.07 
4 0.83 ± 0.01 0.66 ± 0.02 1.60 ± 0.07 1.81 ± 0.03 
5 0.07 ± 0.01 0.76 ± 0.01 0.35 ± 0.00 0.70 ± 0.04 
6 0.47 ± 0.02 0.33 ± 0.03 0.75 ± 0.00 0.80 ± 0.05 
7 1.09 ± 0.03 1.29 ± 0.20 2.47 ± 0.11 3.84 ± 0.07 
8 1.52 ± 0.01 0.74 ± 0.05 1.09 ± 0.04 0.80 ± 0.02 
9 0.57 ± 0.04 0.30 ± 0.05 1.91 ± 0.05 1.25 ± 0.06 
10 0.39 ± 0.01 0.45 ± 0.00 0.58 ± 0.11 1.36 ± 0.00 
11 0.47 ± 0.01 0.95 ± 0.27 0.50 ± 0.08 0.79 ± 0.21 
12 2.56 ± 0.24 0.87 ± 0.18 1.92 ± 0.11 2.34 ± 0.10 
13 1.90 ± 0.12 1.90 ± 0.29 0.60 ± 0.12 1.40 ± 0.13 
14 0.65 ± 0.02 0.79 ± 0.09 0.58 ± 0.03 1.42 ± 0.17 
V3 - 19.11.2011 
 
-24-0h 0-6h 6-12h 12-24h 
1 1.56 ± 0.26 0.91 ± 0.12 0.63 ± 0.03 0.65 ± 0.15 
2 0.37 ± 0.01 0.25 ± 0.02 0.27 ± 0.00 0.41 ± 0.01 
3 0.56 ± 0.06 0.72 ± 0.00 0.71 ± 0.02 1.04 ± 0.00 
4 0.75 ± 0.01 0.47 ± 0.01 1.47 ± 0.05 1.99 ± 0.06 
5 0.31 ± 0.01 0.54 ± 0.05 0.64 ± 0.02 1.06 ± 0.10 
6 0.32 ± 0.07 0.45 ± 0.02 0.40 ± 0.03 0.92 ± 0.03 
7 2.05 ± 0.02 0.65 ± 0.04 1.09 ± 0.01 1.98 ± 0.07 
8 1.98 ± 0.16 0.94 ± 0.05 0.75 ± 0.05 2.34 ± 0.32 
9 1.31 ± 0.02 0.38 ± 0.03 1.04 ± 0.05 1.82 ± 0.11 
10 0.84 ± 0.05 0.98 ± 0.11 0.56 ± 0.07 0.60 ± 0.01 
11 0.41 ± 0.00 0.54 ± 0.01 0.37 ± 0.01 0.85 ± 0.01 
12 2.23 ± 0.06 1.21 ± 0.06 0.65 ± 0.05 0.97 ± 0.15 
13 2.22 ± 0.03 0.87 ± 0.02 0.69 ± 0.02 2.41 ± 0.17 
14 0.88 ± 0.12 0.43 ± 0.00 0.68 ± 0.07 1.79 ± 0.15 
V4 - 03.12.2011 
 
-24-0h 0-6h 6-12h 12-24h 
1 1.95 ± 0.35 0.46 ± 0.02 1.26 ± 0.09 0.83 ± 0.02 
2 0.41 ± 0.04 0.24 ± 0.02 0.30 ± 0.02 0.62 ± 0.01 
3 0.36 ± 0.01 0.32 ± 0.01 1.05 ± 0.11 1.13 ± 0.04 
4 1.01 ± 0.01 0.47 ± 0.01 1.00 ± 0.06 1.78 ± 0.16 
5 0.86 ± 0.05 0.37 ± 0.00 1.20 ± 0.10 0.85 ± 0.06 
6 1.23 ± 0.22 0.28 ± 0.01 0.69 ± 0.01 0.75 ± 0.03 
7 1.36 ± 0.05 0.72 ± 0.07 2.06 ± 0.01 2.04 ± 0.01 
8 1.91 ± 0.16 0.42 ± 0.01 0.87 ± 0.14 1.13 ± 0.04 
9 1.04 ± 0.05 0.27 ± 0.01 1.15 ± 0.04 0.85 ± 0.06 
10 0.96 ± 0.07 0.60 ± 0.01 0.96 ± 0.13 0.72 ± 0.03 
11 0.68 ± 0.08 0.60 ± 0.10 0.52 ± 0.05 0.70 ± 0.05 
12 2.06 ± 0.38 1.26 ± 0.19 1.46 ± 0.04 1.68 ± 0.17 
13 2.34 ± 0.20 1.61 ± 0.19 0.85 ± 0.04 0.74 ± 0.01 
14 0.90 ± 0.03 0.45 ± 0.02 0.57 ± 0.02 1.12 ± 0.07 
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Table 58 Compound dependent parameters (QTrap 5500) for determination of instant coffee 
ingredients and metabolites in plasma [Marmet et al., 2014]. DP: declustering potential, CE: 
collision energy, CXP: cell exit potential, RT: retention time; NA: not available. 
Compound  Parent mass  Product 1  Product 2  DP [V]  CE1 [V]  CE2 [V]  CXP1 [V]  CXP2 [V]  RT [min] 
34MPPA  179 135.2  NA −80 −14  NA −9  NA  18,70 
3CQA15L  335 161 133 −95 −28 −54 −9 −9 10,90 
3CQA  353 190.9  179 -70 -22 -20 -9 -9 5,00 
3FQA15L  349 174.9  160 -115 -26 -42 -9 -9 14,20 
3FQA 367 192,9 133,9 -5 -22 -40 -9 -9 8,10 
3PPA 149 105 NA -65 -14 NA -7 NA  18,50 
4CQA15L  335 161 133 -105 -30 -56 -9 -13 11,70 
4CQA  353 173,1 179,1 -10 -20 -22 -9 -9 7,40 
4FQA15L  349 174,8 160 -70 -24 -50 -7 -9 14,70 
4FQA  367 173 NA -80 -20 NA -9 NA  10,90 
4MCA  176,9 133 117 -60 -14 -42 -9 -7 19,90 
5CQA3S  432,9 190,8 353 -25 -32 -24 -9 -15 7,20 
5CQA4S 432,9 191 179 -100 -38 -32 -9 -7 6,10 
5CQA 353 190,9 85,1 -60 -34 -50 -9 -5 8,00 
5FQA4G 543,1 191 366,9 -120 -38 -24 -5 -17 5,90 
5FQA4S 446,9 190,8 193,1 -30 -32 -30 -11 -9 7,50 
5FQA 367 190,8 172,9 -25 -20 -24 -9 -11 10,80 
CA 179,1 135 134,1 -85 -22 -30 -7 -5 7,80 
CA3G 354,9 178,8 134,8 -25 -24 -52 -11 -7 7,10 
CA3S 259 179,1 134,9 -70 -22 -32 -9 -9 7,20 
CA4G 354,9 178,9 134,8 -25 -24 -52 -11 -7 4,70 
CA4S 259 178,9 135 -60 -22 -40 -9 -9 6,40 
CinAc 147 103 NA -20 -14 NA -9 NA  19,40 
DHCA 181,1 137 109 -65 -16 -20 -7 -7 7,50 
DHCA3G 356,9 112,8 180,9 -90 -22 -24 -7 -11 7,20 
DHCA3S 261 137 180,8 -5 -36 -32 -7 -47 6,60 
DHCA4G 356,9 113 181 -80 -22 -26 -7 -11 6,70 
DHCA4S 261 136,8 180,8 -50 -30 -24 -9 -11 6,30 
DHFA 195,1 136,1 120,9 -105 -20 -36 -7 -11 11,60 
DHFA4G 370,9 112,9 175 -25 -22 -18 -17 -9 8,30 
DHFA4S 275 195 79,9 -75 -22 -58 -11 -11 8,10 
DHiFA 195,1 135,9 150,9 -70 -18 -14 -19 -7 12,80 
DHiFA3G 371 112,9 195 -35 -24 -26 -7 -9 9,90 
DHiFA3S 275 195,1 135,8 -70 -24 -32 -9 -11 9,10 
FA 193,1 134 177,8 -65 -20 -14 -7 -9 12,10 
FA4G 368,9 113 193 -85 -16 -18 -5 -11 6,50 
FA4S 273 193 133,9 -70 -20 -38 -9 -9 8,10 
iFA 193,1 178 133,9 -90 -16 -22 -9 -9 13,00 
iFA3G 369 112,8 193 -20 -20 -22 -7 -11 9,30 
iFA3S 273 177,9 134 -70 -26 -48 -9 -9 9,60 
mCoA 163,1 118,9 90,8 -60 -20 -30 -9 -13 12,70 
mCoAG 339 112,9 119 -55 -22 -56 -13 -11 8,20 
mCoAS 242,9 163 119 -50 -24 -42 -7 -9 9,00 
mDHCoA 165 121 105,9 -70 -16 -30 -7 -5 11,60 
mDHCoAG 341 113 121 -45 -24 -42 -5 -5 8,50 
mDHCoAS 244,9 165 121 -90 -24 -32 -5 -9 8,20 
MeDHFA  209 150 165,1 -120 -16 -16 -11 -9 16,00 
MeFA 207,2 103 163,1 -80 -18 -12 -7 -9 17,00 
oCoA 163,1 119,1 116,9 -55 -16 -30 -7 -11 14,60 
oDHCoA 165 121 106,1 -30 -18 -30 -9 -5 13,10 
pCoA 163,1 118,9 93 -55 -20 -38 -9 -11 10,50 
pCoAG 339 113 118,9 -80 -18 -54 -5 -15 4,80 
pCoAS 242,9 119 163 -55 -38 -20 -7 -7 7,30 
pDHCoA 165 121 59 -80 -14 -16 -9 -9 10,10 
pDHCoAG 341 113 59 -75 -22 -54 -5 -7 6,90 
pDHCoAS 244,9 165 58,9 -65 -24 -36 -7 -9 7,40 
CA13 182,1 137 136 -30 -20 -34 -9 -11 7,80 
DHiFAd3G 374 113 198 -60 -24 -28 -7 -13 9,80 
DHiFAd3S 277,8 198,1 136,2 -15 -24 -36 -5 -9 9,10 
8 Appendices 
192 
 
Table 59 Compound dependent parameters (QTrap 5500) for determination of instant coffee 
ingredients and metabolites in plasma. DP: declustering potential, CE: collision energy, CXP: 
cell exit potential, RT: retention time. 
Compound Parent mass Product DP [V] CE [V] CXP [V] RT [min] 
5-CQA 353,1 191 -70 -24 -11 11.58 
3-CQA 353,2 191 -40 -40 -11 8.90 
4-CQA 353,2 173 -10 -44 -11 11.20 
CA 178,9 135 -85 -18 -9 14.38 
FA 192,9 134 -35 -24 -9 19.99 
DHCA-3-Gluc 357,1 181 -45 -28 -9 19.25 
CQL 335 132,9 -85 -56 -13 17.06 
FAG 250 133,9 -85 -30 -11 14.63 
FA-4-Sulf 273 192,9 -40 -20 -13 10.81 
DHCA 180,9 137 -25 -24 -7 12.47 
DHIFA 194,9 136 -105 -20 -7 18.79 
IFA 192,9 134 -35 -24 -9 20.39 
4-FQA 367,1 172,9 -50 -22 -11 14.88 
CQA-3-Sulf 433,1 191 -75 -36 -11 9.43 
FQA-Gluc 543 190,9 -120 -38 -15 8.48 
FQA-Sulf 447 191 -50 -36 -11 9.60 
CA-3-Gluc 355,2 178,8 -25 -46 -9 10.83 
3-FQA 367 192,9 -45 -24 -17 12.47 
5-FQA 367 191 -60 -22 -13 15.99 
CA-4-Gluc 355,2 178,9 -30 -24 -11 8.44 
CA-4-Sulf 259 179 -25 -22 -11 9.66 
DHCA-3-Sulf 261 180,8 -45 -12 -15 9.11 
DHCA-4-Sulf 261 180,8 -45 -12 -15 8.74 
IFA-3-Gluc 369 178 -80 -36 -9 12.47 
IFA-3-Sulf 272,9 193 -50 -22 -13 11.54 
DHFA-4-Sulf 275 195 -35 -24 -13 9.77 
CA-13C3 181,9 136,9 -20 -22 -15 14.35 
CA-3-Sulf 258,9 179 -45 -22 -11 10.18 
IFA-d3-3-Gluc 372 178 -30 -38 -11 12.40 
IFA-d3-3-Sulf 275,9 196 -25 -22 -9 11.53 
DHFA-4-Gluc 370,9 112,9 -25 -22 -17 10.45 
DHIFA-3-Gluc 371 119 -30 -36 -9 11.89 
DHFA 195,1 136,1 -105 -20 -7 17.86 
5CQA-4-Sulf 432,9 191 -100 -38 -9 9.42 
5FQA-4-Sulf 446,9 190,8 -30 -32 -11 9.58 
5FQA-4-Gluc 543,1 191 -120 -38 -5 8.46 
DHCA-4-Gluc 357 181 -45 -28 -9 8.52 
4-CQL 335 161 -50 -32 -11 17.03 
CQL-Gluc 511,1 132,9 -60 -94 -2 13.08 
CQA-3-Gluc 528,9 191 -75 -36 -11 7.42 
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Table 60 Limits of quantification for determination of coffee ingredients and metabolites in 
plasma samples. 
Analyte LOQ [nM]  Analyte LOQ [nM] 
34MPPA 25  DHCA3G 5 
DHCA 5  iFA3G 5 
FA 5  pCoA 5 
CA 5  DHiFA3G 5 
DHFA 5  iFA3S 5 
4-CQA 5  DHiFA3S 5 
MeFA 5  4CQA15L 5 
iFA 5  5CQA4S 5 
3-CQA 5  5CQA3S 5 
5-CQA 5  3CQA15L 5 
MeDHFA 5  5FQA4G 25 
DHiFA 5  5FQA4S 5 
mCoA 5  3FQA15L 5 
oCoA 5  4FQA15L 5 
3-FQA 5  pCoAS 5 
5-FQA 5  mDHCoAG 5 
4-FQA 5  mCoAS 5 
DHFA4S 5  pDHCoAG 5 
CA4G 5  pCoAG 5 
FA4S 5  mDHCoAS 5 
DHCA4G 5  mCoAG 5 
CA4S 5  pDHCoAS 5 
DHFA4G 5  oDHCoA 5 
DHCA4S 5  3PPA 25 
CA3G 5  mDHCoA 25 
DHCA3S 5  pDHCoA 50 
FA4G 5  CinAc 5 
CA3S 5  4MCA 25 
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Table 61 Limits of quantification for determination of coffee ingredients and metabolites in urin of proband 01 to 05. 
 
 
 
S01 S02 S03 S04 S05 
Substance background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
5CQA 600 7114,6 0,001 900 11180 0,001 300 8776,5 0,001 600 7311,4 0,001 400 6467,4 0,001 
3CQA 800 3118,3 0,004 600 4096,6 0,002 600 3175,6 0,003 600 2393,8 0,004 400 2431 0,003 
4CQA 250 2149,4 0,002 300 2856,3 0,002 200 2354,1 0,001 200 1779,6 0,002 200 1676,3 0,002 
CA  25000 14932 0,056 25000 16825 0,050 14000 9639,2 0,048 25000 11874 0,070 12000 11209 0,036 
FA 500 29687 0,001 600 42003 0,000 200 19607 0,000 300 29016 0,000 200 26710 0,000 
DHCA3G 4000 2380,8 0,028 3000 7343,1 0,007 2000 2647,7 0,013 1000 1073,6 0,016 1400 2074 0,011 
FAG 150 6157,6 0,001 200 10514 0,000 150 4870,5 0,001 100 9154,6 0,000 100 10159 0,000 
FA4S 10000 27371 0,008 2500 44930 0,001 2500 71545 0,001 1500 60067 0,001 1800 52823 0,001 
DHCA 6000 1967,7 0,101 5000 2284,2 0,072 4000 1632,6 0,081 6000 1694 0,117 4500 3006,1 0,049 
DHIFA 
 
3141,3 0,000 600 4353,3 0,004 1400 2121,9 0,020 300 2851,1 0,003 100 7803,7 0,000 
IFA 500 13246 0,001 2000 16677 0,004 2000 7562,7 0,008 4000 15913 0,008 2200 13116 0,005 
4FQA 1000 18920 0,001 250 24081 0,000 500 16132 0,001 300 15926 0,000 300 14570 0,000 
CQA3S 600 3686,2 0,002 600 5682,3 0,001 500 4731,9 0,001 600 3077,1 0,003 700 2775,6 0,003 
FQA4G 140 793,46 0,002 100 812,47 0,001 100 816,06 0,001 70 271,61 0,003 100 278,72 0,004 
FQA4S 600 7092,7 0,001 400 8839,7 0,001 300 8213,6 0,000 250 4675,8 0,001 350 4298,9 0,001 
CA3G 1000 353,57 0,048 600 520,01 0,019 500 349,86 0,024 350 277,72 0,021 350 528,25 0,011 
3FQA 1200 64385 0,000 2000 87372 0,000 1400 77918 0,000 1000 54462 0,000 1200 54033 0,000 
5FQA 1500 8008,8 0,003 900 9686,4 0,002 900 7734,6 0,002 600 7366,9 0,001 500 6666,5 0,001 
CA4G 3000 5641,2 0,009 1500 10038 0,003 2000 8464,3 0,004 500 5392,2 0,002 1500 5300,3 0,005 
CA4S 8000 25429 0,007 2500 31976 0,002 6000 20540 0,007 15000 15829 0,022 1400 16092 0,002 
DHCA3S 2000 2066 0,022 600 907,09 0,015 800 1549 0,012 400 746,21 0,012 150 528,65 0,006 
DHCA4S 5000 2082 0,055 800 1319,4 0,014 600 2000,7 0,007 300 976,37 0,007 150 716,63 0,005 
IFA3G 250 7439,2 0,001 100 7327,9 0,000 200 6840,2 0,000 400 4433,2 0,001 100 3978 0,000 
IFA3S 8000 24923 0,007 2500 38673 0,001 3000 78306 0,001 5000 24097 0,005 1000 27026 0,001 
DHFA4S 3000 20267 0,003 6000 31205 0,004 10000 27508 0,008 1000 20076 0,001 2000 28509 0,002 
CA3S 8000 38811 0,005 2000 33666 0,001 3000 35320 0,002 2500 23490 0,002 100 26806 0,000 
DHFA4G 7000 13785 0,008 1400 7451,5 0,003 2500 8390 0,005 2000 4443,5 0,007 800 3945,5 0,003 
DHIFA3G 250 1465,2 0,003 120 895,85 0,002 150 879,83 0,003 100 576,35 0,003 150 603,11 0,004 
DHFA 3000 44162 0,002 2000 29588 0,002 2000 19250 0,003 5000 3097,5 0,049 2700 3215,2 0,026 
5CQA4S 1000 2078 0,007 400 3145,7 0,002 500 2482,8 0,003 600 2446,4 0,003 500 8279,7 0,001 
DHCA4G 6000 2307,2 0,044 2500 3800,2 0,011 1500 2933,7 0,009 200 2075,2 0,002 1500 2015,2 0,012 
4CQL 900 108572 0,000 800 112626 0,000 700 68898 0,000 400 98389 0,000 150 83910 0,000 
CQLG 160 2159,9 0,001 100 3126,4 0,000 150 2372,1 0,001 200 1736,9 0,001 100 1685,6 0,001 
CQA3G 150 31,085 0,055 100 33,883 0,033 60 34,183 0,020 100 18,94 0,060 100 19,794 0,057 
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Table 62 Limits of quantification for determination of coffee ingredients and metabolites in urin of proband 06 to 10. 
 
S06 S07 S08 S09 S10 
Substance background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
5CQA 400 5741,6 0,001 200 6120,3 0,001 200 6371,7 0,001 150 6226,3 0,000 250 8086,3 0,001 
3CQA 250 2276 0,002 600 2295,8 0,004 250 2705,1 0,002 250 2892,6 0,001 200 3639,5 0,001 
4CQA 200 1606,2 0,002 250 1830 0,002 400 1988,6 0,003 100 1954,7 0,001 300 2280,7 0,002 
CA  14000 8386,1 0,056 10000 6616,7 0,050 5000 11328 0,015 10000 12578 0,027 9000 12573 0,024 
FA 150 27637 0,000 400 14042 0,001 300 28756 0,000 150 30712 0,000 200 32006 0,000 
DHCA3G 1500 1882,9 0,013 2000 2203 0,015 5000 2932,9 0,029 2000 2262,6 0,015 2000 2447,4 0,014 
FAG 100 4429,3 0,001 150 4069 0,001 150 3922,4 0,001 100 4542,3 0,001 150 5443,6 0,001 
FA4S 2000 26047 0,002 3000 13143 0,005 12000 24061 0,011 1500 22010 0,001 3500 47957 0,002 
DHCA 4500 1810,4 0,082 3000 1041,6 0,095 4500 1385,4 0,107 2500 897,42 0,092 3000 2056,6 0,048 
DHIFA 200 2787,6 0,002 150 1539,7 0,003 200 2885,1 0,002 100 2924,5 0,001 100 2972 0,001 
IFA 2500 12759 0,006 1600 NA NA 2000 11283 0,005 1200 11711 0,003 1800 11448 0,005 
4FQA 250 13330 0,000 400 11407 0,001 300 16987 0,000 200 18362 0,000 150 19229 0,000 
CQA3S 900 2861,8 0,004 600 2784,8 0,003 600 3750 0,002 700 3751 0,003 700 3808,6 0,003 
FQA4G 100 306,37 0,004 200 409,29 0,005 100 343,58 0,003 100 305,07 0,004 100 416,87 0,003 
FQA4S 350 4595,4 0,001 1000 6118,7 0,002 600 6597,2 0,001 400 6592 0,001 300 6512,6 0,001 
CA3G 350 269,43 0,022 400 257,2 0,026 600 303,59 0,033 700 280,11 0,042 400 326,15 0,021 
3FQA 800 46876 0,000 900 57544 0,000 900 55215 0,000 700 54036 0,000 500 62289 0,000 
5FQA 500 6250,5 0,001 700 4904,7 0,002 2000 7785,9 0,004 400 6059,8 0,001 700 8613,9 0,001 
CA4G 900 5400,6 0,003 2000 6755,8 0,005 4000 6051,3 0,011 1500 5588,3 0,005 1000 6429,8 0,003 
CA4S 1000 15098 0,002 3000 10156 0,007 3000 17483 0,004 2500 17607 0,003 5000 18775 0,006 
DHCA3S 200 542,11 0,008 400 368,77 0,025 500 435,62 0,026 150 517,66 0,007 400 752,98 0,012 
DHCA4S 100 722,07 0,003 300 835,33 0,008 200 585,67 0,008 250 655,64 0,009 300 933,84 0,007 
IFA3G 150 4102,4 0,001 300 4584,7 0,001 1000 5521,8 0,003 450 5698,4 0,001 100 5318,8 0,000 
IFA3S 4000 22037 0,004 1400 18307 0,002 10000 24661 0,009 2000 24038 0,002 2500 27061 0,002 
DHFA4S 2000 15131 0,003 1500 11011 0,003 3000 24885 0,003 800 16516 0,001 100 18985 0,000 
CA3S 2000 20051 0,002 5000 11079 0,010 3000 22794 0,003 2000 17837 0,003 2000 16214 0,003 
DHFA4G 1500 3551,4 0,007 9000 3600,9 0,040 4500 6291,3 0,012 1500 3129,2 0,008 5000 1292,2 0,062 
DHIFA3G 200 516,6 0,006 200 545,92 0,006 200 572,38 0,006 250 683,26 0,006 150 677,73 0,004 
DHFA 2500 17105 0,004 2000 1541,5 0,040 2500 20181 0,004 2000 29916 0,002 4000 21364 0,006 
5CQA4S 600 2340,5 0,004 600 2346,3 0,004 300 2948,2 0,001 500 2615,6 0,003 700 2643,6 0,004 
DHCA4G 1500 1968,3 0,013 4000 2337,8 0,029 10000 2312,6 0,072 2000 2311,3 0,015 6000 2462,6 0,041 
4CQL 300 85158 0,000 300 58055 0,000 250 98005 0,000 350 109921 0,000 100 115217 0,000 
CQLG 150 1581,6 0,001 150 1672,3 0,001 150 1789,1 0,001 350 1549,2 0,003 150 1871,7 0,001 
CQA3G 200 22,754 0,100 150 23,806 0,071 150 17,217 0,099 100 14,239 0,080 150 17,092 0,099 
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Table 63 Limits of quantification for determination of coffee ingredients and metabolites in urin of proband 11 to 14. 
 
S11 
 
S12 S13 S14 
Substance background gradient 
LOQ 
[nmol/ml]  
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
background gradient 
LOQ 
[nmol/ml] 
5CQA 150 7570 0,000 
 
250 7038,8 0,001 300 9840,8 0,001 250 7715,7 0,001 € 
3CQA 200 3060,5 0,001 
 
150 3159,7 0,001 300 4013,6 0,001 250 3043,2 0,001 € 
4CQA 200 2152,7 0,002 
 
100 2307,8 0,001 200 2964,7 0,001 200 2264,2 0,001 € 
CA  12000 12293 0,033 
 
4000 12037 0,011 6000 17694 0,011 11000 11828 0,031 € 
FA 200 29057 0,000 
 
300 25882 0,000 300 33778 0,000 150 31172 0,000 € 
DHCA3G 6000 2295,7 0,044 
 
4000 2390,3 0,028 4000 3144,5 0,021 2000 2282,4 0,015 € 
FAG 100 5200,8 0,000 
 
300 7963,4 0,001 200 6203,2 0,001 300 5517,8 0,001 € 
FA4S 4000 68371 0,001 
 
4000 13942 0,006 5000 27322 0,004 1600 26369 0,001 € 
DHCA 5000 1920,2 0,086 
 
2500 1874,5 0,044 2500 1 82,418 2000 1879,6 0,035 € 
DHIFA 120 2991,9 0,001 
 
100 2908,2 0,001 500 3173,4 0,005 800 2964 0,008 € 
IFA 1400 11672 0,004 
 
1200 11032 0,003 1000 11412 0,003 100 11398 0,000 € 
4FQA 100 16871 0,000 
 
150 14779 0,000 150 19981 0,000 100 18629 0,000 € 
CQA3S 500 3444,3 0,002 
 
600 3832,6 0,002 300 5425,4 0,001 350 4108,9 0,001 € 
FQA4G 150 375,51 0,004 
 
100 338,82 0,003 150 549,98 0,003 100 435,16 0,003 € 
FQA4S 400 5964,4 0,001 
 
400 7131,8 0,001 200 10907 0,000 300 7644 0,001 € 
CA3G 400 322,08 0,021 
 
500 307,76 0,027 500 429,32 0,020 400 327,86 0,021 € 
3FQA 700 53462 0,000 
 
700 49148 0,000 500 65971 0,000 500 60556 0,000 € 
5FQA 1000 7648,3 0,002 
 
600 6697,9 0,001 800 9889,5 0,001 1000 8422,1 0,002 € 
CA4G 1500 6192,4 0,004 
 
3000 6367,4 0,008 1600 7492,9 0,004 1000 6929,2 0,002 € 
CA4S 4000 18388 0,005 
 
7000 20912 0,008 4000 30070 0,003 3500 20998 0,004 € 
DHCA3S 200 767,14 0,006 
 
400 613,73 0,015 500 810,51 0,014 150 709,9 0,005 € 
DHCA4S 300 857,33 0,008 
 
300 653,61 0,011 500 960,21 0,012 150 1059,8 0,003 € 
IFA3G 400 5517,6 0,001 
 
300 4940,2 0,001 250 7717,6 0,000 250 6024,9 0,001 € 
IFA3S 6000 26428 0,005 
 
7000 28228 0,005 10000 30641 0,007 2000 25841 0,002 € 
DHFA4S 2000 17942 0,002 
 
1500 15789 0,002 1500 17473 0,002 2000 25984 0,002 € 
CA3S 4500 23890 0,004 
 
7000 241193 0,001 5000 35214 0,003 3000 21671 0,003 € 
DHFA4G 2000 5170,2 0,006 
 
2000 3382,5 0,010 2000 5215,1 0,006 2000 5138,4 0,006 € 
DHIFA3G 200 640,17 0,005 
 
150 642,85 0,004 200 1216 0,003 250 1000,4 0,004 € 
DHFA 2000 25985 0,002 
 
1600 3535,5 0,014 1000 33887 0,001 1000 27700 0,001 € 
5CQA4S 500 2472,9 0,003 
 
400 2724,2 0,002 300 4038,5 0,001 300 3242,6 0,001 € 
DHCA4G 4000 2337,5 0,029 
 
3000 2426,4 0,021 3000 2683,5 0,019 3000 2371,3 0,021 € 
4CQL 150 105206 0,000 
 
200 109519 0,000 250 98040 0,000 150 96513 0,000 € 
CQLG 200 1721,4 0,001 
 
200 1769,1 0,001 100 2499,5 0,000 150 2088,9 0,001 € 
CQA3G 100 18,489 0,061 
 
100 20 0,057 100 29,408 0,038 100 20,7 0,055 € 
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